<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001869.pub8" GROUP_ID="NEUROMUSC" ID="092299072712144655" MERGED_FROM="" MODIFIED="2015-10-29 23:02:30 +0000" MODIFIED_BY="Ruth Brassington" NOTES="&lt;p&gt;number of trials needs updating: please check for consistency throughout&lt;/p&gt;" NOTES_MODIFIED="2015-10-15 14:20:12 +0100" NOTES_MODIFIED_BY="Ruth  Brassington" REVIEW_NO="026" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="18.0">
<COVER_SHEET MODIFIED="2015-10-29 23:02:30 +0000" MODIFIED_BY="Ruth Brassington">
<TITLE MODIFIED="2009-05-06 12:27:16 +0100" MODIFIED_BY="Kate Jewitt">Antiviral treatment for Bell's palsy (idiopathic facial paralysis)</TITLE>
<CONTACT MODIFIED="2015-10-29 23:02:30 +0000" MODIFIED_BY="Ruth Brassington"><PERSON ID="z1309111008522937273859629128343" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ildiko</FIRST_NAME><LAST_NAME>Gagyor</LAST_NAME><POSITION>Academic GP</POSITION><EMAIL_1>Ildiko.Gagyor@medizin.uni-goettingen.de</EMAIL_1><MOBILE_PHONE>+49(0)175 531 4779</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of General Practice/Family Medicine</DEPARTMENT><ORGANISATION>University of Göttingen</ORGANISATION><ADDRESS_1>Humboldtalle 38</ADDRESS_1><CITY>Göttingen</CITY><ZIP>37073</ZIP><REGION>Lower Saxony</REGION><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+495513914226</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-10-29 23:02:30 +0000" MODIFIED_BY="Ruth Brassington"><PERSON ID="z1309111008522937273859629128343" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ildiko</FIRST_NAME><LAST_NAME>Gagyor</LAST_NAME><POSITION>Academic GP</POSITION><EMAIL_1>Ildiko.Gagyor@medizin.uni-goettingen.de</EMAIL_1><MOBILE_PHONE>+49(0)175 531 4779</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of General Practice/Family Medicine</DEPARTMENT><ORGANISATION>University of Göttingen</ORGANISATION><ADDRESS_1>Humboldtalle 38</ADDRESS_1><CITY>Göttingen</CITY><ZIP>37073</ZIP><REGION>Lower Saxony</REGION><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+495513914226</PHONE_1></ADDRESS></PERSON><PERSON ID="z1305211200234164391015338304569" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Vishnu</FIRST_NAME><MIDDLE_INITIALS>B</MIDDLE_INITIALS><LAST_NAME>Madhok</LAST_NAME><SUFFIX>MBChB</SUFFIX><POSITION>SCREDS Clinical Lecturer in General Practice</POSITION><EMAIL_1>vishnumadhok@nhs.net</EMAIL_1><EMAIL_2>vmadhok@doctors.org.uk</EMAIL_2><URL>http://medicine.dundee.ac.uk/staff-member/dr-vishnu-b-madhok</URL><MOBILE_PHONE>07703473808</MOBILE_PHONE><ADDRESS><DEPARTMENT>Centre for Primary Care and Population Research, Division of Clinical and Population Sciences and Education</DEPARTMENT><ORGANISATION>University of Dundee</ORGANISATION><ADDRESS_1>Mackenzie Buildiing</ADDRESS_1><ADDRESS_2>Kirsty Semple Way</ADDRESS_2><CITY>Dundee</CITY><ZIP>DD2 4BF</ZIP><REGION>Tayside, Scotland</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0) 7703 473 808</PHONE_1></ADDRESS></PERSON><PERSON ID="08C0070D82E26AA200C1C7C47268A583" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Fergus</FIRST_NAME><LAST_NAME>Daly</LAST_NAME><POSITION>Dr F Daly Biostatistics Team Lead</POSITION><ADDRESS><ORGANISATION>Frontier Science (Scotland) Ltd</ORGANISATION><ADDRESS_1>Grampian View Kincraig,</ADDRESS_1><CITY>Kingussie</CITY><ZIP>PH21 1NA</ZIP><REGION>Inverness-shire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>1540 651012</PHONE_1></ADDRESS></PERSON><PERSON ID="z1309040956374904322560980402530" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Dhruvashree</FIRST_NAME><LAST_NAME>Somasundara</LAST_NAME><POSITION>General Practice Registrar</POSITION><EMAIL_1>d.somasundara@nhs.net</EMAIL_1><ADDRESS><DEPARTMENT>Centre for Primary Care and Population Research, Division of Clinical and Population Sciences and Education</DEPARTMENT><ORGANISATION>University of Dundee</ORGANISATION><ADDRESS_1>The Mackenzie Building</ADDRESS_1><ADDRESS_2>Kirsty Semple Way</ADDRESS_2><CITY>Dundee</CITY><ZIP>DD2 4BF</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="z1310220943237134598852299548582" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Michael</FIRST_NAME><LAST_NAME>Sullivan</LAST_NAME><POSITION>MSc Student</POSITION><EMAIL_1>sullivanmk@doctors.org.uk</EMAIL_1><EMAIL_2>s1371258@ed.ac.uk</EMAIL_2><MOBILE_PHONE>07763 109784</MOBILE_PHONE><ADDRESS><DEPARTMENT>School of Clinical Sciences</DEPARTMENT><ORGANISATION>University of Edinburgh</ORGANISATION><ADDRESS_1>Old College</ADDRESS_1><ADDRESS_2>South Bridge</ADDRESS_2><CITY>Edinburgh</CITY><ZIP>EH8 9YL</ZIP><REGION>Lothian</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>0131 650 1000</PHONE_1><FAX_1>0131 650 2147</FAX_1></ADDRESS></PERSON><PERSON ID="z1401151148553872165321071188561" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Fiona</FIRST_NAME><LAST_NAME>Gammie</LAST_NAME><POSITION>Clinical Research Nurse</POSITION><EMAIL_1>fiona.gammie@gmail.com</EMAIL_1><EMAIL_2>f.gammie@abdn.ac.uk</EMAIL_2><ADDRESS><DEPARTMENT>Centre for Primary Care and Population Research, Division of Clinical and Population Sciences and Education</DEPARTMENT><ORGANISATION>University of Dundee</ORGANISATION><ADDRESS_1>Mackenzie Building, Rm FF2</ADDRESS_1><ADDRESS_2>Ninewells Hospital and Medical School</ADDRESS_2><CITY>Dundee</CITY><ZIP>DD2 4BF</ZIP><REGION>Scotland</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>01382 383800 ext 83957</PHONE_1></ADDRESS></PERSON><PERSON ID="8188" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Frank</FIRST_NAME><LAST_NAME>Sullivan</LAST_NAME><POSITION>Gordon F. Cheesbrough Chair in Family &amp; Community Medicine, Director of UTOPIAN the University of Toronto Practice Based Research Network</POSITION><EMAIL_1>utopian.director@utoronto.ca</EMAIL_1><EMAIL_2>frank.sullivan@nygh.on.ca</EMAIL_2><ADDRESS><DEPARTMENT>Department of Family and Community Medicine</DEPARTMENT><ORGANISATION>North York General Hospital, University of Toronto</ORGANISATION><ADDRESS_1>500 University Avenue, 5th Floor</ADDRESS_1><CITY>Toronto</CITY><ZIP>M5G 1V7</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2015-09-08 19:26:50 +0100" MODIFIED_BY="Ildiko Gagyor">
<UP_TO_DATE>
<DATE DAY="7" MONTH="10" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="7" MONTH="10" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="7" MONTH="10" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="10" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-10-15 09:23:35 +0100" MODIFIED_BY="Ruth  Brassington" NOTES="&lt;p&gt;&lt;span modified=&quot;2015-09-15 17:10:00 +0100&quot; modified_by=&quot;Ruth  Brassington&quot; class=&quot;inserted&quot;&gt;moderate quality?&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-10-15 09:23:35 +0100" NOTES_MODIFIED_BY="Ruth  Brassington">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-10-15 09:23:35 +0100" MODIFIED_BY="Ruth  Brassington">
<DATE DAY="14" MONTH="9" YEAR="2015"/>
<DESCRIPTION>
<P>Authors have removed a previously included study (<LINK REF="STD-Abdelghany-2013" TYPE="STUDY">Abdelghany 2013</LINK>) from the included studies owing to potential unreliability of evidence. Future substantive updates of the review will include <LINK REF="STD-Abdelghany-2013" TYPE="STUDY">Abdelghany 2013</LINK> only if investigations conclude that the trial data are reliable.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2015-10-14 10:44:00 +0100" MODIFIED_BY="Ruth  Brassington">
<DATE DAY="14" MONTH="9" YEAR="2015"/>
<DESCRIPTION>
<P>With the removal of <LINK REF="STD-Abdelghany-2013" TYPE="STUDY">Abdelghany 2013</LINK>, this review concludes that there is a benefit from the combination of antivirals with corticosteroids compared to corticosteroids alone for the treatment of Bell's palsy of various degrees of severity. The evidence continues to support a benefit of combination therapy compared with corticosteroids alone in severe Bell&#8217;s palsy. The evidence on which these findings are based is of low quality.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-09-14 13:07:31 +0100" MODIFIED_BY="Ruth  Brassington">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2015-09-14 13:07:27 +0100" MODIFIED_BY="Ruth  Brassington">
<DATE DAY="22" MONTH="5" YEAR="2015"/>
<DESCRIPTION>
<P>The authors have reviewed and reworded the conclusions, which bear re-reading for clarification. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-09-14 13:07:31 +0100" MODIFIED_BY="Ruth  Brassington">
<DATE DAY="12" MONTH="5" YEAR="2015"/>
<DESCRIPTION>
<P>As an updated search was recently incorporated, there has been no new search for this amended version.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-05-12 17:09:26 +0100" MODIFIED_BY="Ruth  Brassington">
<DATE DAY="28" MONTH="2" YEAR="2014"/>
<DESCRIPTION>
<P>Review updated with no change to conclusions. New authors: Ildiko Gagyor, Vishnu B Madhok, Dhruvashree Somasundara, Michael Sullivan, and Fiona Gammie. Previous authors Pauline Lockhart, Marie Pitkethly, and Natalia Comerford withdrew.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-05-12 17:09:29 +0100" MODIFIED_BY="Ruth  Brassington">
<DATE DAY="22" MONTH="1" YEAR="2014"/>
<DESCRIPTION>
<P>New trials added, text rewritten, new calculations, references updated. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-02-28 17:39:58 +0000" MODIFIED_BY="Ruth Brassington">
<DATE DAY="12" MONTH="5" YEAR="2010"/>
<DESCRIPTION>
<P>Correction to reference</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-05-12 14:28:39 +0100" MODIFIED_BY="Ruth Brassington">
<DATE DAY="10" MONTH="11" YEAR="2009"/>
<DESCRIPTION>
<P>Correction of minor error in Discussion.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2009-11-10 21:15:24 +0000" MODIFIED_BY="Ruth Brassington">
<DATE DAY="25" MONTH="2" YEAR="2009"/>
<DESCRIPTION>
<P>This is a substantive update to the previous edition of the review with a new review team. Five new studies added to the analysis with changes made to Results and Discussion sections as necessary.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-11-10 21:15:07 +0000" MODIFIED_BY="Ruth Brassington">
<DATE DAY="5" MONTH="2" YEAR="2009"/>
<DESCRIPTION>
<P>Substantive update to previous edition of review.</P>
<P>Abstract and background information re-written. Modification of outcomes: all data from trials, whatever the trial length as opposed to 6 month outcomes. Five new studies added to the analysis with necessary changes made to Results and Discussion sections. One study removed from the previous review as no data contributed and none forthcoming to previous authors when approached.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-07-17 16:15:47 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="11" YEAR="2007"/>
<DESCRIPTION>
<P>Two trials, one with 551 participants comparing prednisolone with aciclovir with both and with neither, another with 221 participants comparing prednisolone and valaciclovir with prednisolone and placebo have just been published and will be included in an update of this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="1" MONTH="3" YEAR="2004"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-05-06 16:46:24 +0100" MODIFIED_BY="Kate Jewitt">
<DATE DAY="1" MONTH="1" YEAR="2004"/>
<DESCRIPTION>
<P>The review was updated in January 2004. Searches were updated as follows: Neuromuscular Disease Group Trials Register (searched April 2003), MEDLINE (searched January 1966 to April 2003), EMBASE (searched January 1980 to April 2003), and LILACS (searched January 1982 to April 2003).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2009-02-05 16:22:26 +0000" MODIFIED_BY="Pauline Lockhart">
<INTERNAL_SOURCES MODIFIED="2009-02-05 16:22:26 +0000" MODIFIED_BY="Pauline Lockhart">
<SOURCE MODIFIED="2009-02-05 16:22:26 +0000" MODIFIED_BY="Pauline Lockhart">
<NAME>University of Dundee</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-10-15 14:20:12 +0100" MODIFIED_BY="Ruth  Brassington">
<SUMMARY MODIFIED="2015-10-15 14:19:20 +0100" MODIFIED_BY="Ruth  Brassington">
<TITLE MODIFIED="2009-05-07 16:26:40 +0100" MODIFIED_BY="[Empty name]">Antiviral treatment for Bell's palsy</TITLE>
<SUMMARY_BODY MODIFIED="2015-10-15 14:19:20 +0100" MODIFIED_BY="Ruth  Brassington" NOTES="&lt;p&gt;&lt;u&gt;&lt;/u&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-10-15 14:19:20 +0100" NOTES_MODIFIED_BY="Ruth  Brassington">
<P>
<B>Review question</B>
</P>
<P>We reviewed the evidence about the effect of antiviral therapy alone or in combination with any other therapy, on Bell's palsy.</P>
<P>
<B>Background</B>
</P>
<P>Bell's palsy is a disease of the facial nerve that causes one side of the face to be paralysed. Some studies have suggested that it is caused by the same viral infections that cause cold sores (herpes simplex) or shingles (varicella zoster). If this is correct, antiviral drugs would be likely to help recovery. The paralysis is usually temporary even when left untreated, although without treatment about one person in five is left with permanent facial disfigurement or pain. A Cochrane review has already confirmed the effectiveness of corticosteroids in Bell&#8217;s palsy. This review was first published in 2001 and has been revised several times, most recently in 2009. This version replaces an update in Issue 7 of the Cochrane Library withdrawn because of an ongoing investigation into the reliability of data in one of the included studies.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We identified 10 trials, which included 2280 participants with mild, moderate, or severe one-sided Bell&#8217;s palsy of unknown cause. Participants were aged from 14 to 84 years. The trials compared antivirals in combination with corticosteroids to corticosteroids; antivirals alone to placebo or no treatment; antivirals alone to corticosteroid treatment alone; and antiviral treatment in combination with corticosteroids to placebo or no treatment. The duration of the included studies ranged from three months to 12 months.</P>
<P>
<B>Key results and quality of the evidence</B>
</P>
<P>
<I>Incomplete recovery</I>
</P>
<P>According to low-quality evidence, combining antivirals with corticosteroids improved rates of incomplete recovery from Bell's palsy compared to corticosteroids alone. This finding was based on data from eight trials involving 1315 people with Bell's palsy of various degrees of severity.</P>
<P>We were able to use data from four of the studies (478 participants) to examine treatment effects in severe Bell's palsy (that is people who have complete or almost-complete facial paralysis). The results showed that in this group, the addition of antiviral treatment to corticosteroids probably improved rates of incomplete recovery over corticosteroid treatment alone, although we assessed this evidence as low quality.</P>
<P>In other analyses, we found the following:</P>
<P>&#8226; corticosteroids alone were more effective than antivirals alone in terms of incomplete recovery (768 participants);</P>
<P>&#8226; antivirals plus corticosteroids were more effective than placebo or no treatment (658 participants); and</P>
<P>&#8226; antivirals alone were less effective than placebo (although this difference was not significant) (658 participants).</P>
<P>
<I>Long-term after-effects of Bell's palsy</I>
</P>
<P>Three trials (941 participants) assessed the long-term after-effects of Bell's palsy, such as excessive tear production and synkinesis (involuntary movement of muscles occurring at the same time as deliberate movement). The combination of antivirals and corticosteroids reduced long-term after-effects of Bell's palsy compared with corticosteroids alone. The evidence was of moderate quality.</P>
<P>There were fewer long-term after-effects of Bell's palsy after treatment with corticosteroids alone than with antivirals alone (two trials, 472 participants).</P>
<P>
<I>Adverse events</I>
</P>
<P>Based on the evidence from three trials (1528 participants), none of the treatments showed significant differences in adverse events, taking into account that the evidence for this outcome was low quality.</P>
<P>The evidence in this review is current to October 2014.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-10-15 14:18:10 +0100" MODIFIED_BY="Ruth  Brassington">
<ABS_BACKGROUND MODIFIED="2015-10-15 09:20:48 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Corticosteroids are widely used in the treatment of idiopathic facial paralysis (Bell&#8217;s palsy), but the effectiveness of additional treatment with an antiviral agent is uncertain. Significant morbidity can be associated with severe cases of Bell's palsy. This review was first published in 2001 and revised several times, most recently in 2009. This version replaces an update of the review in Issue 7 of the Cochrane Library subsequently withdrawn because of an ongoing investigation into the reliability of data from an included study.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-07-20 21:20:31 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effects of antiviral treatments alone or in combination with any other therapy for Bell&#8217;s palsy. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-04-16 10:58:22 +0100" MODIFIED_BY="Ruth  Brassington">
<P>On 7 October 2014 we searched the Cochrane Neuromuscular Disease Group Specialized Register, CENTRAL, MEDLINE, EMBASE, LILACS, DARE, NHS EED, and HTA. We also reviewed the bibliographies of the identified trials and contacted trial authors and known experts in the field and relevant drug companies to identify additional published or unpublished data. We searched clinical trials registries for ongoing studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-04-16 07:40:53 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We considered randomised controlled trials or quasi-randomised controlled trials of antivirals with and without corticosteroids versus control therapies for the treatment of Bell's palsy. We excluded trials that had a high risk of bias in several domains.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-04-09 15:06:27 +0100" MODIFIED_BY="Ruth Brassington">
<P>Pairs of authors independently assessed trials for relevance, eligibility, and risk of bias, using standard Cochrane procedures.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-10-12 20:30:27 +0100" MODIFIED_BY="Ildiko Gagyor" NOTES="&lt;p&gt;&lt;span modified=&quot;2015-05-18 16:02:52 +0100&quot; modified_by=&quot;Ruth  Brassington&quot; class=&quot;inserted&quot;&gt;Highlighted: favours&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2015-05-18 16:02:52 +0100&quot; modified_by=&quot;Ruth  Brassington&quot; class=&quot;inserted&quot;&gt;AV + CS vs. CS + placebo &lt;i&gt;&lt;b&gt;no diff&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2015-05-18 16:02:52 +0100&quot; modified_by=&quot;Ruth  Brassington&quot; class=&quot;inserted&quot;&gt;Severe: &lt;/span&gt;&lt;span modified=&quot;2015-05-18 16:02:52 +0100&quot; modified_by=&quot;Ruth  Brassington&quot;  class=&quot;inserted&quot;&gt;AV + CS &lt;/span&gt;&lt;span modified=&quot;2015-05-18 16:02:52 +0100&quot; modified_by=&quot;Ruth  Brassington&quot; class=&quot;inserted&quot;&gt;vs. CS + placebo &lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2015-05-18 16:02:52 +0100&quot; modified_by=&quot;Ruth  Brassington&quot; class=&quot;inserted&quot;&gt;AV + placebo vs. &lt;/span&gt;&lt;span modified=&quot;2015-05-18 16:02:52 +0100&quot; modified_by=&quot;Ruth  Brassington&quot;  class=&quot;inserted&quot;&gt;placebo or no treatment&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2015-05-18 16:02:52 +0100&quot; modified_by=&quot;Ruth  Brassington&quot; class=&quot;inserted&quot;&gt;AV + placebo vs. &lt;/span&gt;&lt;span modified=&quot;2015-05-18 16:02:52 +0100&quot; modified_by=&quot;Ruth  Brassington&quot;  class=&quot;inserted&quot;&gt;CS &lt;/span&gt;&lt;span modified=&quot;2015-05-18 16:02:52 +0100&quot; modified_by=&quot;Ruth  Brassington&quot; class=&quot;inserted&quot;&gt;(alone or with placebo)&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2015-05-18 16:02:52 +0100&quot; modified_by=&quot;Ruth  Brassington&quot;  class=&quot;inserted&quot;&gt;AV + CS &lt;/span&gt;&lt;span modified=&quot;2015-05-18 16:02:52 +0100&quot; modified_by=&quot;Ruth  Brassington&quot; class=&quot;inserted&quot;&gt;vs. placebo or no treatment&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-10-12 20:30:27 +0100" NOTES_MODIFIED_BY="Ildiko Gagyor">
<P>Ten trials, including 2280 participants, met the inclusion criteria and are included in the final analysis. Some of the trials were small, and a number were at high or unclear risk of bias. Other trials did not meet current best standards in allocation concealment and blinding.</P>
<P>
<B>Incomplete recovery</B>
</P>
<P>We found a significant benefit from adding antivirals to corticosteroids in comparison with corticosteroids alone for people with Bell&#8217;s palsy (risk ratio (RR) 0.61, 95% confidence interval (CI) 0.39 to 0.97, n = 1315). For people with severe Bell&#8217;s palsy (House-Brackmann scores of 5 and 6 or the equivalent in other scales), we found a reduction in the rate of incomplete recovery at month six when antivirals plus corticosteroids were used, compared to corticosteroids alone (RR 0.64, 95% CI 0.41 to 0.99, n = 478). The outcome for the participants receiving corticosteroids alone was significantly better than for those receiving antivirals alone (RR 2.82, 95% CI 1.09 to 7.32, n = 768). The treatment effect of placebo was significantly lower than that of antivirals plus corticosteroids (RR 0.56, 95% CI 0.41 to 0.76, n = 658). Antivirals alone produced no benefit compared with placebo (RR 1.10, 95% CI 0.87 to 1.40, n = 658).</P>
<P>
<B>Motor synkinesis or crocodile tears</B>
</P>
<P>In two trials comparing antivirals and corticosteroids with corticosteroids and placebo that assessed this outcome, we found a significant difference in long-term sequelae in favour of antivirals plus corticosteroids (RR 0.56, 95% CI 0.36 to 0.87, n = 469). Two trials comparing antivirals alone with corticosteroids alone investigating this outcome showed fewer sequelae with corticosteroids (RR 1.52, 95% CI 1.08 to 2.12, n = 472). We found no data on long-term sequelae for other comparisons.</P>
<P>
<B>Adverse events </B>
</P>
<P>Adverse event data were available in three studies giving comparison data on 1528 participants. None of the four comparisons (antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment; antivirals versus corticosteroids; antivirals plus corticosteroids versus placebo; antivirals versus placebo) showed significant differences in adverse events between treatment and control arms. We could find no correlation with specific treatment within these results.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-10-15 14:18:10 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Low-quality evidence from randomised controlled trials showed a benefit from the combination of antivirals with corticosteroids compared to corticosteroids alone for the treatment of Bell's palsy of various degrees of severity. Low-quality evidence showed a benefit of combination therapy compared with corticosteroids alone in severe Bell&#8217;s palsy. Corticosteroids alone were more effective than antivirals alone and antivirals plus corticosteroids were more effective than placebo or no treatment. There was no benefit from antivirals alone over placebo.</P>
<P>Moderate-quality evidence indicated that the combination of antivirals and corticosteroids reduced sequelae of Bell's palsy compared with corticosteroids alone.</P>
<P>We found no significant increase in adverse events from the use of antivirals compared with either placebo or corticosteroids, based on low-quality evidence.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-10-15 14:20:12 +0100" MODIFIED_BY="Ruth  Brassington">
<BACKGROUND MODIFIED="2015-10-12 20:38:25 +0100" MODIFIED_BY="Ildiko Gagyor">
<CONDITION MODIFIED="2015-04-16 08:03:47 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Bell's palsy is an acute, generally unilateral paralysis or weakness of facial musculature consistent with peripheral facial nerve dysfunction, of no detectable cause (<LINK REF="REF-Niparko-1993" TYPE="REFERENCE">Niparko 1993</LINK>). Additional symptoms frequently include pain around or behind the ear on the affected side, sometimes extending into the occipital or cervical regions. Impaired tolerance to ordinary levels of noise and disturbed sense of taste on the affected side may also be present (<LINK REF="REF-Burgess-1984" TYPE="REFERENCE">Burgess 1984</LINK>).</P>
<P>Epidemiological studies have reported an annual incidence of 23 to 25 per 100,000 per year, but a recent study using a general-practice database suggests it may be even higher, at 37 per 100,000 per year (<LINK REF="REF-Victor-1994" TYPE="REFERENCE">Victor 1994</LINK>
<U>;</U> <LINK REF="REF-Martyn-1997" TYPE="REFERENCE">Martyn 1997</LINK>
<U>; </U>
<LINK REF="REF-Morales-2013" TYPE="REFERENCE">Morales 2013</LINK>). The condition affects men and women more or less equally, and was once thought to be most common in the 30- to 45-year age group (<LINK REF="REF-Peitersen-1982" TYPE="REFERENCE">Peitersen 1982</LINK>
<U>; </U>
<LINK REF="REF-Katusic-1986" TYPE="REFERENCE">Katusic 1986</LINK>
<U>; </U>
<LINK REF="REF-Yanagihara-1988" TYPE="REFERENCE">Yanagihara 1988</LINK>
<U>; </U>
<LINK REF="REF-Bateman-1992" TYPE="REFERENCE">Bateman 1992</LINK>
<U>; </U>
<LINK REF="REF-Brandenberg-1993" TYPE="REFERENCE">Brandenberg 1993</LINK>
<U>; </U>
<LINK REF="REF-Peitersen-2002" TYPE="REFERENCE">Peitersen 2002</LINK>). However, a recent primary-care database study suggests a second peak in the over-70s (<LINK REF="REF-Morales-2013" TYPE="REFERENCE">Morales 2013</LINK>). Bell's palsy presents disproportionately amongst pregnant women and people who have diabetes, influenza, a cold, or some other upper respiratory ailment. On average, a British general practitioner will see one person who has developed the condition every 12 to 18 months. Both sides of the face are affected equally often (<LINK REF="REF-Prescott-1988" TYPE="REFERENCE">Prescott 1988</LINK>).</P>
<P>The aetiology of Bell's palsy is still debated. A viral infection, vascular ischaemia, autoimmune inflammatory disorders, and heredity have been proposed as underlying causes (<LINK REF="REF-Adour-1982" TYPE="REFERENCE">Adour 1982</LINK>
<U>; </U>
<LINK REF="REF-Burgess-1984" TYPE="REFERENCE">Burgess 1984</LINK>
<U>; </U>
<LINK REF="REF-Lorber-1996" TYPE="REFERENCE">Lorber 1996</LINK>
<U>; </U>
<LINK REF="REF-Lackner-2010" TYPE="REFERENCE">Lackner 2010</LINK>). A viral aetiology has gained popularity since the isolation of herpes simplex virus type 1 genome from the saliva and facial nerve endoneurial fluid of people with this condition (<LINK REF="REF-Murakami-1996" TYPE="REFERENCE">Murakami 1996</LINK>
<U>; </U>
<LINK REF="REF-Lackner-2010" TYPE="REFERENCE">Lackner 2010</LINK>). On the whole, the prognosis is favourable, though a significant proportion of people who are left untreated have residual symptoms. One of the largest series of people with Bell's palsy, which included people receiving no treatment, showed that 85% of people began to recover within three weeks after onset (<LINK REF="REF-Peitersen-1982" TYPE="REFERENCE">Peitersen 1982</LINK>). Partial recovery usually occurred within three to six months for the remaining 15%. The same series showed that normal facial expression reappeared in 71% of cases, 13% had insignificant sequelae (long-term after-effects), and the final 16% had permanently diminished function with aberrant innervation (expressed as motor synkinesis or autonomic dysfunction), and postparalytic spasms.</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-04-16 08:08:07 +0100" MODIFIED_BY="Ruth  Brassington">
<P>The treatment of Bell's palsy was highly controversial until 2008, at which time corticosteroids alone were shown to be effective in treating the condition (<LINK REF="REF-Salinas-2010" TYPE="REFERENCE">Salinas 2010</LINK>). Previous Cochrane reviews on the treatment of Bell&#8217;s palsy examined the effectiveness of oral prednisolone and aciclovir or valaciclovir (<LINK REF="REF-Allen--2004" TYPE="REFERENCE">Allen 2004</LINK>; <LINK REF="REF-Lockhart-2009" TYPE="REFERENCE">Lockhart 2009</LINK>). Several studies excluded from the analysis in these reviews either failed to randomise participants or, when correctly randomised, results were erroneously interpreted in a favourable light (<LINK REF="REF-May-1976" TYPE="REFERENCE">May 1976</LINK>
<U>; </U>
<LINK REF="REF-Wolf-1978" TYPE="REFERENCE">Wolf 1978</LINK>). High-dose corticosteroid therapy has several potential side effects, including peptic ulceration, hypertension, and confusional states. Antiviral therapy was considered expensive, and treatment was reserved for circumstances in which a clear benefit appeared likely.Previous recommendations suggested that antivirals needed to be started within 48 hours, although a study of viral replication in participants with Bell&#8217;s palsy suggests that the window might be extended (<LINK REF="REF-Abiko-2002" TYPE="REFERENCE">Abiko 2002</LINK>).</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2015-10-12 20:38:25 +0100" MODIFIED_BY="Ildiko Gagyor" NOTES="&lt;p&gt;U&lt;span modified=&quot;2015-09-15 17:33:00 +0100&quot; modified_by=&quot;Ruth  Brassington&quot; class=&quot;inserted&quot;&gt;nclear whether the lockhart review found a signfi&lt;/span&gt;&lt;span modified=&quot;2015-09-15 17:34:00 +0100&quot; modified_by=&quot;Ruth  Brassington&quot; class=&quot;inserted&quot;&gt; diff when adding av to corticosteroids. &lt;/span&gt;&lt;/p&gt;&lt;p&gt;You are right. There was one main analysis of all trial groups even which had a factorial design. This was the reason why we made more specified analyses. &lt;/p&gt;" NOTES_MODIFIED="2015-10-12 20:38:25 +0100" NOTES_MODIFIED_BY="Ildiko Gagyor">
<P>The 2009 update of this Cochrane review included large-scale randomised controlled trials (RCTs) of antivirals (A) and corticosteroids (S) that had been published in the years before the review. The authors stated that, compared to placebo, A did not contribute to a significant improvement in the rate or extent of recovery of trial participants (<LINK REF="REF-Lockhart-2009" TYPE="REFERENCE">Lockhart 2009</LINK>), but that when added to S, the rate of recovery was slightly better than S alone. The current review updates these findings based on three additional studies. An update of the review published earlier this year (most recently as <LINK REF="REF-Gagyor-2015b" TYPE="REFERENCE">Gagyor 2015b</LINK>) also included <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1506161411540953244104488116595&amp;format=REVMAN#STD-Abdelghany-2013">Abdelghany 2013</A>, a trial currently undergoing investigation for potential data unreliability. We requested withdrawal of that version of the review and here republish our analyses having removed the data from that trial pending the outcome of the investigation.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-04-16 07:42:00 +0100" MODIFIED_BY="Ruth  Brassington">
<P>To assess the effects of antiviral treatments alone or in combination with any other therapy for Bell&#8217;s palsy. </P>
</OBJECTIVES>
<METHODS MODIFIED="2015-10-12 12:08:53 +0100" MODIFIED_BY="Ruth  Brassington">
<SELECTION_CRITERIA MODIFIED="2015-05-20 21:46:42 +0100" MODIFIED_BY="Ildiko Gagyor">
<CRIT_STUDIES MODIFIED="2015-04-16 07:42:11 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We searched for all randomised controlled trials (RCTs) or quasi-RCTs (which are trials that employ alternate or other systematic allocation) involving aciclovir, valaciclovir, or famciclovir alone or in combination with any other therapy in the treatment of Bell's palsy, published in any language. The duration of studies included in this review ranges from 3 to 12 months; the minimum study duration was 3 months. As in previous versions of the review, we used study quality as an exclusion criterion, excluding trials with a high risk of bias in several domains.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-03-25 09:07:03 +0000" MODIFIED_BY="Ruth  Brassington">
<P>We considered all trials where participants had a diagnosis of unilateral facial paralysis of unknown cause and satisfied the trial authors&#8217; requirements for eligibility and inclusion.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-04-09 15:26:54 +0100" MODIFIED_BY="Ruth Brassington">
<P>We considered all trials of treatment with any oral antiviral licensed for the treatment of herpes simplex infections in immunocompetent participants. The list comprised aciclovir; valaciclovir, which is a prodrug of aciclovir; and famciclovir, which is a prodrug of penciclovir. We considered trials where participants received antiviral therapy versus placebo or any other treatment.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-05-20 21:46:42 +0100" MODIFIED_BY="Ildiko Gagyor">
<P>We have described changes to outcome measures in this and previous versions of the review in <LINK TAG="PRO_REV_DIFF" TYPE="SECTION">Differences between protocol and review</LINK>.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-05-11 16:50:36 +0100" MODIFIED_BY="Ruth Brassington">
<P>Incomplete recovery of facial function at the end of study measured using a validated rating scale.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-05-20 21:46:42 +0100" MODIFIED_BY="Ildiko Gagyor">
<OL>
<LI>Motor synkinesis or crocodile tears at the end of the study. </LI>
<LI>Adverse events.</LI>
<LI>Incomplete recovery at month six in severe cases.</LI>
</OL>
<P>Some trials have reported other symptoms (pain, discomfort, and embarrassment) as outcomes, but we did not consider them in this review.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-04-16 07:42:17 +0100" MODIFIED_BY="Ruth  Brassington">
<ELECTRONIC_SEARCHES MODIFIED="2015-04-16 07:42:17 +0100" MODIFIED_BY="Ruth  Brassington">
<P>On 7 October 2014, we searched the Cochrane Neuromuscular Disease Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL; 2014, Issue 9), MEDLINE (January 1966 to September 2014), EMBASE (January 1980 to September 2014), and LILACS (January 1982 to September 2014). On the same date we also searched the National Institute for Health Research Database of Abstracts and Reviews of Effects (DARE), Health Technology Assessment (HTA) database, and the National Health Service Economic Evaluation Database (NHS EED). We searched for registered trials in ClinicalTrials.gov (<A HREF="http://www.ClinicalTrials.gov">www.clinicaltrials.gov</A>) and in the World Health Organization International Clinical Trials Registry Platform (<A HREF="http://www.who.int/ictrp/en/">www.who.int/ictrp/en/</A>).</P>
<P>We have provided detailed search strategies in the appendices: Cochrane Neuromuscular Disease Group Specialized Register (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), CENTRAL (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), MEDLINE (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>), EMBASE (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>), and LILACS (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-03-30 22:33:51 +0100" MODIFIED_BY="Ruth Brassington">
<P>We also reviewed the bibliographies of the identified trials and contacted trial authors and known experts in the field and relevant drug companies to identify additional published or unpublished data.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-10-12 12:08:53 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Since a significant benefit of S for the early management of Bell&#8217;s palsy has been previously demonstrated (<LINK REF="REF-Lockhart-2009" TYPE="REFERENCE">Lockhart 2009</LINK>; <LINK REF="REF-Salinas-2010" TYPE="REFERENCE">Salinas 2010</LINK>), the main focus of this review was to determine the effect of A in combination with S.</P>
<P>Throughout we utilised the following notation:</P>
<UL>
<LI>AO: antiviral treatment alone or in combination with placebo</LI>
<LI>AS: antiviral treatment in combination with corticosteroids</LI>
<LI>OO: placebo or no treatment only</LI>
<LI>OS: corticosteroid treatment alone or in combination with placebo</LI>
</UL>
<P>Using these notations we conducted four comparisons altogether:</P>
<UL>
<LI>AS versus OS</LI>
<LI>AO versus OO</LI>
<LI>AO versus OS</LI>
<LI>AS versus OO</LI>
</UL>
<P>For an overall comparison of treatment with and without A we used the following notations:</P>
<UL>
<LI>A: antiviral treatment in any combination (i.e. AO or AS);</LI>
<LI>not-A: treatment not including antiviral treatment (i.e. OS or OO).</LI>
</UL>
<STUDY_SELECTION MODIFIED="2015-03-30 22:34:32 +0100" MODIFIED_BY="Ruth Brassington">
<P>Six review authors working in pairs (FG and VM, DS and MS, IG and FS) scrutinised titles and abstracts to determine eligibility for review of the full-text article. At least two review authors independently assessed each full-text paper for relevance, eligibility, and quality. We had no disagreements about inclusion. Two review authors independently analysed each full-text report and selected studies for inclusion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-04-16 07:42:18 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Two review authors extracted data onto a data extraction form and double-checked data extraction in pairs. Two review authors (IG and VM) agreed data input into the Cochrane authoring and statistical software, Review Manager 5 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). Any disagreements were discussed with FD to reach a resolution. We arranged translation of any papers where necessary.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-04-09 15:38:46 +0100" MODIFIED_BY="Ruth Brassington">
<P>Two review authors (IG and VM) independently assessed the risk of bias in included studies using the 'Risk of bias' methodology described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). FD reviewed the 'Risk of bias' assessments. The review authors considered methods of randomisation and allocation concealment, blinding (of treatment administrator, participants, and outcome assessors), selective outcome reporting (for example failure to report adverse events), and incomplete outcome data (that is dropouts). We assessed each trial as at high, low, or unclear risk of bias for each of these criteria.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-04-16 07:42:20 +0100" MODIFIED_BY="Ruth  Brassington">
<P>All our outcomes were dichotomous. We analysed the data as risk ratios (RRs) with corresponding 95% confidence interval (CI).</P>
<P>When comparing studies that used differing symptom scores to assess outcome, we used the House-Brackmann scale when available, as this was used most widely and could be compared with other scales.</P>
<P>When assessing adverse events, we used the number of participants affected as opposed to the number of events, to facilitate data comparison.</P>
<SUBSECTION>
<HEADING LEVEL="3">'Summary of findings' table</HEADING>
<P>We created a 'Summary of findings' table for the comparison 'Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment' using the following outcomes.</P>
<OL>
<LI>Incomplete recovery at the end of the study (House-Brackmann scale)</LI>
<LI>Motor synkinesis or crocodile tears at the end of the study (House-Brackmann scale)</LI>
<LI>Adverse events</LI>
</OL>
<P>We used the five GRADE considerations (risk of bias, inconsistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence (studies that contribute data for the prespecified outcomes). We employed methods and recommendations described in Section 8.5 and Chapter 12 of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) using GRADEpro software (<LINK REF="REF-GRADEpro-2008" TYPE="REFERENCE">GRADEpro 2008</LINK>). We justified all decisions to down- or upgrade the quality of studies using footnotes.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-10-12 12:08:38 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Each of the included studies carried out randomisation at the participant level. Nine trials used a simple parallel-group design (<A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-Adour-1996">Adour 1996</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-Li--1997">Li 1997</A>; <LINK REF="STD-De-Diego-1998" TYPE="STUDY">De Diego 1998</LINK>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-Hato-2007">Hato 2007</A>
<U>;</U> <LINK REF="STD-Kawaguchi-2007" TYPE="STUDY">Kawaguchi 2007</LINK>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-V_x00e1_zquez-2008">Vázquez 2008</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-Yeo-2008">Yeo 2008</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-Lee-2013">Lee 2013</A>) and two trials used a factorial design (<LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>; <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>).</P>
<P>For studies with a factorial design, we aggregated groups according to whether or not antivirals were administered. We described details in the <LINK TAG="RESULTS" TYPE="SECTION">Results</LINK>.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-04-09 15:39:29 +0100" MODIFIED_BY="Ruth Brassington">
<P>We contacted authors of two studies (Kawaguchi and Engström) for additional data that were required for analysis but which were not provided in their papers, and one (Engström) responded with data. We contacted a previous review author (Lockhart) for information on other studies and we received a response. We used the <LINK REF="STD-Kawaguchi-2007" TYPE="STUDY">Kawaguchi 2007</LINK> data provided in previous versions of this review.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-12-19 16:46:41 +0000" MODIFIED_BY="Ruth  Brassington">
<P>We used the I<SUP>2 </SUP>statistic to assess heterogeneity among the included studies in each analysis. If we found substantial unexplained heterogeneity, we reported it and explored possible causes.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-01-06 17:11:36 +0000" MODIFIED_BY="Ruth  Brassington">
<P>As a result of the small number of included trials, we were not able to produce meaningful funnel plots to assess the likelihood of publication bias (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-04-09 15:39:36 +0100" MODIFIED_BY="Ruth Brassington">
<P>We calculated a treatment effect using the Mantel-Haenszel method (<LINK REF="REF-Egger-2007" TYPE="REFERENCE">Egger 2007</LINK>). We used the random-effects model where we found marked heterogeneity (I<SUP>2 </SUP>greater than 40%) between studies. If we had found little or no heterogeneity, we would have used a fixed-effect analysis. The main outcome in all trials was complete recovery. For this review, the review authors calculated the number of participants with incomplete recovery by subtracting the number of participants with complete recovery from the number of participants in the reference group.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-10-12 12:08:53 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We calculated a subgroup analysis for incomplete recovery of people with severe Bell&#8217;s palsy at baseline using data from four trials (<LINK REF="STD-Hato-2007" TYPE="STUDY">Hato 2007</LINK>; <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>; <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>; <LINK REF="STD-Lee-2013" TYPE="STUDY">Lee 2013</LINK>). Severe Bell&#8217;s palsy was defined as severe to complete facial paralysis, graded as equal to or greater than V in the House-Brackmann grading system (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>), equal to or less than 20 in the Sunnybrook score (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>), and equal to or less than 20 in the Yanagihara score (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-03-30 22:38:31 +0100" MODIFIED_BY="Ruth Brassington">
<P>We used sensitivity analyses to assess the effects of combining trials with and without additional treatments in an analysis of A versus S and to assess the impact of length of follow-up on the results of the meta-analysis. We performed sensitivity analyses to assess the potential difference in participant response to aciclovir versus valaciclovir and further sensitivity analyses to investigate whether the exclusion of trials not meeting current best standards (that is those that had a high or unclear risk of bias in more than five categories or trials with less than 200 participants) would influence the results. An analysis investigated whether our conclusions were altered when we excluded the study with a follow-up of less than six months (<LINK REF="STD-Adour-1996" TYPE="STUDY">Adour 1996</LINK>). Furthermore, in the analysis of AS versus OS in severe cases, we performed a sensitivity analysis to assess differences between trials in which only a subgroup of participants had severe Bell&#8217;s palsy versus the trials where almost all participants had severe Bell&#8217;s palsy.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-10-15 10:23:38 +0100" MODIFIED_BY="Ruth  Brassington" NOTES="&lt;p&gt;The number of papers found by the new, current strategies which were run on 7 October 2014 are:&lt;/p&gt;&lt;p&gt;MEDLINE - 375&lt;/p&gt;&lt;p&gt;EMBASE - 102&lt;/p&gt;&lt;p&gt;LILACS - 4&lt;/p&gt;&lt;p&gt;Cochrane Neuromuscular Disease Group Specialized Register &amp;#160;- 28&lt;/p&gt;&lt;p&gt;CENTRAL - 39&lt;/p&gt;&lt;p&gt;The NMD Group is now following the Cochrane policy of giving the total number of references found by each database, the number of references after deduplication, the number of references selected for further review and the number meeting the inclusion criteria for the review.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;The following Databases are included in the Cochrane Library. You may wish to use the results in the discussion section&lt;/p&gt;&lt;p&gt;NHSEED (NHDS Economic Evaluation Database) - 1 papers&lt;/p&gt;&lt;p&gt;HTA (Health Technology Assessment Database) - 1 paper&lt;/p&gt;&lt;p&gt;DARE (Database of Abstracts of Reviews of Effectiveness) - 8 papers&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-10-15 10:23:38 +0100" NOTES_MODIFIED_BY="Ruth  Brassington">
<STUDY_DESCRIPTION MODIFIED="2015-10-15 09:20:56 +0100" MODIFIED_BY="Ruth  Brassington">
<SEARCH_RESULTS MODIFIED="2015-09-15 16:26:57 +0100" MODIFIED_BY="Ruth  Brassington">
<P>For this review, we found 375 references in MEDLINE, 102 in EMBASE, 4 in LILACS, 28 in the Cochrane Neuromuscular Disease Group Specialized Register, and 39 in CENTRAL. We also found 12 additional trials in the Database of Abstracts of Reviews of Effects (DARE), one in the Health Technology Assessments (HTA), one in the Economic Evaluation Database (EED) and two by hand searching. We found two ongoing studies in the World Health Organization International Clinical Trials Registry Platform (<LINK REF="STD-IRCT201109187575N1" TYPE="STUDY">IRCT201109187575N1</LINK>; <LINK REF="STD-IRCT2012062210087N1" TYPE="STUDY">IRCT2012062210087N1</LINK>). See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for a flow chart of the study selection process.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-10-15 09:20:56 +0100" MODIFIED_BY="Ruth  Brassington" NOTES="&lt;p&gt;&lt;span modified=&quot;2015-09-15 17:37:00 +0100&quot; modified_by=&quot;Ruth  Brassington&quot; class=&quot;inserted&quot;&gt;Were Li and Vasquez identified via the search through references? Woudl be useful to say as otherwise readers might wonder why they were not previously included.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2015-09-15 17:37:00 +0100&quot; modified_by=&quot;Ruth  Brassington&quot; class=&quot;inserted&quot;&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Lee and Vazquez was found by your search, Li by me as stated in the paper now. I have no idea why Vazquez wasn't included in the previous update.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-10-15 09:20:56 +0100" NOTES_MODIFIED_BY="Ruth  Brassington">
<P>We added three RCTs with 293 participants in total to the previous version of this review, which had seven trials and 1987 participants. The newly added trials were <LINK REF="STD-Lee-2013" TYPE="STUDY">Lee 2013</LINK>, <LINK REF="STD-Li--1997" TYPE="STUDY">Li 1997</LINK>, and <LINK REF="STD-V_x00e1_zquez-2008" TYPE="STUDY">Vázquez 2008</LINK>. Two of these were published after the search in the 2009 review (<LINK REF="STD-Lee-2013" TYPE="STUDY">Lee 2013</LINK>; <LINK REF="STD-V_x00e1_zquez-2008" TYPE="STUDY">Vázquez 2008</LINK>), and we identified <LINK REF="STD-Li--1997" TYPE="STUDY">Li 1997</LINK> via a Google search that was additional to our prespecified searches.</P>
<P>The 10 studies in the current review included 2280 participants (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
<P>
<LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK> recruited 829 participants who were treated within 72 hours of onset and randomised by a computerised mechanism in a two-stage process into four treatment groups: valaciclovir with prednisolone or valaciclovir with placebo or placebo with prednisolone or double placebo in a factorial design. The trial was double blind (administrator and participant) for assessment of recovery status until the end of follow-up. Participants were assessed at onset, after 2 weeks (11 to 17 days), and after 1, 2, 3, 6, and 12 months. Disease status was measured using the House-Brackmann grading system and the Sunnybrook scale. Complete recovery status was defined by a Sunnybrook score of 100 and a House-Brackmann grade of 1. Time to recovery was estimated. Data analysis included an assessment of treatment interaction.</P>
<P>For this review, we aggregated groups and analysed AS plus AO versus OS plus OO as A versus not-A in order to achieve the most powerful comparison for the effect of treatment with valaciclovir on recovery rates at 12 months. We analysed the recovery rates 12 months after the onset of facial palsy using the Sunnybrook definition and defined complete recovery as a House-Brackmann grade of I.</P>
<P>
<LINK REF="STD-Hato-2007" TYPE="STUDY">Hato 2007</LINK> randomised 296 participants within seven days of onset using sealed envelopes into two treatment groups: valaciclovir with prednisolone or placebo with prednisolone, to provide a comparison AS versus OS. The final analysis included 221 participants. Administrators were not blinded to the treatment allocation, but participants were blinded to treatment received. Those assessing recovery status were not blinded to treatment. Participants&#8217; disease severity was assessed using the Yanagihara 40-point scoring system; participants were considered completely recovered if attaining a score greater than 36. Participants were assessed at onset and monthly thereafter for six months or until completely recovered if recovery occurred before six months.</P>
<P>
<LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK> recruited 551 participants who were treated within 72 hours of onset and randomised by a dedicated remote telephone-computerised mechanism in a two-stage process into four treatment groups: aciclovir with prednisolone or aciclovir with placebo or placebo with prednisolone or double placebo in a factorial design. The trial was blinded for administrator, participant, and assessment of recovery status until the end of follow-up. Participants were assessed at onset, after three months, and if still unwell at three months, after nine months. Recovery status was measured using the House-Brackmann scale, with complete recovery defined by House-Brackmann grade I. Data analysis included an assessment of treatment interaction. <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK> reported final outcomes on 496 completed participants at three months and nine months in treatment groups that were aggregated as for Engstrom.</P>
<P>
<LINK REF="STD-Yeo-2008" TYPE="STUDY">Yeo 2008</LINK> recruited 91 participants who were randomised to receive either aciclovir and prednisolone or prednisolone alone, to provide a comparison AS versus OS. Participants also received physical therapy and plasma volume expanders as adjuncts. The trial was double blind and investigators followed up participants for six months or until complete recovery. Recovery was assessed using the House-Brackmann scale and defined as a House-Brackmann score of II or less.</P>
<P>
<LINK REF="STD-Li--1997" TYPE="STUDY">Li 1997</LINK> recruited 51 participants within four days of onset of Bell's palsy. Participants were randomly assigned into two groups, receiving either aciclovir plus prednisolone or prednisolone. Good recovery was defined as a House-Brackmann score of II or I at month six. Li 1997 reported outcomes for 46 participants; five were lost to follow-up.</P>
<P>
<LINK REF="STD-Lee-2013" TYPE="STUDY">Lee 2013</LINK> was a RCT in participants with severe to complete Bell&#8217;s palsy that used the House-Brackmann score for assessment. The trial included 201 participants with a score of V or more. After randomisation into two groups, participants received either famciclovir plus prednisolone simultaneously or prednisolone alone. Recovery rate was designated as scores of I or II on the House-Brackmann scale at month six.</P>
<P>
<LINK REF="STD-V_x00e1_zquez-2008" TYPE="STUDY">Vázquez 2008</LINK> included 42 participants and reported outcomes at 6 and 12 months using the Sunnybrook Facial Grading System. Scores of greater than 90 were defined as a satisfactory recovery. Participants in the intervention group were treated with prednisone and valaciclovir and in the control group with prednisone and placebo. The main study outcome was rate of participants with total recovery at six months&#8217; follow-up in each group and average time to recovery in each group.</P>
<P>
<LINK REF="STD-Adour-1996" TYPE="STUDY">Adour 1996</LINK> recruited 119 participants, of whom 99 were included in the published analysis. The study was double blind and placebo controlled. Participants were recruited within three or days or less of onset of paralysis and received either aciclovir and prednisolone or placebo and prednisolone. The study duration was four months; participants were reviewed at two weeks, two months, and four months. This was a single-centre study. The Facial Paralysis Recovery Index (FPRI) was used to measure facial function; the primary trial outcome was incomplete recovery defined by a FPRI of 7 or less.</P>
<P>
<LINK REF="STD-De-Diego-1998" TYPE="STUDY">De Diego 1998</LINK> recruited 113 participants, including 101 in the final analysis. Participants were randomly assigned to treatment. Baseline assessment was carried out within 48 hours of onset of symptoms. Participants received either aciclovir for 10 days or prednisolone for 16 days (reducing dose). Reviews were scheduled for 1, 3, 6, and 12 weeks after initial contact, with further contact if persistent incomplete recovery was noted. The primary study outcome was recovery as defined by a House-Brackmann score of II or less or a Facial Paralysis Recovery Profile of 8 or more. The report did not give the final length of follow-up but stated that it continued "until complete recovery or stabilization of the paralysis".</P>
<P>
<LINK REF="STD-Kawaguchi-2007" TYPE="STUDY">Kawaguchi 2007</LINK> recruited 150 participants who were treated within seven days of onset and randomised using sealed envelopes into two treatment groups: valaciclovir plus prednisolone or prednisolone alone. There was inadequate blinding of the clinician. Kawaguchi et al. provided unpublished data on incomplete recovery for the previous update. Participants were assessed at 1, 2, 3, 4, 5, and 6 months after inclusion using the Yanagihara scale. We could not contact the authors to obtain data for this review, but we have included the data previously published in this review.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-10-12 20:48:47 +0100" MODIFIED_BY="Ildiko Gagyor">
<P>Authors of the previous version of this review excluded <LINK REF="STD-Antunes-2000" TYPE="STUDY">Antunes 2000</LINK> because of incomplete data in 44 participants. Despite our attempts to contact the authors, there was still insufficient information for the data to be usefully included in the analyses.</P>
<P>The authors of a previous version of this review reassessed the inclusion of the two studies that were awaiting assessment (<LINK REF="STD-de-Aquino-2001" TYPE="STUDY">de Aquino 2001</LINK>; <LINK REF="STD-Roy-2005" TYPE="STUDY">Roy 2005</LINK>). Dr. D. Allen, the author of a previous version of this review, attempted to contact the lead author of the former paper for clarification of the data, but this was not forthcoming and so we have excluded this trial because of a lack of adequate information. The latter study recruited 82 participants, of whom 18 dropped out, and compared aciclovir plus methylprednisolone to methylprednisolone alone, reporting no benefit from the addition of aciclovir. The authors did not provide outcome data in the abstract, which appeared in a journal supplement, and according to the search strategies employed, the trial has not been published as a full paper to date. We excluded this trial due to a lack of adequate information.</P>
<P>A further study was classified as awaiting assessment in the previous version of this review (<LINK REF="STD-Inanli-2001" TYPE="STUDY">Inanli 2001</LINK>). This paper was included in a systematic review and a meta-analysis (<LINK REF="REF-de-Almeida-2009" TYPE="REFERENCE">de Almeida 2009</LINK>; <LINK REF="REF-Goudakos-2009" TYPE="REFERENCE">Goudakos 2009</LINK>). We excluded the paper from the current review because we could not find it in print or electronic form. See <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<P>Overall, we excluded five studies for not being RCTs (<LINK REF="STD-Ibarrondo-1999" TYPE="STUDY">Ibarrondo 1999</LINK>; <LINK REF="STD-Axelsson-2003" TYPE="STUDY">Axelsson 2003</LINK>; <LINK REF="STD-Hato-2003" TYPE="STUDY">Hato 2003</LINK>; <LINK REF="STD-Hultcrantz-2005" TYPE="STUDY">Hultcrantz 2005</LINK>; <LINK REF="STD-Ahangar-2006" TYPE="STUDY">Ahangar 2006</LINK>); two for having a very short follow-up (<LINK REF="STD-Zhou-1999" TYPE="STUDY">Zhou 1999</LINK>; <LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK>); three because reports provided insufficient information to assess methods or outcomes (<LINK REF="STD-Antunes-2000" TYPE="STUDY">Antunes 2000</LINK>; <LINK REF="STD-de-Aquino-2001" TYPE="STUDY">de Aquino 2001</LINK>; <LINK REF="STD-Roy-2005" TYPE="STUDY">Roy 2005</LINK>); four because of high risk of bias in several domains: <LINK REF="STD-Minnerop-2008" TYPE="STUDY">Minnerop 2008</LINK> (inadequate randomisation, unblinded, 50 of 167 participants lost to follow-up), <LINK REF="STD-Ramos-Macias-1992" TYPE="STUDY">Ramos Macias 1992</LINK> (only abstract available, 15 of 45 participants had Ramsay Hunt syndrome and were given intravenous therapy), <LINK REF="STD-Roy-2005" TYPE="STUDY">Roy 2005</LINK> (lack of outcome data, as described above), <LINK REF="STD-Shahidullah-2011" TYPE="STUDY">Shahidullah 2011</LINK> (inadequate randomisation, unblinded, 39 of 107 participants lost to follow-up); and one paper was not available (<LINK REF="STD-Inanli-2001" TYPE="STUDY">Inanli 2001</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Ongoing studies</HEADING>
<P>We identified two trial reports in a search of ClinicalTrials.gov just prior to completion of the review. The current status of these trials is unknown; we will assess them fully in a future update of the review. See <LINK TAG="ONGOING_STUDIES" TYPE="SECTION">Ongoing studies</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Studies awaiting classification</HEADING>
<P>
<LINK REF="STD-Abdelghany-2013" TYPE="STUDY">Abdelghany 2013</LINK> is awaiting classification pending the results of an investigation into the reliability of the trial data.</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-10-15 09:21:00 +0100" MODIFIED_BY="Ruth  Brassington">
<P>We have summarised our 'Risk of bias' assessments in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<ALLOCATION MODIFIED="2015-10-15 09:20:58 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Three studies were at low risk of selection bias, being adequately randomised with allocation concealment (<LINK REF="STD-Adour-1996" TYPE="STUDY">Adour 1996</LINK>; <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>; <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>). Two other studies were at low risk of bias from randomisation but at high risk of bias from inadequate allocation concealment (<LINK REF="STD-Kawaguchi-2007" TYPE="STUDY">Kawaguchi 2007</LINK>; <LINK REF="STD-Lee-2013" TYPE="STUDY">Lee 2013</LINK>). In the remaining studies, the risk of bias from the method of randomisation was unclear, and the risk of bias for allocation concealment was either unclear, in <LINK REF="STD-Li--1997" TYPE="STUDY">Li 1997</LINK>, <LINK REF="STD-Hato-2007" TYPE="STUDY">Hato 2007</LINK>, <LINK REF="STD-V_x00e1_zquez-2008" TYPE="STUDY">Vázquez 2008</LINK>, and <LINK REF="STD-Yeo-2008" TYPE="STUDY">Yeo 2008</LINK>, or high, in <LINK REF="STD-De-Diego-1998" TYPE="STUDY">De Diego 1998</LINK>.</P>
</ALLOCATION>
<BLINDING MODIFIED="2015-10-12 12:46:48 +0100" MODIFIED_BY="Ruth  Brassington">
<P>
<LINK REF="STD-Adour-1996" TYPE="STUDY">Adour 1996</LINK>, <LINK REF="STD-Li--1997" TYPE="STUDY">Li 1997</LINK>, <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>, <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>, and <LINK REF="STD-V_x00e1_zquez-2008" TYPE="STUDY">Vázquez 2008</LINK> were described as double blind and placebo controlled. <LINK REF="STD-Lee-2013" TYPE="STUDY">Lee 2013</LINK> did not use a placebo to ensure blinding. <LINK REF="STD-De-Diego-1998" TYPE="STUDY">De Diego 1998</LINK>, <LINK REF="STD-Hato-2007" TYPE="STUDY">Hato 2007</LINK>, and <LINK REF="STD-Kawaguchi-2007" TYPE="STUDY">Kawaguchi 2007</LINK> did not describe blinding or placebo use. The <LINK REF="STD-Yeo-2008" TYPE="STUDY">Yeo 2008</LINK> report stated that the study was double blind, however, the text does not describe this, so we assessed the risk of bias for blinding as unclear.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-10-12 12:10:24 +0100" MODIFIED_BY="Ruth  Brassington">
<P>All studies except <LINK REF="STD-Yeo-2008" TYPE="STUDY">Yeo 2008</LINK> reported frequencies, and often reasons, for failure to complete follow-up.</P>
<P>Most trials reported a dropout rate of 10% or less (<LINK REF="STD-Li--1997" TYPE="STUDY">Li 1997</LINK>; <LINK REF="STD-De-Diego-1998" TYPE="STUDY">De Diego 1998</LINK>; <LINK REF="STD-Kawaguchi-2007" TYPE="STUDY">Kawaguchi 2007</LINK>; <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>; <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>; <LINK REF="STD-V_x00e1_zquez-2008" TYPE="STUDY">Vázquez 2008</LINK>; <LINK REF="STD-Yeo-2008" TYPE="STUDY">Yeo 2008</LINK>). Exceptions were <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-Lee-2013">Lee 2013</A> with a dropout rate of 13.1%, <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-Adour-1996">Adour 1996</A> with a dropout rate of 17%, and <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-Hato-2007">Hato 2007</A> with a dropout rate of 25%.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2015-10-12 20:49:14 +0100" MODIFIED_BY="Ildiko Gagyor">
<P>All studies except <LINK REF="STD-Adour-1996" TYPE="STUDY">Adour 1996</LINK> and <LINK REF="STD-Kawaguchi-2007" TYPE="STUDY">Kawaguchi 2007</LINK> reported all their intended primary outcomes. <LINK REF="STD-Adour-1996" TYPE="STUDY">Adour 1996</LINK> failed to report on audiometry and stapedial reflex testing. <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK> reported all primary outcomes; secondary outcomes were reported in later published papers (<LINK REF="REF-Axelsson-2012" TYPE="REFERENCE">Axelsson 2012</LINK>; <LINK REF="REF-Berg-2012" TYPE="REFERENCE">Berg 2012</LINK>).</P>
<P>Five studies did not report adverse events (<LINK REF="STD-Li--1997" TYPE="STUDY">Li 1997</LINK>; <LINK REF="STD-De-Diego-1998" TYPE="STUDY">De Diego 1998</LINK>; <LINK REF="STD-Kawaguchi-2007" TYPE="STUDY">Kawaguchi 2007</LINK>; <LINK REF="STD-Yeo-2008" TYPE="STUDY">Yeo 2008</LINK>; <LINK REF="STD-Lee-2013" TYPE="STUDY">Lee 2013</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2015-10-15 09:21:00 +0100" MODIFIED_BY="Ruth  Brassington">
<SUBSECTION>
<HEADING LEVEL="4">Diagnostic criteria</HEADING>
<P>Nine studies gave adequate information (<LINK REF="STD-Li--1997" TYPE="STUDY">Li 1997</LINK>; <LINK REF="STD-De-Diego-1998" TYPE="STUDY">De Diego 1998</LINK>; <LINK REF="STD-Hato-2007" TYPE="STUDY">Hato 2007</LINK>; <LINK REF="STD-Kawaguchi-2007" TYPE="STUDY">Kawaguchi 2007</LINK>; <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>; <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>; <LINK REF="STD-V_x00e1_zquez-2008" TYPE="STUDY">Vázquez 2008</LINK>; <LINK REF="STD-Yeo-2008" TYPE="STUDY">Yeo 2008</LINK>; <LINK REF="STD-Lee-2013" TYPE="STUDY">Lee 2013</LINK>). All studies explicitly mentioned a diagnosis of Bell's palsy and stated that they had considered and excluded other causes of facial palsy. Two trials, <LINK REF="STD-Hato-2007" TYPE="STUDY">Hato 2007</LINK> and <LINK REF="STD-Kawaguchi-2007" TYPE="STUDY">Kawaguchi 2007</LINK>, retrospectively excluded participants on the basis of positive serology for herpes simplex or varicella zoster viruses. <LINK REF="STD-Lee-2013" TYPE="STUDY">Lee 2013</LINK> excluded participants who did not fulfil inclusion criteria, without specifying the reasons. Two studies mentioned referral to specialists for diagnostic confirmation (<LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>; <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>). The remaining study, <LINK REF="STD-Adour-1996" TYPE="STUDY">Adour 1996</LINK>, stated participants were diagnosed with Bell's palsy but did not give any further information.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome criteria</HEADING>
<P>All studies used referenced facial function scoring systems to grade recovery from facial paralysis. <LINK REF="STD-Adour-1996" TYPE="STUDY">Adour 1996</LINK> and <LINK REF="STD-De-Diego-1998" TYPE="STUDY">De Diego 1998</LINK> used the Facial Paralysis Recovery Profile and <LINK REF="STD-Adour-1996" TYPE="STUDY">Adour 1996</LINK> also used the Facial Paralysis Recovery Index. <LINK REF="STD-Hato-2007" TYPE="STUDY">Hato 2007</LINK> and <LINK REF="STD-Kawaguchi-2007" TYPE="STUDY">Kawaguchi 2007</LINK> used the Yanagihara scoring system (<LINK REF="REF-Yanagihara-2003" TYPE="REFERENCE">Yanagihara 2003</LINK>), which has a validated system for conversion to the House-Brackmann scale (<LINK REF="REF-House-1985" TYPE="REFERENCE">House 1985</LINK>). <LINK REF="STD-Li--1997" TYPE="STUDY">Li 1997</LINK>, <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>, <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>, <LINK REF="STD-Yeo-2008" TYPE="STUDY">Yeo 2008</LINK>, and <LINK REF="STD-Lee-2013" TYPE="STUDY">Lee 2013</LINK> presented results using the House-Brackmann scale (<LINK REF="REF-House-1985" TYPE="REFERENCE">House 1985</LINK>). <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK> supplemented this with use of the Sunnybrook scale to minimise the effects of interrater variability (<LINK REF="REF-Ross-1996" TYPE="REFERENCE">Ross 1996</LINK>). <LINK REF="STD-V_x00e1_zquez-2008" TYPE="STUDY">Vázquez 2008</LINK> used a facial grading scale related to Sunnybrook (<LINK REF="REF-Ross-1996" TYPE="REFERENCE">Ross 1996</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Statistical analysis</HEADING>
<P>Nine of the 10 studies analysed gave adequate detail; they clearly stated and then used appropriate statistical tests. Only <LINK REF="STD-Hato-2007" TYPE="STUDY">Hato 2007</LINK> scored 'unclear' in this category, as it did not state the tests used.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Baseline differences between groups</HEADING>
<P>Eight of the 10 trials were adequate in this category. <LINK REF="STD-De-Diego-1998" TYPE="STUDY">De Diego 1998</LINK> found a significant difference in rates of hypertension between the two groups, but further analysis revealed that there was no significant difference in trial outcomes as a result. <LINK REF="STD-Kawaguchi-2007" TYPE="STUDY">Kawaguchi 2007</LINK> reported a significant difference between mean ages of the treatment groups, but further analysis of the age distribution using Chi<SUP>2</SUP> test revealed no significant difference. <LINK REF="STD-Lee-2013" TYPE="STUDY">Lee 2013</LINK> reported a later onset of the treatment in the combination treatment without significance.</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-10-15 10:23:38 +0100" MODIFIED_BY="Ruth  Brassington">
<P>As the included trials reported different intervals and lengths of follow-up, we performed the analyses on data reported at three months (<LINK REF="STD-De-Diego-1998" TYPE="STUDY">De Diego 1998</LINK>), six months (<LINK REF="STD-Li--1997" TYPE="STUDY">Li 1997</LINK>; <LINK REF="STD-Hato-2007" TYPE="STUDY">Hato 2007</LINK>; <LINK REF="STD-Kawaguchi-2007" TYPE="STUDY">Kawaguchi 2007</LINK>; <LINK REF="STD-V_x00e1_zquez-2008" TYPE="STUDY">Vázquez 2008</LINK>; <LINK REF="STD-Yeo-2008" TYPE="STUDY">Yeo 2008</LINK>; <LINK REF="STD-Lee-2013" TYPE="STUDY">Lee 2013</LINK>), nine months (<LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>), or 12 months (<LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>) after the start of treatment.</P>
<P>For the subgroup analysis of incomplete recovery in participants with severe Bell&#8217;s palsy at onset, we either extracted data at month six, in <LINK REF="STD-Hato-2007" TYPE="STUDY">Hato 2007</LINK> and <LINK REF="STD-Lee-2013" TYPE="STUDY">Lee 2013</LINK>, or imputed data to month six, in <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK> and <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Incomplete recovery</HEADING>
<P>This comparison contained eight studies with 1315 participants in total (<LINK REF="STD-Adour-1996" TYPE="STUDY">Adour 1996</LINK>; <LINK REF="STD-Li--1997" TYPE="STUDY">Li 1997</LINK>; <LINK REF="STD-Hato-2007" TYPE="STUDY">Hato 2007</LINK>; <LINK REF="STD-Kawaguchi-2007" TYPE="STUDY">Kawaguchi 2007</LINK>; <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>; <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>; <LINK REF="STD-V_x00e1_zquez-2008" TYPE="STUDY">Vázquez 2008</LINK>; <LINK REF="STD-Yeo-2008" TYPE="STUDY">Yeo 2008</LINK>). We excluded <LINK REF="STD-Lee-2013" TYPE="STUDY">Lee 2013</LINK> from this analysis due to its selected participants (severe cases only).</P>
<P>The risk ratio (RR) of incomplete recovery at the end of the study showed a statistically significant difference between AS and OS treatments, favouring AS over OS. The RR of incomplete recovery was 0.68 (95% confidence interval (CI) 0.52 to 0.89). Heterogeneity was substantial when we used the fixed-effect model (Chi<SUP>2 </SUP>= 13.19, df = 7 (P value = 0.007), I<SUP>2</SUP> = 47%); we used the random-effects model to partially correct for this (RR 0.61, 95% CI 0.39 to 0.97) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>, <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Motor synkinesis or crocodile tears</HEADING>
<P>
<LINK REF="STD-Adour-1996" TYPE="STUDY">Adour 1996</LINK> and <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK> provided data for the outcome motor synkinesis or crocodile tears at the end of the study (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). The analysis included 469 participants and showed a significant difference between AS and OS (RR 0.56, 95% CI 0.36 to 0.87).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<P>Adverse events were not significantly less likely in AS versus OS (RR 1.18, 95% CI 0.83 to 1.69). This analysis included data from 877 participants in three studies (<LINK REF="STD-Hato-2007" TYPE="STUDY">Hato 2007</LINK>; <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>; <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Antivirals versus corticosteroids (A versus S)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Incomplete recovery</HEADING>
<P>This comparison contained three studies (<LINK REF="STD-De-Diego-1998" TYPE="STUDY">De Diego 1998</LINK>; <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>; <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>).</P>
<P>All studies (768 participants) provided data for our primary outcome of incomplete recovery at the end of the study. Incomplete recovery was significantly less common in the participants treated with A versus those treated with S. Initial calculations using the fixed-effect model showed a RR of 1.96 (95% CI 1.48 to 2.59), but with a high degree of heterogeneity (Chi<SUP>2 </SUP>= 8.78, df = 2, P value = 0.01, I<SUP>2</SUP> = 77%). We repeated the analysis using the random-effects model to partially correct for this, and the RR was 2.82 (95% CI 1.09 to 7.32) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>, <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Motor synkinesis or crocodile tears</HEADING>
<P>
<LINK REF="STD-De-Diego-1998" TYPE="STUDY">De Diego 1998</LINK> and <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK> provided data for the outcome motor synkinesis or crocodile tears at the end of the study (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>). The analysis included 472 participants and showed significantly fewer sequelae in S than in A (RR 1.52, 95% CI 1.08 to 2.12).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<P>Fewer participants experienced adverse events in the antiviral group than the corticosteroids group (RR 0.85, 95% CI 0.57 to 1.28, <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>), but the CIs included the possibility of the opposite effect.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Antivirals plus corticosteroids versus placebo (AS versus OO)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Incomplete recovery</HEADING>
<P>This comparison contained two studies and outcome data on 658 participants (<LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>; <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>).</P>
<P>Incomplete recovery at the end of the study was significantly much less common with AS versus OO (RR 0.56, 95% CI 0.41 to 0.76) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>, <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Motor synkinesis or crocodile tears</HEADING>
<P>Not reported</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<P>Adverse events (among 649 participants) were slightly but not significantly more common with AS than with OO (RR 1.14, 95% CI 0.79 to 1.65) (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Antivirals versus placebo (AO versus OO)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Incomplete recovery</HEADING>
<P>For two trials (658 participants) that compared antivirals versus placebo without any complicating additional treatment, the RR of incomplete recovery was non-significant (RR 1.10, 95% CI 0.87 to 1.40) (<LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>; <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>). The heterogeneity was moderate (Chi<SUP>2 </SUP>= 0.63, P value = 0.20, I<SUP>2</SUP> = 39%) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Motor synkinesis or crocodile tears</HEADING>
<P>Not reported</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<P>Adverse events (among 651 participants) were not significantly more common in OO (RR 0.83, 95% CI 0.56 to 1.24) (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS) in severe cases</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Incomplete recovery</HEADING>
<P>For this comparison, we extracted data from four studies with 478 participants (<LINK REF="STD-Hato-2007" TYPE="STUDY">Hato 2007</LINK>; <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>; <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>; <LINK REF="STD-Lee-2013" TYPE="STUDY">Lee 2013</LINK>). The RR of incomplete recovery in this subgroup was just significantly less in AS versus OS (RR 0.64, 95% CI 0.41 to 0.99, random-effects model). The heterogeneity was moderate (Chi<SUP>2 </SUP>= 5.2, P value = 0.16, I<SUP>2 </SUP>= 42%) (see <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>, <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analyses</HEADING>
<P>We investigated the effect of using the comparison AS versus OS by performing further analysis to investigate whether excluding the study with a follow-up of less than six months altered our conclusions (<LINK REF="STD-Adour-1996" TYPE="STUDY">Adour 1996</LINK>). We performed further sensitivity analyses to assess the potential difference in participant response to aciclovir, in <LINK REF="STD-Adour-1996" TYPE="STUDY">Adour 1996</LINK>, <LINK REF="STD-Li--1997" TYPE="STUDY">Li 1997</LINK>, <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>, and <LINK REF="STD-Yeo-2008" TYPE="STUDY">Yeo 2008</LINK>, versus valaciclovir, in <LINK REF="STD-Hato-2007" TYPE="STUDY">Hato 2007</LINK>, <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>, and <LINK REF="STD-V_x00e1_zquez-2008" TYPE="STUDY">Vázquez 2008</LINK>.</P>
<P>We performed sensitivity analyses to investigate whether the exclusion of trials not meeting current best standards (that is a high or unclear risk of bias in more than five categories or trials with less than 200 participants) would influence the results.</P>
<SUBSECTION>
<HEADING LEVEL="4">Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS)</HEADING>
<P>When we excluded <LINK REF="STD-Adour-1996" TYPE="STUDY">Adour 1996</LINK>, the RR of incomplete recovery was 0.67 (95% CI 0.41 to 1.07, n = 1216). This represents a small but statistically significant change compared with the main analysis (RR 0.61, 95% CI 0.39 to 0.97, n = 1315, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) with the removal of outcomes that reported follow-up at six months or less.</P>
<P>When we performed sensitivity analyses to assess the potential difference in participant response to aciclovir versus valaciclovir, we found no significant difference from the results of the main analysis (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). When we excluded <LINK REF="STD-Adour-1996" TYPE="STUDY">Adour 1996</LINK>, <LINK REF="STD-Li--1997" TYPE="STUDY">Li 1997</LINK>, <LINK REF="STD-Kawaguchi-2007" TYPE="STUDY">Kawaguchi 2007</LINK>, <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>, and <LINK REF="STD-Yeo-2008" TYPE="STUDY">Yeo 2008</LINK>, the RR of incomplete recovery was 0.74 (95% CI 0.42 to 1.31, n = 678). When we excluded trials using aciclovir, the RR was 0.65 (95% CI 0.36 to 1.16, n = 678).</P>
<P>Exclusion of trials with fewer than 200 participants (<LINK REF="STD-Adour-1996" TYPE="STUDY">Adour 1996</LINK>; <LINK REF="STD-Li--1997" TYPE="STUDY">Li 1997</LINK>; <LINK REF="STD-V_x00e1_zquez-2008" TYPE="STUDY">Vázquez 2008</LINK>; <LINK REF="STD-Yeo-2008" TYPE="STUDY">Yeo 2008</LINK>; <LINK REF="STD-Kawaguchi-2007" TYPE="STUDY">Kawaguchi 2007</LINK>), and trials not meeting current best standards (<LINK REF="STD-Li--1997" TYPE="STUDY">Li 1997</LINK>; <LINK REF="STD-Hato-2007" TYPE="STUDY">Hato 2007</LINK>; <LINK REF="STD-Kawaguchi-2007" TYPE="STUDY">Kawaguchi 2007</LINK>; <LINK REF="STD-V_x00e1_zquez-2008" TYPE="STUDY">Vázquez 2008</LINK>; <LINK REF="STD-Yeo-2008" TYPE="STUDY">Yeo 2008</LINK>), did not significantly change the results of <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> (RR 0.83, 95% CI 0.41 to 1.71, n = 888 and RR 0.81, 95% CI 0.38 to 1.74, n = 766, respectively).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS) in severe cases</HEADING>
<P>We performed a sensitivity analysis to assess differences between <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK> and <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>, where only a subgroup of participants had severe Bell&#8217;s palsy, versus <LINK REF="STD-Hato-2007" TYPE="STUDY">Hato 2007</LINK> and <LINK REF="STD-Lee-2013" TYPE="STUDY">Lee 2013</LINK>, where almost all participants had severe Bell&#8217;s palsy. The results showed a remarkable difference between the analyses: RR 0.47 (95% CI 0.30 to 0.75) versus RR 0.82 (95% CI 0.57 to 1.17).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-10-15 14:20:04 +0100" MODIFIED_BY="Ruth  Brassington">
<SUMMARY_OF_RESULTS MODIFIED="2015-10-15 09:20:34 +0100" MODIFIED_BY="Ruth  Brassington">
<P>The results of this updated review show a benefit from combining antivirals with steroids in comparison with steroids alone for people with Bell&#8217;s palsy of various degrees of severity at commencement of treatment. This is based on a reduction of incomplete recovery (RR 0.61, 95% CI 0.39 to 0.97, n = 1315). Comparing the data of participants with severe Bell&#8217;s palsy, we also demonstrated a reduction in the rate of incomplete recovery for the combination treatment at month six.</P>
<P>Remarkably, the data of <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK> and <LINK REF="STD-V_x00e1_zquez-2008" TYPE="STUDY">Vázquez 2008</LINK> showed a non-significant detrimental effect of antivirals on recovery compared with <LINK REF="STD-Hato-2007" TYPE="STUDY">Hato 2007</LINK>, <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>, and <LINK REF="STD-Lee-2013" TYPE="STUDY">Lee 2013</LINK> (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). Possible reasons for this are that the trials were heterogeneous in ways that we discuss below.</P>
<P>The reduction in incomplete recovery was significantly better in participants receiving corticosteroids compared with antivirals. The treatment effect of antivirals plus corticosteroids was significantly better than placebo.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-10-15 09:21:09 +0100" MODIFIED_BY="Ruth  Brassington">
<P>When antivirals were compared to placebo, antivirals produced no benefit. This result was influenced by the <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-Sullivan-2007">Sullivan 2007</A> trial, which suggested that antiviral treatment had a non-significant detrimental effect on recovery.</P>
<P>Heterogeneity may be due to clinical variation, for example in study participant characteristics, disease severity at baseline, and delay in receiving treatment or different type of antiviral agent used and the small numbers in the subgroups. Equally, variation may be due to methodological considerations such as method of randomisation, the use of blinding, the choice of outcome assessment measures and recovery cut-off points or the trial duration. In particular, <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-Li--1997">Li 1997</A>, <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-Hato-2007">Hato 2007</A>, and <LINK REF="STD-Kawaguchi-2007" TYPE="STUDY">Kawaguchi 2007</LINK> had methodological weaknesses in baseline group assessment, completeness of follow-up, and adequacy of blinding. Any of these factors could result in bias and introduce inaccuracy. The heterogeneity was exacerbated in many studies by keeping the inclusion criteria fairly broad; this maximises data inclusion and therefore power, but results must be interpreted with this in mind. The sensitivity analysis of participants with severe Bell&#8217;s palsy showed a remarkable difference between the studies with data from subgroups and trials with a complete dataset. The different definitions of severe Bell&#8217;s palsy depending on the symptom scores used in the trial should also be considered a potential source of heterogeneity.</P>
<P>Sensitivity analysis of trials with a six-month endpoint or longer showed a change of results from significant into non-significant compared to the whole-group analysis. This change was probably caused by the heterogeneity of the studies.</P>
<P>Subgroup analysis of the relative treatment difference with different antivirals showed no significant changes in the outcomes for combined treatment versus treatment with steroids alone. Given this finding, it is unlikely that different antiviral compounds will have a significant effect on the outcome 'Incomplete recovery at the end of the study', despite the difference in bio-availability (<A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-Sullivan-2007">Sullivan 2007</A>).</P>
<P>We found insufficient data to examine any of the other variables reported in the studies, such as pain, quality of life, and variation in response due to time to treatment and severity at onset. These variables may be useful for hypothesis generation for future work in this area.</P>
<P>From the data available for comparison of motor synkinesis or crocodile tears at the end of the study, the results of three studies with a total of 941 participants were significant in two comparisons (<LINK REF="STD-Adour-1996" TYPE="STUDY">Adour 1996</LINK>; <LINK REF="STD-De-Diego-1998" TYPE="STUDY">De Diego 1998</LINK>; <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>). <LINK REF="STD-De-Diego-1998" TYPE="STUDY">De Diego 1998</LINK> and <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK> compared antivirals with corticosteroids and found fewer episodes of these long-term sequelae in the corticosteroid-treated participants, while <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-Adour-1996">Adour 1996</A> and <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK> compared antivirals plus corticosteroids with corticosteroids alone and found fewer episodes of these sequelae in the antiviral treatment group. A degree of clinical heterogeneity (different clinical assessment scales used) and methodological heterogeneity (different treatment regimens and follow-up plans) limit the interpretation of these data.</P>
<P>Adverse event data were available in three studies giving comparison data for 1528 participants (<A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-Hato-2007">Hato 2007</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-Sullivan-2007">Sullivan 2007</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-Engstr_x00f6_m-2008">Engström 2008</A>). None of the comparisons showed significant differences in adverse events between arms. We could find no correlation with specific treatment within these results.</P>
<P>We found variation in the clinical endpoints chosen as defining recovery: <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-Sullivan-2007">Sullivan 2007</A> and <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-Engstr_x00f6_m-2008">Engström 2008</A> used House-Brackmann Grade 1, while <LINK REF="STD-Yeo-2008" TYPE="STUDY">Yeo 2008</LINK> used House-Brackmann Grade 2. The other studies used a variety of different scales that show more or less equivalence to these. We have provided details of the symptoms scales and comparison where available (<A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#TBL-01">Table 1</A>, <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#TBL-02">Table 2</A>, <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#TBL-03">Table 3</A>).</P>
<P>Neither <LINK REF="STD-Kawaguchi-2007" TYPE="STUDY">Kawaguchi 2007</LINK> nor <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-Yeo-2008">Yeo 2008</A> found a significant association between time to treatment and final recovery status.</P>
<P>We found differences in severity at recruitment: <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-Li--1997">Li 1997</A>, <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-Hato-2007">Hato 2007</A>, <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-V_x00e1_zquez-2008">Vázquez 2008</A>, <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-Yeo-2008">Yeo 2008</A>, and <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-Lee-2013">Lee 2013</A> included a more severe spectrum of palsy than <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>. <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-Hato-2007">Hato 2007</A> and <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK> stratified participants by severity-of-disease status at onset. <LINK REF="STD-Hato-2007" TYPE="STUDY">Hato 2007</LINK> found that in cases of complete or severe palsy, the recovery rate for the combination treatment was significantly greater than for participants treated with steroids only. <A HREF="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-Lee-2013">Lee 2013</A> included only severe cases and found a significantly higher rate of recovery in the group receiving a combination treatment using famciclovir. In contrast, <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK> could not confirm these findings in treatment of participants with severe Bell's palsy, whereas <LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK> showed a non-significant detrimental effect on complete recovery.</P>
<P>The primary-outcome result raises another important consideration, that is the health economic issues: a 10-day course of aciclovir 400 mg 5 times per day costs GBP 5.33 (USD 8.75, EUR 6.47); an equivalent course of valaciclovir costs GBP 8.50 (USD 13.96, EUR 10.31). Famciclovir is significantly more expensive at GBP 138.79 (USD 227.89, EUR 168.42). A 10-day course of prednisolone (two 25 mg tablets daily) costs about GBP 7.14 (USD 11.72, EUR 8.66) (<LINK REF="REF-BNF-2013" TYPE="REFERENCE">BNF 2013</LINK>). These cost data are specific to the UK market (2013); costs vary significantly in other countries (<LINK REF="REF-Hern_x00e1_ndez-2008" TYPE="REFERENCE">Hernández 2008</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-10-15 14:20:04 +0100" MODIFIED_BY="Ruth  Brassington" NOTES="&lt;p&gt;Authors talk earlier about bias ('In particular, Abdelghany 2013, &lt;a href=&quot;http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-Hato-2007&quot; protected=&quot;true&quot;&gt;Hato 2007&lt;/a&gt;, &lt;a link_type=&quot;STUDY&quot; href=&quot;Kawaguchi 2007&quot; protected=&quot;true&quot;&gt;Kawaguchi 2007&lt;/a&gt;, and &lt;a href=&quot;http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298&amp;format=REVMAN#STD-Li--1997&quot; protected=&quot;true&quot;&gt;Li 1997&lt;/a&gt; had methodological weaknesses in baseline group assessment, completeness of follow-up and adequacy of blinding. Any of these factors could result in bias and introduce inaccuracy') &lt;/p&gt;&lt;p&gt;Quality of evidence is used only to refer to GRADE quality assessments - here seems to be used to refer to bias &lt;/p&gt;&lt;p&gt;It was the suggestion of one of the reviewer (first submission) to downgrade the quality of evidence for the main analysis due to the heterogeneity of the included trials. I changed but did not remove the comment Nr. 1 in the GRADE table for it. IG&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-10-15 14:20:04 +0100" NOTES_MODIFIED_BY="Ruth  Brassington">
<P>We downgraded the evidence on incomplete recovery for the comparison antivirals plus corticosteroids versus corticosteroids alone to low due to heterogeneity, imprecision of the study results, and risk of bias. We further downgraded the evidence to low quality in the group with severe Bell's palsy, as the effect in this group was particularly sensitive to removal of studies at high risk of bias. We found the quality of the evidence for other outcomes such as motor synkinesis and crocodile tears, and adverse events to be low because of imprecision and publication bias&#8212;only three of the included trials reported these outcomes.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-03-30 23:10:00 +0100" MODIFIED_BY="Ruth Brassington">
<P>To help ensure that decisions about which studies to include in this review were reproducible, two review authors repeated the review process (we divided the studies into three groups). We made no distinction on the experience and expertise of each review author in the reviewing pairs. Regarding applying the eligibility criteria and assessing the relevance of studies, review authors were aware of the names of the study authors, institutions, journal of publication, and results. FS and FD were excluded from the assessment of their own trial (<LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>). We had no final disagreements about which studies should be included. </P>
<P>According to previous practice in this review, we excluded several studies and a published abstract that provided insufficient information. As a result there could be some risk of publication and selective reporting bias due to data from some studies being unavailable.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-04-09 18:02:09 +0100" MODIFIED_BY="Ruth Brassington">
<P>We have included studies conducted in Asia, North and Middle America, and Europe. It is possible that genetic differences in drug metabolism or response or even different aetiological processes may account for some of the observed variation in response.</P>
<P>We found two systematic reviews and two meta-analyses comparing steroids and antivirals for the treatment of Bell&#8217;s palsy (<LINK REF="REF-de-Almeida-2009" TYPE="REFERENCE">de Almeida 2009</LINK>; <LINK REF="REF-Goudakos-2009" TYPE="REFERENCE">Goudakos 2009</LINK>; <LINK REF="REF-Quant-2009" TYPE="REFERENCE">Quant 2009</LINK>; <LINK REF="REF-Numthavaj-2011" TYPE="REFERENCE">Numthavaj 2011</LINK>). De Almeida et al. compared any corticosteroid treatment with antivirals and included 18 trials in the meta-analysis. Most of the trials did not meet the inclusion criteria for this review. De Almeida states a benefit of corticosteroids for people with Bell&#8217;s palsy and the probability of an additional benefit when corticosteroids are combined with antivirals. A systematic review and meta-analysis by Goudakos et al. compared corticosteroids with corticosteroids plus antivirals for the treatment of Bell&#8217;s palsy. This review included only four trials and omitted other important studies, for example <LINK REF="STD-Engstr_x00f6_m-2008" TYPE="STUDY">Engström 2008</LINK>, which is the largest trial conducted on this topic. Goudakos did not find an additional benefit from combining corticosteroids with antivirals. The meta-analyses by Numthavaj and Quant each included six trials for analysis, with a great overlap. In both papers the authors reported higher rates of recovery when steroids were combined with antivirals compared to steroids alone, but the difference was non-significant.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-10-15 14:20:12 +0100" MODIFIED_BY="Ruth  Brassington">
<IMPLICATIONS_PRACTICE MODIFIED="2015-10-15 14:20:12 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Among participants with Bell's palsy of various degrees of severity, low-quality evidence shows an additional benefit from combination therapy with antivirals and corticosteroids over corticosteroids alone on incomplete recovery.</P>
<P>Low-quality evidence from trials involving people with severe Bell's palsy indicates a benefit on rates of incomplete recovery from combined corticosteroids and antivirals over corticosteroids alone.</P>
<P>Corticosteroids alone were more effective than antivirals alone and antivirals plus corticosteroids were more effective than placebo or no treatment.</P>
<P>There was no benefit from antivirals alone over placebo.</P>
<P>Moderate-quality evidence indicated that the combination of antivirals and corticosteroids reduced sequelae of Bell's palsy compared with corticosteroids alone.</P>
<P>We found no significant increase in adverse events from the use of antivirals compared with either placebo or corticosteroids, based on low-quality evidence.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-10-15 10:34:16 +0100" MODIFIED_BY="Ruth  Brassington">
<P>The novel finding in this analysis of a benefit in terms of incomplete recovery of Bell's palsy through the combination of antivirals with corticosteroids may merit further investigation. We also found a benefit in people with severe Bell's palsy. Additional work in this area could address the question of the best treatment for mild-to-moderate and severe Bell&#8217;s palsy raised by the possible causes of heterogeneity in some of the comparisons in this review. This may be achieved through a meta-analysis of individual participant data of both participants with severe and participants with mild-to-moderate Bell's palsy separately. Depending upon the results of this analysis, an adequately powered randomised controlled trial in people with Bell&#8217;s palsy comparing different potential treatment options such as additional antiviral agents or immune modulators may be indicated.</P>
<P>More work is needed to assess the likelihood of long-term cosmetic sequelae, which should be reported in each further trial. There is no further need to conduct trials with a placebo group on this topic, as a clear benefit from steroid therapy is evident. Moreover, antivirals should be tested in combination with steroids and not alone in future studies. Subgroup analysis of existing data and future studies should be done to assess the impact on the outcome of variables such as time from diagnosis until treatment, severity of palsy at baseline, and age of participants at presentation. Work assessing a wider range of endpoints, such as quality of life and perceived disability, should be undertaken with the goal of developing a better understanding of Bell's palsy for the affected person.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-10-12 20:57:00 +0100" MODIFIED_BY="Ildiko Gagyor">
<P>Dr J Sipe, Mrs L Dunn, Dr D Allen, Dr P Lockhart, Ms N Comerford, and Ms M Pitkethly authored the previous editions of this review; we are very grateful for their hard work and enthusiasm. We also extend our thanks to Ruth Brassington for her valuable assistance with the writing process; to Angela Gunn, who provided search results; and to Cochrane Neuromuscular for their extensive technical assistance and support.</P>
<P>This project was supported by the National Institute for Health Research via Cochrane Infrastructure funding to Cochrane Neuromuscular. The views and opinions expressed therein are those of the review authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS, or the Department of Health. Cochrane Neuromuscular is also supported by the MRC Centre for Neuromuscular Diseases.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-04-16 07:42:55 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Ildiko Gagyor: None known</P>
<P>Vishnu B Madhok: I have received payment for reviewing a review prepared by BMJ Evidence.</P>
<P>Fergus Daly: The fact that I am a named author on one of the included articles (<LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>) did not influence in any way my thinking, presentation or contribution to this review.</P>
<P>Dhruvashree Somasundara: None known</P>
<P>Michael Sullivan: None known</P>
<P>Fiona Gammie: None known</P>
<P>Frank Sullivan: I am the author of one of the included studies (<LINK REF="STD-Sullivan-2007" TYPE="STUDY">Sullivan 2007</LINK>). I have no other known conflicts of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-04-09 18:02:13 +0100" MODIFIED_BY="Ruth Brassington">
<P>All review authors contributed to the review and data extraction process. Dr I Gagyor wrote the first draft of the report with additional clinical input from Professor F Sullivan, Dr V Madhok, Dr F Daly, Dr D Somasundara, and Dr M Sullivan. Dr I Gagyor incorporated the work into the existing review and was responsible for the 'Risk of bias' assessment, data analysis, and use of the RevMan 5 software.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-10-12 20:57:38 +0100" MODIFIED_BY="Ildiko Gagyor">
<P>There were several differences between the published review protocol and the 2009 update of the review (<LINK REF="REF-Lockhart-2009" TYPE="REFERENCE">Lockhart 2009</LINK>). These mainly reflected changes over time to treatment options and Cochrane methodology. As for the previous update, the search for studies now includes treatment with valaciclovir and famciclovir, either alone or in combination with any other therapy, to reflect the treatment options now available for Bell's palsy. We undertook the methodological assessment according to Chapter 8 of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>As implemented in previous versions of the review, we documented in this update the selection criteria relating to high risk of bias and study duration. The minimum study duration was three months. As in previous updates, we used study quality as an exclusion criterion, especially in trials with a high risk of bias in several domains.</P>
<P>For this update, seven review authors read a selection of papers, reviewed them for quality, and extracted data. The review authors distributed the work so that at least two review authors reviewed each paper. IG performed the final 'Risk of bias' assessment, which FS and VM independently reviewed.</P>
<P>We focused this search on people who were immunocompetent, which we did not stipulate in the original protocol. We did this as treatment protocols for immunocompromised individuals and treatment response may differ significantly from other individuals and could not be fully explored in this analysis.</P>
<P>The authors of <LINK REF="REF-Lockhart-2009" TYPE="REFERENCE">Lockhart 2009</LINK> widened the outcome criteria to include outcomes at the end of the study, as opposed to one year or six months after treatment, in order to allow for the inclusion of a maximal number of published studies. This previous update included studies with durations of three to 12 months, which allowed for maximum data inclusion. As it was understood that this method might introduce significant heterogeneity to the results, the review authors included a sensitivity analysis looking at outcomes in participants in studies reporting at 12 weeks or less and 6 months or less in order to assess the influence this had on the robustness of published results. The authors of the current review accepted these changes. For the subgroup analysis of incomplete recovery, we extracted data on the severity Bell&#8217;s palsy at month six or imputed using the last measure carried forward. As for the previous update, we omitted the outcome 'Complete facial paralysis at the end of the study'.</P>
<P>We have added in this update the outcome 'incomplete recovery in severe cases', measured at month six or imputed using the last measure carried forward. We defined severe cases as a severe-to-complete facial paralysis, graded as equal to or greater than V in the House-Brackmann grading system, equal to or less than 20 in the Sunnybrook score, and equal to or less than 20 in the Yanagihara score.</P>
<P>We modified the outcome measures since the previous review to take into account the heterogeneity of this group of studies.</P>
<P>We altered incomplete recovery to include the range of definitions used by the included studies in order to allow for maximum data capture: As opposed to the previous definition of moderate dysfunction, the term now includes participants with a lack of full function. By this definition, more participants will be classified as 'incomplete recovery'.</P>
<P>The <LINK REF="REF-Lockhart-2009" TYPE="REFERENCE">Lockhart 2009</LINK> update replaced 'adverse events attributable to antiviral treatment' with 'adverse events'; in studies where both agents are administered, it is difficult to assess which agent is causing the adverse event. Similarly, even when only an antiviral is being prescribed, it is difficult to know whether a specific event should be attributed to the medication or to another intercurrent cause. The level of detailed analysis of adverse events in studies did not permit such a judgement to be made. This review reported adverse events for each analysis separately.</P>
<P>The review authors added a 'Summary of findings' table and additional sections to the methods to comply with current Cochrane standards.</P>
<P>We performed sensitivity analyses to investigate whether the exclusion of trials not meeting current best standards (that is a high or unclear risk of bias in more than five categories or trials with less than 200 participants) would influence the results.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2009-02-05 14:51:09 +0000" MODIFIED_BY="Pauline Lockhart"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-10-15 09:22:11 +0100" MODIFIED_BY="Ruth  Brassington">
<STUDIES MODIFIED="2015-10-12 21:00:47 +0100" MODIFIED_BY="Ildiko Gagyor">
<INCLUDED_STUDIES MODIFIED="2015-09-15 16:16:14 +0100" MODIFIED_BY="Ruth  Brassington">
<STUDY DATA_SOURCE="PUB" ID="STD-Adour-1996" MODIFIED="2015-09-15 16:16:14 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Adour 1996" YEAR="1996">
<REFERENCE MODIFIED="2015-09-15 16:16:14 +0100" MODIFIED_BY="Ruth  Brassington" NOTES="&lt;p&gt;Adour KK, Ruboyianes JM, Von Doeersten PG, Byl FM, Trent CS, Queensberry CP, et al. Bell's palsy treatment with acyclovir and prednisone compared with prednisone alone: a double-blind, randomised, controlled trial. Ann Otol Rhinol Laryngol 1996;105:371-378&lt;/p&gt;" NOTES_MODIFIED="2015-09-15 16:16:14 +0100" NOTES_MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adour KK, Ruboyianes JM, Von Doersten PG, Byl FM, Trent CS, Quesenberry CP Jr, et al</AU>
<TI>Bell's palsy treatment with acyclovir and prednisone compared with prednisone alone: a double-blind, randomized, controlled trial</TI>
<SO>Annals of Otology, Rhinology and Laryngology</SO>
<YR>1996</YR>
<VL>105</VL>
<NO>5</NO>
<PG>371-8</PG>
<IDENTIFIERS MODIFIED="2011-11-08 20:58:12 +0000" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2011-11-08 20:58:12 +0000" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="8651631"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Diego-1998" MODIFIED="2014-08-03 11:28:08 +0100" MODIFIED_BY="[Empty name]" NAME="De Diego 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-08-03 11:28:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Diego JI, Prim MP, De Sarria MJ, Madero R, Gavilan J</AU>
<TI>Idiopathic facial paralysis: a randomized, prospective, and controlled study using single-dose prednisone versus acyclovir three times daily</TI>
<SO>Laryngoscope</SO>
<YR>1998</YR>
<VL>108</VL>
<NO>4 Pt 1</NO>
<PG>573-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="9546272"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Engstr_x00f6_m-2008" MODIFIED="2015-04-09 18:11:02 +0100" MODIFIED_BY="Ruth Brassington" NAME="Engström 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-04-09 18:11:02 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Engström M, Berg T, Stjernquist-Desatnik A, Axelsson S, Pitkäranta A, Hultkrantz M, et al</AU>
<TI>Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial</TI>
<SO>Lancet Neurology</SO>
<YR>2008</YR>
<VL>7</VL>
<NO>11</NO>
<PG>993-1000</PG>
<IDENTIFIERS MODIFIED="2014-05-15 16:49:31 +0100" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2010-04-20 13:58:56 +0100" MODIFIED_BY="Angela Gunn" TYPE="DOI" VALUE="10.1016/51474-4422(08)70221-7"/>
<IDENTIFIER MODIFIED="2014-05-15 16:49:31 +0100" MODIFIED_BY="Ruth Brassington" TYPE="PUBMED" VALUE="18849193"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-05-06 17:43:32 +0100" MODIFIED_BY="Kate Jewitt"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hato-2007" MODIFIED="2015-04-09 18:15:06 +0100" MODIFIED_BY="Ruth Brassington" NAME="Hato 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-04-09 18:15:06 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hato N, Yamada H, Kohno H, Matsumoto S, Honda N, Gyo K, et al</AU>
<TI>Valacyclovir and prednisolone treatment for Bell's palsy: A multicenter, randomized, placebo-controlled study</TI>
<SO>Otology and Neurotology</SO>
<YR>2007</YR>
<VL>28</VL>
<NO>3</NO>
<PG>408-13</PG>
<IDENTIFIERS MODIFIED="2011-11-08 21:05:37 +0000" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2011-11-08 21:05:37 +0000" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="17414047"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-06-05 20:21:12 +0100" MODIFIED_BY="Pauline Lockhart"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kawaguchi-2007" MODIFIED="2014-08-03 11:28:33 +0100" MODIFIED_BY="[Empty name]" NAME="Kawaguchi 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-08-03 11:28:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kawaguchi K, Inamura H, Abe Y, Koshu H, Takashita E, Muraki Y, et al</AU>
<TI>Reactivation of herpes simplex virus type 1 and varicella-zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell's palsy</TI>
<SO>Laryngoscope</SO>
<YR>2007</YR>
<VL>117</VL>
<NO>1</NO>
<PG>147-56</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="    17202945"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2013" MODIFIED="2014-07-21 16:47:00 +0100" MODIFIED_BY="[Empty name]" NAME="Lee 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-07-21 16:47:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee HY, Byun JY, Park MS, Yeo SG</AU>
<TI>Steroid-antiviral treatment improves the recovery rate in patients with severe Bell's palsy</TI>
<SO>American Journal of Medicine</SO>
<YR>2013</YR>
<VL>126</VL>
<NO>4</NO>
<PG>336-41</PG>
<IDENTIFIERS MODIFIED="2014-03-31 11:17:57 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2014-03-31 11:17:57 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="23394867"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-11-13 19:07:27 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li--1997" MODIFIED="2014-07-21 16:49:36 +0100" MODIFIED_BY="[Empty name]" NAME="Li  1997" YEAR="1997">
<REFERENCE MODIFIED="2014-07-21 16:49:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li Y, Gao P, Mao X, Cao P</AU>
<TI>Randomized clinical trial of acyclovir plus prednisone versus prednisone alone in Bell's palsy</TI>
<SO>Ceylon Journal of Medical Science</SO>
<YR>1997</YR>
<VL>40</VL>
<NO>2</NO>
<PG>37-41</PG>
<IDENTIFIERS MODIFIED="2013-11-13 19:22:22 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-11-13 19:14:59 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Sullivan-2007" MODIFIED="2015-04-09 20:33:24 +0100" MODIFIED_BY="Ruth Brassington" NAME="Sullivan 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-04-09 20:33:24 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sullivan FM, Swan IRC, Donnan PT, Morrison JM, Smith BH, McKinstry B, et al</AU>
<TI>Early treatment with prednisolone or acyclovir in Bell's palsy</TI>
<SO>New England Journal of Medicine</SO>
<YR>2007</YR>
<VL>357</VL>
<NO>16</NO>
<PG>1598-607</PG>
<IDENTIFIERS MODIFIED="2011-11-08 21:11:26 +0000" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2011-11-08 21:11:26 +0000" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="17942873"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-02-04 10:46:47 +0000" MODIFIED_BY="Pauline Lockhart">
<IDENTIFIER MODIFIED="2009-02-04 10:46:47 +0000" MODIFIED_BY="Pauline Lockhart" TYPE="ISRCTN" VALUE="71548196"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-V_x00e1_zquez-2008" MODIFIED="2014-07-21 16:50:02 +0100" MODIFIED_BY="[Empty name]" NAME="Vázquez 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-07-21 16:50:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vázquez MC, Sánchez N, Calvo J, Perna A</AU>
<TI>Efficacy of antiviral in treatment of Bell's palsy</TI>
<TO>Eficacia de los antivirales en la parálisis de Bell</TO>
<SO>Revista Medica del Uruguay</SO>
<YR>2008</YR>
<VL>24</VL>
<NO>3</NO>
<PG>167-74</PG>
<IDENTIFIERS MODIFIED="2014-03-31 11:42:15 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2014-03-31 11:42:15 +0100" MODIFIED_BY="Angela A Gunn" TYPE="OTHER" VALUE="LILACS 501670"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-11-13 18:58:09 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-11-13 18:58:09 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="NCT00561106"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yeo-2008" MODIFIED="2014-07-21 16:50:21 +0100" MODIFIED_BY="[Empty name]" NAME="Yeo 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-07-21 16:50:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yeo SG, Lee YC, Park DC, Cha CI</AU>
<TI>Acyclovir plus steroid versus steroid alone in the treatment of Bell's palsy</TI>
<SO>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</SO>
<YR>2008</YR>
<VL>29</VL>
<NO>3</NO>
<PG>163-6</PG>
<IDENTIFIERS MODIFIED="2014-05-15 17:17:58 +0100" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2014-05-15 17:17:58 +0100" MODIFIED_BY="Ruth Brassington" TYPE="PUBMED" VALUE="18439948"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-04-16 07:43:33 +0100" MODIFIED_BY="Ruth  Brassington">
<STUDY DATA_SOURCE="PUB" ID="STD-Ahangar-2006" MODIFIED="2015-04-09 18:11:37 +0100" MODIFIED_BY="Ruth Brassington" NAME="Ahangar 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-04-09 18:11:37 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ahangar AA, Hosseini S, Saghebi R</AU>
<TI>Comparison of the efficacy of prednisolone versus prednisolone and acyclovir in the treatment of Bell's palsy</TI>
<SO>Neurosciences</SO>
<YR>2006</YR>
<VL>11</VL>
<NO>4</NO>
<PG>256-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Antunes-2000" MODIFIED="2015-04-16 07:43:33 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Antunes 2000" YEAR="2000">
<REFERENCE MODIFIED="2015-04-16 07:43:33 +0100" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Antunes ML, Fukuda Y, Testa JRG</AU>
<TI>Clinical treatment of Bell's palsy: comparative study among valaciclovir plus deflazacort, deflazacort and placebo</TI>
<TO>Tratamento clinico da paralisia de Bell: estudo comparativo com o uso de valaciclovir mais deflazacort versus deflazacort versus placebo</TO>
<SO>Acta Associação William House de Otologia</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>2</NO>
<PG>68-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Axelsson-2003" MODIFIED="2014-05-15 20:37:37 +0100" MODIFIED_BY="Ruth Brassington" NAME="Axelsson 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-05-15 20:37:37 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Axelsson S, Lindberg S, Stjernquist-Desatnik A</AU>
<TI>Outcome of treatment with valacyclovir and prednisone in patients with Bell's palsy</TI>
<SO>Annals of Otology, Rhinology and Laryngology</SO>
<YR>2003</YR>
<VL>112</VL>
<NO>3</NO>
<PG>197-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2005" MODIFIED="2014-07-21 16:51:30 +0100" MODIFIED_BY="[Empty name]" NAME="Chen 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-07-21 16:51:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen WL, Yang ZH, Huang ZQ</AU>
<TI>Outcome of treatment of 46 patients with Bell's palsy with aciclovir and prednisone</TI>
<SO>Shanghai Kou Qiang Yi Xue [Shanghai Journal of Stomatology]</SO>
<YR>2005</YR>
<VL>14</VL>
<NO>6</NO>
<PG>590-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-de-Aquino-2001" MODIFIED="2015-04-16 07:43:33 +0100" MODIFIED_BY="Ruth  Brassington" NAME="de Aquino 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-04-16 07:43:33 +0100" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Aquino JEAP, Cruz Filho AN</AU>
<TI>Comparative study of three types of treatment of idiopathic facial palsy (Bell)</TI>
<TO>Estudo comparativo com tres tipos de tratamento clinico na paralisa facial idiopatica (Bell)</TO>
<SO>Acta Associação William House de Otologia</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>4</NO>
<PG>195-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hato-2003" MODIFIED="2014-07-21 16:52:22 +0100" MODIFIED_BY="[Empty name]" NAME="Hato 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-07-21 16:52:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hato N, Matsumoto S, Kisaki H, Takahashi H, Wakisaka H, Honda N, et al</AU>
<TI>Efficacy of early treatment of Bell's palsy with oral acyclovir and prednisolone</TI>
<SO>Otology and Neurotology</SO>
<YR>2003</YR>
<VL>24</VL>
<NO>6</NO>
<PG>948-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hultcrantz-2005" MODIFIED="2014-10-10 09:19:26 +0100" MODIFIED_BY="[Empty name]" NAME="Hultcrantz 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-10-10 09:19:26 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt; Do we have the original title for this paper??&lt;/p&gt;" NOTES_MODIFIED="2014-10-10 09:19:26 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hultcrantz M</AU>
<TI>Treatment of facial paralysis - evidence-based recommendations</TI>
<SO>Lakartidningen</SO>
<YR>2005</YR>
<VL>102</VL>
<NO>10</NO>
<PG>744-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ibarrondo-1999" MODIFIED="2015-04-09 20:33:48 +0100" MODIFIED_BY="Ruth Brassington" NAME="Ibarrondo 1999" YEAR="1999">
<REFERENCE MODIFIED="2015-04-09 20:33:48 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ibarrondo J, Navarrete ML, Encarnación LF, Quesada P, Crespo F, García M, et al</AU>
<TI>Treatment of idiopathic facial paralysis: corticoids versus acyclovir versus empirical treatment</TI>
<TO>Tratamiento de la paralisis facial idiopatica: corticoides versus aciclovir versus empirico</TO>
<SO>Acta Otorrinolaringologica Espanola</SO>
<YR>1999</YR>
<VL>50</VL>
<NO>2</NO>
<PG>118-20</PG>
<IDENTIFIERS MODIFIED="2012-11-06 09:11:45 +0000" MODIFIED_BY="Angela A Gunn"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Inanli-2001" MODIFIED="2014-07-21 16:53:24 +0100" MODIFIED_BY="[Empty name]" NAME="Inanli 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-07-21 16:53:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Inanli S, Tutkun A, Ozturk O</AU>
<TI>Idiopathic facial nerve paralysis treatment with acyclovir and prednisolone alone</TI>
<SO>Turkish Archives of Otolaryngology</SO>
<YR>2001</YR>
<VL>39</VL>
<PG>19-24</PG>
<IDENTIFIERS MODIFIED="2013-11-13 20:48:12 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-11-13 20:40:23 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Minnerop-2008" MODIFIED="2015-04-09 18:11:56 +0100" MODIFIED_BY="Ruth Brassington" NAME="Minnerop 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-04-09 18:11:56 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Minnerop M, Herbst M, Fimmers R, Kaabar P, Matz B, Klockgether T, et al</AU>
<TI>Bell's palsy: combined treatment of famciclovir and prednisone is superior to prednisone alone</TI>
<SO>Journal of Neurology</SO>
<YR>2008</YR>
<VL>255</VL>
<PG>1726-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ramos-Macias-1992" MODIFIED="2014-07-21 16:54:13 +0100" MODIFIED_BY="[Empty name]" NAME="Ramos Macias 1992" YEAR="1992">
<REFERENCE MODIFIED="2014-07-21 16:54:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ramos Macías A, De Miguel Martínez I, Martín Sánchez AM, Gómez González JL, Martín Galán A</AU>
<TI>Incorporation of acyclovir in the treatment of peripheral paralysis. A study of 45 cases</TI>
<TO>Incorporación del aciclovir en el tratamiento de la parálisis periférica. Un estudio en 45 casos</TO>
<SO>Acta Otorrinolaringológica Espanola</SO>
<YR>1992</YR>
<VL>43</VL>
<NO>2</NO>
<PG>117-20</PG>
<IDENTIFIERS MODIFIED="2012-11-06 09:12:14 +0000" MODIFIED_BY="Angela A Gunn"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roy-2005" MODIFIED="2009-02-05 14:26:44 +0000" MODIFIED_BY="Pauline Lockhart" NAME="Roy 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-02-05 14:26:44 +0000" MODIFIED_BY="Pauline Lockhart" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roy A, Jose J, Kamath V, Matthew T</AU>
<TI>Efficacy of aciclovir and methylprednisolone versus methylprednisolone alone in the treatment of Bell's palsy</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2005</YR>
<VL>238</VL>
<NO>Suppl 1</NO>
<PG>S207</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shahidullah-2011" MODIFIED="2015-04-09 18:12:08 +0100" MODIFIED_BY="Ruth Brassington" NAME="Shahidullah 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-04-09 18:12:08 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shahidullah M, Haque A, Islam MR, Rizvi AN, Sultana N, Mia BA</AU>
<TI>Comparative study between combination of famciclovir and prednisolone with prednisolone alone in acute Bell's palsy</TI>
<SO>Mymensingh Medical Journal</SO>
<YR>2011</YR>
<VL>20</VL>
<NO>4</NO>
<PG>605-13</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="8300125000010514"/>
<IDENTIFIER TYPE="EMBASE" VALUE="EMBASE 22081178"/>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00857180"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-1999" MODIFIED="2014-07-21 16:54:29 +0100" MODIFIED_BY="[Empty name]" NAME="Zhou 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-07-21 16:54:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou P</AU>
<TI>Aciclovir in treating Bell's palsy</TI>
<SO>Chinese Journal of New Drugs and Clinical Remedies</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>1</NO>
<PG>13-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2015-10-12 21:00:47 +0100" MODIFIED_BY="Ildiko Gagyor">
<STUDY DATA_SOURCE="PUB" ID="STD-Abdelghany-2013" MODIFIED="2015-10-12 21:00:47 +0100" MODIFIED_BY="Ildiko Gagyor" NAME="Abdelghany 2013" YEAR="1999">
<REFERENCE MODIFIED="2015-10-12 21:00:47 +0100" MODIFIED_BY="Ildiko Gagyor" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abdelghany AM, Kamel SB</AU>
<TI>The effect of prednisolone and/or acyclovir in relation to severity of Bell's palsy at presentation</TI>
<SO>Egyptian Journal of Ear, Nose, Throat and Allied Sciences</SO>
<YR>2013</YR>
<VL>14</VL>
<NO>3</NO>
<PG>155-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2015-04-16 07:43:33 +0100" MODIFIED_BY="Ruth  Brassington">
<STUDY DATA_SOURCE="PUB" ID="STD-IRCT201109187575N1" MODIFIED="2015-04-16 07:43:33 +0100" MODIFIED_BY="Ruth  Brassington" NAME="IRCT201109187575N1" YEAR="2011">
<REFERENCE MODIFIED="2015-04-16 07:43:33 +0100" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="OTHER">
<AU>IRCT201109187575N1</AU>
<TI>Comparison of therapeutic effects of prednisolone, acyclovir, and combination of these drugs in Bell's palsy</TI>
<SO>http://www.irct.ir/searchresult.php?id=7575&amp;number=1</SO>
<YR>(accessed 14.October 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-IRCT2012062210087N1" MODIFIED="2015-04-16 07:43:33 +0100" MODIFIED_BY="Ruth  Brassington" NAME="IRCT2012062210087N1" YEAR="2013">
<REFERENCE MODIFIED="2015-04-16 07:43:33 +0100" MODIFIED_BY="Ruth  Brassington" PRIMARY="NO" TYPE="OTHER">
<AU>IRCT2012062210087N1</AU>
<TI>Efficacy of corticosteroid and acyclovir in Bell's palsy</TI>
<SO>http://www.irct.ir/searchresult.php?id=10087&amp;number=1</SO>
<YR>(accessed 14.October 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-10-15 09:22:11 +0100" MODIFIED_BY="Ruth  Brassington">
<ADDITIONAL_REFERENCES MODIFIED="2015-04-09 20:35:47 +0100" MODIFIED_BY="Ruth Brassington">
<REFERENCE ID="REF-Abiko-2002" MODIFIED="2014-07-23 13:40:24 +0100" MODIFIED_BY="[Empty name]" NAME="Abiko 2002" TYPE="JOURNAL_ARTICLE">
<AU>Abiko Y, Ikeda M, Hondo R</AU>
<TI>Secretion and dynamics of herpes simplex virus in tears and saliva of patients with Bell's Palsy</TI>
<SO>Otology and Neurology</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>5</NO>
<PG>779-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Adour-1982" MODIFIED="2015-04-09 18:13:13 +0100" MODIFIED_BY="Ruth Brassington" NAME="Adour 1982" TYPE="JOURNAL_ARTICLE">
<AU>Adour KK</AU>
<TI>Current concepts in neurology: diagnosis and management of facial paralysis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1982</YR>
<VL>307</VL>
<NO>6</NO>
<PG>348-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Axelsson-2012" MODIFIED="2014-07-21 17:11:50 +0100" MODIFIED_BY="[Empty name]" NAME="Axelsson 2012" TYPE="JOURNAL_ARTICLE">
<AU>Axelsson S, Berg T, Jonsson L, Engström M, Kanerva M, Stjernquist-Desatnik A</AU>
<TI>Bell's palsy - the effect of prednisolone and/or valaciclovir versus placebo in relation to baseline severity in a randomised controlled trial</TI>
<SO>Clinical Otolaryngology</SO>
<YR>2012</YR>
<VL>37</VL>
<NO>4</NO>
<PG>283-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bateman-1992" MODIFIED="2015-04-09 18:13:02 +0100" MODIFIED_BY="Ruth Brassington" NAME="Bateman 1992" TYPE="JOURNAL_ARTICLE">
<AU>Bateman DE</AU>
<TI>Facial palsy</TI>
<SO>British Journal of Hospital Medicine</SO>
<YR>1992</YR>
<VL>47</VL>
<NO>6</NO>
<PG>430-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berg-2012" MODIFIED="2015-04-09 20:34:21 +0100" MODIFIED_BY="Ruth Brassington" NAME="Berg 2012" TYPE="JOURNAL_ARTICLE">
<AU>Berg T, Bylund N, Marsk E, Jonsson L, Kanerva M, Hultcrantz M, et al</AU>
<TI>The effect of prednisolone on sequelae in Bell's palsy</TI>
<SO>Archives of Otolaryngology - Head &amp; Neck Surgery</SO>
<YR>2012</YR>
<VL>138</VL>
<NO>5</NO>
<PG>445-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BNF-2013" MODIFIED="2014-01-21 18:39:53 +0000" MODIFIED_BY="Pauline Lockhart" NAME="BNF 2013" TYPE="BOOK">
<AU>British Medical Association and Royal Pharmaceutical Society of Great Britain</AU>
<SO>British National Formulary</SO>
<YR>2013</YR>
<EN>66th</EN>
<PB>British Medical Association and the Royal Pharmaceutical Society of Great Britain</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brandenberg-1993" MODIFIED="2014-07-21 17:10:02 +0100" MODIFIED_BY="[Empty name]" NAME="Brandenberg 1993" TYPE="JOURNAL_ARTICLE">
<AU>Brandenberg NA, Annegers JF</AU>
<TI>Incidence and risk factors for Bell's Palsy in Laredo, Texas: 1974-1982</TI>
<SO>Neuroepidemiology</SO>
<YR>1993</YR>
<VL>12</VL>
<NO>6</NO>
<PG>313-25</PG>
<IDENTIFIERS MODIFIED="2012-11-06 09:12:52 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Burgess-1984" MODIFIED="2014-07-21 17:10:17 +0100" MODIFIED_BY="[Empty name]" NAME="Burgess 1984" TYPE="JOURNAL_ARTICLE">
<AU>Burgess LP, Yim DW, Lepore ML</AU>
<TI>Bell's palsy: the steroid controversy revisited</TI>
<SO>Laryngoscope</SO>
<YR>2000</YR>
<VL>94</VL>
<NO>11 Pt 1</NO>
<PG>1472-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Almeida-2009" MODIFIED="2015-04-09 20:35:47 +0100" MODIFIED_BY="Ruth Brassington" NAME="de Almeida 2009" TYPE="JOURNAL_ARTICLE">
<AU>de Almeida JR, Al Khabori M, Guyatt GH, Witterick IJ, Lin VY, Nedzelski JM, et al</AU>
<TI>Combined corticosteroid and antiviral treatment for Bell palsy: a systematic review and meta-analysis</TI>
<SO>JAMA</SO>
<YR>2009</YR>
<VL>302</VL>
<NO>9</NO>
<PG>985-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2014-12-20 17:22:04 +0000" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Smith GD, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-2007" MODIFIED="2014-07-21 17:10:30 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 2007" TYPE="BOOK">
<AU>Egger M, Davey Smith G, Altman DG</AU>
<SO>Systematic Reviews in Health Care: Meta-Analysis in Context</SO>
<YR>2007</YR>
<EN>6th</EN>
<PB>BMJ Books</PB>
<CY>London</CY>
<IDENTIFIERS MODIFIED="2009-02-10 11:47:07 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-10 11:47:07 +0000" MODIFIED_BY="[Empty name]" OTHERTYPE="ISBN" TYPE="OTHER" VALUE="978-0-7279-1488-0"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Goudakos-2009" MODIFIED="2015-04-09 18:12:51 +0100" MODIFIED_BY="Ruth Brassington" NAME="Goudakos 2009" TYPE="JOURNAL_ARTICLE">
<AU>Goudakos JK, Markou KD</AU>
<TI>Corticosteroids versus corticosteroids plus antiviral agents in the treatment of Bell Palsy: a systematic review and meta-analysis</TI>
<SO>Archives of Otolaryngology - Head &amp; Neck Surgery</SO>
<YR>2009</YR>
<VL>135</VL>
<NO>6</NO>
<PG>558-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-2008" MODIFIED="2014-07-21 17:10:45 +0100" MODIFIED_BY="[Empty name]" NAME="GRADEpro 2008" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro</TI>
<YR>2008</YR>
<EN>3.2 for Windows</EN>
<PB>Jan Brozek, Andrew Oxman, Holger Schünemann</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hern_x00e1_ndez-2008" MODIFIED="2014-07-21 17:11:17 +0100" MODIFIED_BY="[Empty name]" NAME="Hernández 2008" TYPE="JOURNAL_ARTICLE">
<AU>Hernández RA, Sullivan F, Donnan P, Swan I, Vale L; BELLS Trial Group</AU>
<TI>Economic evaluation of early administration of prednisolone and/or aciclovir for the treatment of Bell's palsy</TI>
<SO>Family Practice</SO>
<YR>2009</YR>
<VL>26</VL>
<NO>2</NO>
<PG>137-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-07-30 17:33:28 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-House-1985" MODIFIED="2012-11-06 09:13:09 +0000" MODIFIED_BY="Pauline Lockhart" NAME="House 1985" TYPE="JOURNAL_ARTICLE">
<AU>House JW, Brackmann DE</AU>
<TI>Facial nerve grading system</TI>
<SO>Otolarnygology - Head &amp; Neck Surgery</SO>
<YR>1985</YR>
<VL>93</VL>
<NO>2</NO>
<PG>146-7</PG>
<IDENTIFIERS MODIFIED="2012-11-06 09:13:09 +0000" MODIFIED_BY="Angela A Gunn"/>
</REFERENCE>
<REFERENCE ID="REF-Katusic-1986" MODIFIED="2014-07-21 17:08:11 +0100" MODIFIED_BY="[Empty name]" NAME="Katusic 1986" TYPE="JOURNAL_ARTICLE">
<AU>Katusic SK, Beard CM, Wiederholt WC, Bergstralh EJ, Kurland LT</AU>
<TI>Incidence, clinical features and prognosis in Bell's Palsy, Rochester, Minnesota, 1968-1982</TI>
<SO>Annals of Neurology</SO>
<YR>1986</YR>
<VL>20</VL>
<NO>5</NO>
<PG>622-7</PG>
<IDENTIFIERS MODIFIED="2012-11-06 09:13:21 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Lackner-2010" MODIFIED="2014-07-21 17:09:33 +0100" MODIFIED_BY="[Empty name]" NAME="Lackner 2010" TYPE="JOURNAL_ARTICLE">
<AU>Lackner A, Kessler HH, Walch C, Quasthoff S, Raggam RB</AU>
<TI>Early and reliable detection of herpes simplex virus type 1 and varicella zoster virus DNAs in oral fluid of patients with idiopathic peripheral facial nerve palsy: Decision support regarding antiviral treatment?</TI>
<SO>Journal of Medical Virology</SO>
<YR>2010</YR>
<VL>82</VL>
<NO>9</NO>
<PG>1582-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lorber-1996" MODIFIED="2014-01-21 20:40:07 +0000" MODIFIED_BY="[Empty name]" NAME="Lorber 1996" TYPE="JOURNAL_ARTICLE">
<AU>Lorber B</AU>
<TI>Are all diseases infectious?</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1996</YR>
<VL>125</VL>
<NO>10</NO>
<PG>844-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martyn-1997" MODIFIED="2014-07-21 17:09:07 +0100" MODIFIED_BY="[Empty name]" NAME="Martyn 1997" TYPE="JOURNAL_ARTICLE">
<AU>Martyn CN, Hughes RA</AU>
<TI>Epidemiology of peripheral neuropathy</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>1997</YR>
<VL>62</VL>
<NO>4</NO>
<PG>310-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-May-1976" MODIFIED="2014-07-21 17:08:46 +0100" MODIFIED_BY="[Empty name]" NAME="May 1976" TYPE="JOURNAL_ARTICLE">
<AU>May M, Wette R, Hardin WB Jr, Sullivan J</AU>
<TI>The use of steroids in Bell's palsy: a prospective controlled study</TI>
<SO>Laryngoscope</SO>
<YR>1976</YR>
<VL>86</VL>
<NO>8</NO>
<PG>1111-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morales-2013" MODIFIED="2014-07-21 17:07:26 +0100" MODIFIED_BY="[Empty name]" NAME="Morales 2013" TYPE="JOURNAL_ARTICLE">
<AU>Morales DR, Donnan PT, Daly F, Staa TV, Sullivan FM</AU>
<TI>Impact of clinical trial findings on Bell's palsy management in general practice in the UK 2001-2012: interrupted time series regression analysis</TI>
<SO>BMJ Open</SO>
<YR>2013</YR>
<VL>3</VL>
<NO>7</NO>
<PG>1-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murakami-1996" MODIFIED="2014-07-21 17:07:10 +0100" MODIFIED_BY="[Empty name]" NAME="Murakami 1996" TYPE="JOURNAL_ARTICLE">
<AU>Murakami S, Mizobuchi M, Nakashiro Y, Doi T, Hato N, Yanagihara N</AU>
<TI>Bell palsy and herpes simpex virus: identification of viral DNA in endoneurial fluid and muscle</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1996</YR>
<VL>124</VL>
<NO>1 Pt 1</NO>
<PG>27-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Niparko-1993" MODIFIED="2015-04-09 18:13:42 +0100" MODIFIED_BY="Ruth Brassington" NAME="Niparko 1993" TYPE="BOOK_SECTION">
<AU>Niparko JK, Mattox DE</AU>
<TI>Bell's palsy and herpes zoster oticus</TI>
<SO>Current Therapy in Neurologic Disease</SO>
<YR>1993</YR>
<PG>355-61</PG>
<EN>4th</EN>
<ED>Johnson RT, Griffin JW</ED>
<PB>BC Decker</PB>
<CY>St Louis, Missouri</CY>
<IDENTIFIERS MODIFIED="2014-01-21 20:18:47 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-01-21 20:18:47 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ISBN: 0801677300"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Numthavaj-2011" MODIFIED="2015-03-30 05:55:55 +0100" MODIFIED_BY="[Empty name]" NAME="Numthavaj 2011" TYPE="JOURNAL_ARTICLE">
<AU>Numthavaj P, Thakkinstian A, Dejthevaporn C, Attia J</AU>
<TI>Corticosteroid and antiviral therapy for Bell's palsy: a network meta-analysis</TI>
<SO>BMC Neurology</SO>
<YR>2011</YR>
<VL>11</VL>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2014-09-01 23:27:37 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-09-01 23:27:37 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1186/1471-2377-11-1"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Peitersen-1982" MODIFIED="2014-07-21 17:06:04 +0100" MODIFIED_BY="[Empty name]" NAME="Peitersen 1982" TYPE="JOURNAL_ARTICLE">
<AU>Peitersen E</AU>
<TI>The natural history of Bell's Palsy</TI>
<SO>American Journal of Otology</SO>
<YR>1982</YR>
<VL>4</VL>
<NO>2</NO>
<PG>107-11</PG>
<IDENTIFIERS MODIFIED="2014-05-15 23:10:30 +0100" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Peitersen-2002" MODIFIED="2014-07-21 17:05:35 +0100" MODIFIED_BY="[Empty name]" NAME="Peitersen 2002" TYPE="JOURNAL_ARTICLE">
<AU>Peitersen E</AU>
<TI>Bell's palsy: the spontaneous course of 2,500 peripheral facial nerve palsies of different etiologies</TI>
<SO>Acta Oto-Laryngologica</SO>
<YR>2002</YR>
<VL>122</VL>
<NO>Suppl 549</NO>
<PG>4-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Prescott-1988" MODIFIED="2014-07-21 17:04:34 +0100" MODIFIED_BY="[Empty name]" NAME="Prescott 1988" TYPE="JOURNAL_ARTICLE">
<AU>Prescott CA</AU>
<TI>Idiopathic facial nerve palsy (the effect of treatment with steroids)</TI>
<SO>Journal of Laryngology and Otology</SO>
<YR>1988</YR>
<VL>102</VL>
<NO>5</NO>
<PG>403-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Quant-2009" MODIFIED="2014-07-30 17:42:24 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Quant 2009" TYPE="JOURNAL_ARTICLE">
<AU>Quant CE, Jeste SS, Muni RH, Cape AV, Bhussar MK, Peleg AY</AU>
<TI>The benefits of steroids versus steroids plus antivirals for treatment of Bell's palsy: a meta-analysis</TI>
<SO>BMJ</SO>
<YR>2009</YR>
<VL>339</VL>
<PG>b3354</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2015-04-09 18:13:52 +0100" MODIFIED_BY="Ruth Brassington" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ross-1996" MODIFIED="2015-01-06 14:37:02 +0000" MODIFIED_BY="Ruth  Brassington" NAME="Ross 1996" TYPE="JOURNAL_ARTICLE">
<AU>Ross BG, Fradet G, Nedzelski JM</AU>
<TI>Development of a sensitive clinical facial grading system</TI>
<SO>Otolargynology - Head and Neck Surgery</SO>
<YR>1996</YR>
<VL>114</VL>
<NO>3</NO>
<PG>380-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Salinas-2010" MODIFIED="2014-01-25 14:01:45 +0000" MODIFIED_BY="[Empty name]" NAME="Salinas 2010" TYPE="COCHRANE_REVIEW">
<AU>Salinas RA, Alvarez G, Daly F, Ferreira J</AU>
<TI>Corticosteroids for Bell's palsy (idiopathic facial paralysis)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2014-01-25 14:01:45 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-01-25 14:01:45 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001942.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Victor-1994" MODIFIED="2015-04-09 18:14:10 +0100" MODIFIED_BY="Ruth Brassington" NAME="Victor 1994" TYPE="BOOK_SECTION">
<AU>Victor M, Martin J</AU>
<TI>Disorders of the cranial nerves</TI>
<SO>Harrison's Principles of Internal Medicine</SO>
<YR>1994</YR>
<PG>2347-52</PG>
<EN>13th</EN>
<ED>Isselbacher KJ</ED>
<PB>McGraw-Hill</PB>
<CY>New York</CY>
<IDENTIFIERS MODIFIED="2014-01-21 20:26:21 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-01-21 20:26:21 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ISBN: 0070323704"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wolf-1978" MODIFIED="2014-07-21 17:01:12 +0100" MODIFIED_BY="[Empty name]" NAME="Wolf 1978" TYPE="JOURNAL_ARTICLE">
<AU>Wolf SM, Wagner JH, Davidson S, Forsythe A</AU>
<TI>Treatment of Bell palsy with prednisone: a prospective randomized study</TI>
<SO>Neurology</SO>
<YR>1978</YR>
<VL>28</VL>
<NO>2</NO>
<PG>158-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yanagihara-1988" MODIFIED="2014-07-21 17:00:36 +0100" MODIFIED_BY="[Empty name]" NAME="Yanagihara 1988" TYPE="JOURNAL_ARTICLE">
<AU>Yanagihara N, Yumoto E, Shibahara T</AU>
<TI>Familial Bell's palsy: analysis of 25 families</TI>
<SO>Annals of Otology, Rhinology and Laryngology</SO>
<YR>1988</YR>
<VL>137</VL>
<PG>8-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yanagihara-2003" MODIFIED="2014-07-21 17:00:18 +0100" MODIFIED_BY="[Empty name]" NAME="Yanagihara 2003" TYPE="BOOK_SECTION">
<AU>Yanagihara N, Hato N</AU>
<TI>Assessment of facial nerve function following acoustic neuroma surgery: facial nerve grading system</TI>
<SO>Acoustic Neuroma. Consensus on Systems for Reporting Results</SO>
<YR>2003</YR>
<VL>10</VL>
<PG>91-98</PG>
<EN>1st</EN>
<ED>Kanzaki J, Tos M, Sanna M, Moffat DA, Kunihiro T, Inoue Y</ED>
<PB>Springer Japan</PB>
<CY>Tokyo</CY>
<IDENTIFIERS MODIFIED="2014-07-21 17:00:18 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-07-21 17:00:18 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE=" 10.1007/978-4-431-53942-116"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-10-15 09:22:11 +0100" MODIFIED_BY="Ruth  Brassington">
<REFERENCE ID="REF-Allen--2004" MODIFIED="2015-04-09 18:14:25 +0100" MODIFIED_BY="Ruth Brassington" NAME="Allen  2004" TYPE="COCHRANE_REVIEW">
<AU>Allen D, Dunn L</AU>
<TI>Aciclovir or valaciclovir for Bell's palsy (idiopathic facial paralysis)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2014-07-23 13:41:38 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-07-23 13:41:38 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001869.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gagyor-2015a" MODIFIED="2015-10-12 21:02:12 +0100" MODIFIED_BY="Ildiko Gagyor" NAME="Gagyor 2015a" TYPE="COCHRANE_REVIEW">
<AU>Gagyor I, Madhok VB, Daly F, Somasundara D, Sullivan M, Gammie F, et al</AU>
<TI>Antiviral treatment for Bell's palsy (idiopathic facial paralysis)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<NO>5</NO>
<IDENTIFIERS MODIFIED="2015-09-14 13:52:02 +0100" MODIFIED_BY="Ruth  Brassington">
<IDENTIFIER MODIFIED="2015-09-14 13:52:02 +0100" MODIFIED_BY="Ruth  Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD001869.pub5"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gagyor-2015b" MODIFIED="2015-10-12 21:01:54 +0100" MODIFIED_BY="Ildiko Gagyor" NAME="Gagyor 2015b" TYPE="COCHRANE_REVIEW">
<AU>Gagyor I, Madhok VB, Daly F, Somasundara D, Sullivan M, Gammie F et al</AU>
<TI>Antiviral treatment for Bell's palsy (idiopathic facial paralysis)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2015-09-14 13:55:16 +0100" MODIFIED_BY="Ruth  Brassington">
<IDENTIFIER MODIFIED="2015-09-14 13:55:16 +0100" MODIFIED_BY="Ruth  Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD001869.pub6"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lockhart-2009" MODIFIED="2014-07-17 17:08:29 +0100" MODIFIED_BY="[Empty name]" NAME="Lockhart 2009" TYPE="COCHRANE_REVIEW">
<AU>Lockhart P, Daly F, Pitkethly M, Comerford N, Sullivan F</AU>
<TI>Antiviral treatment for Bell's palsy (idiopathic facial paralysis)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2014-07-17 17:08:29 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-07-17 17:08:29 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001869.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sipe--2001" MODIFIED="2015-10-15 09:21:48 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Sipe  2001" TYPE="COCHRANE_REVIEW">
<AU>Sipe J, Dunn L</AU>
<TI>Aciclovir for Bell's palsy (idiopathic facial paralysis)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2014-01-25 14:39:22 +0000" MODIFIED_BY="Pauline Lockhart">
<IDENTIFIER MODIFIED="2014-01-25 14:39:22 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001869"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sipe-2001b" MODIFIED="2015-10-15 09:22:11 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Sipe 2001b" TYPE="COCHRANE_REVIEW">
<AU>Sipe J, Dunn L</AU>
<TI>Aciclovir for Bell's palsy (idiopathic facial paralysis)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2015-10-09 12:05:30 +0100" MODIFIED_BY="Ruth  Brassington">
<IDENTIFIER MODIFIED="2015-10-09 12:05:30 +0100" MODIFIED_BY="Ruth  Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD001869.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2014-10-11 16:41:20 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-10-12 20:58:40 +0100" MODIFIED_BY="Ildiko Gagyor">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-09-01 14:36:10 +0100" MODIFIED_BY="Ildiko Gagyor" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-04-16 07:40:23 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Adour-1996">
<CHAR_METHODS MODIFIED="2014-07-21 08:33:18 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-04-16 07:40:23 +0100" MODIFIED_BY="Ruth  Brassington">
<P>119 randomised, 99 included in published analysis. Initial diagnosis of idiopathic facial paralysis in primary care clinics or emergency departments confirmed in facial paralysis research clinic. Enrolment criteria: paralysis commenced &#8804; 3 days before treatment; all participants over 18 years of age; good physical health determined by history and physical exam; no contraindication for steroid or aciclovir treatment; all women of childbearing age had a negative pregnancy test result</P>
<P>lack of clear definition of diagnostic criteria (possibly affects generalisability/validity)</P>
<P>Exclusion criteria: any other medication for idiopathic facial paralysis; urea nitrogen or creatinine &gt; 2x upper limit of normal; liver transaminase &gt; 3x upper limit of normal; haemoglobin level &lt; 100 g/L; platelet count &lt; 75,000/mm<SUP>3</SUP>; or neutrophil count &lt; 1 x 10 to the 6/L</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-21 08:33:18 +0100" MODIFIED_BY="[Empty name]">
<P>Aciclovir (2000 mg per day for 10 days) and prednisone (1 mg/kg for 5 days tapered to 10 mg/day for remaining 5 days) or placebo and prednisone (1 mg/kg for 5 days tapered to 10 mg/day for remaining 5 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-09 17:47:47 +0100" MODIFIED_BY="Ruth Brassington">
<P>Primary outcome: recovery on facial paralysis recovery index where incomplete recovery is Facial Paralysis Recovery Profile &#8804; 7 at 4 months</P>
<P>Maximal stimulation test with or without electroneurography at follow-up at 2 weeks, 2, 3, and 4 months (if incomplete recovery) after paralysis onset</P>
<P>Final outcomes reported at 3 months or when recovered or palsy stabilised (not more clearly defined)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-04-09 17:47:59 +0100" MODIFIED_BY="Ruth Brassington">
<P>Single centre</P>
<P>The authors stated a dropout rate of 16.8%. The reason for dropout was documented for each participant, such as inability to keep appointments, low adherence to the treatment regimen, adverse events, and moving from the area.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-16 07:42:58 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-De-Diego-1998">
<CHAR_METHODS MODIFIED="2014-10-30 14:49:52 +0000" MODIFIED_BY="Ruth  Brassington">
<P>Randomised controlled trial with 2 parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-04-16 07:42:57 +0100" MODIFIED_BY="Ruth  Brassington">
<P>113 participants with Bell's palsy were randomised, 101 were included in published analysis: 54 in the aciclovir group, 47 in the prednisone group; baseline assessment was carried out within 96 hours</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-04-09 17:48:44 +0100" MODIFIED_BY="Ruth Brassington">
<P>Aciclovir (2400 mg/day for 10 days) or prednisone (1 mg/kg for 10 days then tapered to zero over the next 6 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-16 07:42:58 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Primary outcome: complete recovery using the House-Brackmann scale (&#8804; II) and the Facial Paralysis Recovery Profile (&#8805; 8)</P>
<P>Secondary outcomes: sequelae and synkinesis reported separately</P>
<P>Final outcomes reported at 4 months</P>
<P>Follow-up at 1, 3, 6, 12 weeks after first visit. Participants with incomplete recovery at 12 weeks were followed up until recovery or stabilisation of paralysis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-30 14:50:35 +0000" MODIFIED_BY="Ruth  Brassington">
<P>Single centre</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-16 07:42:59 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Engstr_x00f6_m-2008">
<CHAR_METHODS MODIFIED="2014-08-17 18:29:35 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled trial with 4 treatment groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-17 18:29:38 +0100" MODIFIED_BY="[Empty name]">
<P>829 participants randomised within 72 hours of facial palsy onset. No contraindications to corticosteroid or antiviral use</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-04-09 18:03:53 +0100" MODIFIED_BY="Ruth Brassington">
<P>Participants allocated into 1 of 4 treatment groups: valaciclovir with prednisolone, valaciclovir with placebo, placebo with prednisolone, or double placebo</P>
<P>Dosages: valaciclovir 1000 mg 3 times daily for 7 days; prednisolone 60 mg daily for 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-16 07:42:59 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Primary outcome: recovery of facial function, as assessed at all visits with the Sunnybrook scale and the House-Brackmann scale. Complete recovery was taken as Sunnybrook scale 100 and House-Brackmann scale grade I</P>
<P>Other outcomes:</P>
<P>Degree of pain, as recorded during the first 2 months; adverse events recorded for the first month</P>
<P>Frequency of severe pain, synkinesis, facial spasm, and residual facial symptoms at 12 months</P>
<P>Follow-up at 2 weeks, 1, 2, 3, 6, and 12 months after randomisation, according to recovery</P>
<P>Final outcomes reported at 12 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-04-09 18:04:19 +0100" MODIFIED_BY="Ruth Brassington">
<P>Multicentre</P>
<P>Some secondary outcomes were reported in papers published separately (<LINK REF="REF-Axelsson-2012" TYPE="REFERENCE">Axelsson 2012</LINK>; <LINK REF="REF-Berg-2012" TYPE="REFERENCE">Berg 2012</LINK>)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-16 07:43:01 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Hato-2007">
<CHAR_METHODS MODIFIED="2014-08-17 18:30:01 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel-group, placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-04-09 18:04:35 +0100" MODIFIED_BY="Ruth Brassington">
<P>296 participants recruited, 221 randomised: 114 to valaciclovir and prednisolone, 107 to prednisolone and placebo. All participants commenced treatment within 7 days of onset of palsy. All participants were over 15 years of age and had no contraindications to antivirals or corticosteroids. The final analysis included 221 participants</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-04-16 07:43:01 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Randomised to receive prednisolone 60 mg for 5 days, 30 mg for 3 days, and 10 mg for 2 days ± valaciclovir 1000 mg/day for 5 days. Following corticosteroids, all participants received methylcobalamin 1500 µg per day for 6 months or until complete recovery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-09 18:04:56 +0100" MODIFIED_BY="Ruth Brassington">
<P>Primary outcome: full recovery based on a score of &#8805; 36 on the Yanagihara scale (conversion scale to House-Brackmann scale included in paper)</P>
<P>Follow-up at 1, 3, and 6 months after commencing treatment</P>
<P>Final outcomes reported at 6 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-04-09 18:05:03 +0100" MODIFIED_BY="Ruth Brassington">
<P>Multicentre: 6 academic tertiary referral centres. 23 participants were excluded after randomisation because of herpes zoster; 52 were lost to follow-up (25.3%). Frequency and reasons for drop out of participants who did not complete the study were documented.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-16 07:43:03 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Kawaguchi-2007">
<CHAR_METHODS MODIFIED="2014-10-30 14:51:48 +0000" MODIFIED_BY="Ruth  Brassington">
<P>Randomised, controlled, parallel-group design</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-04-09 18:05:21 +0100" MODIFIED_BY="Ruth Brassington">
<P>150 participants randomly assigned to prednisolone group (66) or prednisolone and aciclovir group (84). All participants received treatment within 7 days of onset of Bell's palsy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-04-09 18:05:22 +0100" MODIFIED_BY="Ruth Brassington">
<P>Participants received either 20 mg prednisolone 3 times daily for 5 days, then 10 mg 3 times daily for 2 days, then 10 mg daily for 2 days plus valaciclovir 500 mg twice daily for 5 days or prednisolone (the same regimen) alone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-16 07:43:03 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Virological examination for anti-herpes simplex virus and anti-varicella zoster virus antibodies; detection of herpes simplex virus and herpes zoster virus reactivation</P>
<P>Facial movement and recovery measured using the Yanagihara rating scale, defined as a score of &#8805; 36</P>
<P>Follow-up for 6 months at 1 and 2 weeks after treatment and then at 1, 2, 3, 4, 5, and 6 months after treatment</P>
<P>Frequency of incomplete recovery at end of the study and adverse events</P>
<P>Final outcomes reported at 6 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-06 11:57:26 +0000" MODIFIED_BY="Ruth  Brassington">
<P>Multicentre: 12 university hospitals</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-09 18:05:55 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Lee-2013">
<CHAR_METHODS MODIFIED="2014-08-17 18:30:19 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, controlled, parallel-group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-04-09 17:49:26 +0100" MODIFIED_BY="Ruth Brassington">
<P>269 participants with severe Bell's palsy were recruited; 206 were included in the final analysis. 99 participants were assigned to the famciclovir and prednisolone group, 107 participants to the prednisolone group. All participants received treatment within 7 days of onset of palsy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-04-09 18:05:55 +0100" MODIFIED_BY="Ruth Brassington">
<P>Randomised to receive prednisolone 64 mg for 4 days, 48 mg for 2 days, 32 mg for 2 days, and 16 mg for 2 days ± famciclovir 750 mg/day for 7 days intravenously. In the famciclovir and prednisolone group, both drugs were given simultaneously</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-09 17:49:38 +0100" MODIFIED_BY="Ruth Brassington">
<P>Primary outcome: full recovery based on the House-Brackmann scale (grades I and II) at 6 months</P>
<P>Follow-up at 2 weeks and 6 months after commencing treatment</P>
<P>Apart from 2 excluded participants with adverse events, no further information reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-21 08:33:19 +0100" MODIFIED_BY="[Empty name]">
<P>Single centre</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-09 18:05:59 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Li--1997">
<CHAR_METHODS MODIFIED="2014-08-17 18:30:27 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled, double-blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-04-09 18:05:59 +0100" MODIFIED_BY="Ruth Brassington">
<P>Included 51 participants, 5 of whom were lost to follow-up. Participants with other causes of facial palsy were excluded. The age range was 15 to 73 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-04-09 17:49:50 +0100" MODIFIED_BY="Ruth Brassington">
<P>Randomised to receive either aciclovir and prednisone or placebo and prednisone. Prednisone was administered to both groups in a dose of 60 mg for 5 days then tapered in steps of 10 mg for a further 5 days. In the intervention group 800 mg aciclovir was given 5 times daily for 7 days. All participants received artificial tears and ophthalmic ointments</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-09 17:49:57 +0100" MODIFIED_BY="Ruth Brassington">
<P>Primary outcome: recovery of facial motor function up to 6 months</P>
<P>House-Brackmann scale was used for assessment; recovery was taken as grade I to II</P>
<P>Follow-up weekly for the first month, then monthly until recovery</P>
<P>Final outcomes reported at 6 months, adverse events were not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-21 08:33:20 +0100" MODIFIED_BY="[Empty name]">
<P>Single centre</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-16 07:43:04 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Sullivan-2007">
<CHAR_METHODS MODIFIED="2014-08-17 18:30:31 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, placebo-controlled, randomised, factorial trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-04-09 17:50:05 +0100" MODIFIED_BY="Ruth Brassington">
<P>551 participants randomised; 496 included in final outcome assessment. Referred for assessment and treatment within 72 hours of paralysis onset. All participants aged 16 or older and no contraindications to corticosteroids or antivirals</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-04-09 17:50:08 +0100" MODIFIED_BY="Ruth Brassington">
<P>Participants allocated to 1 of 4 treatment groups: either aciclovir, prednisolone, both agents, or placebo. Participants received prednisolone 25 mg twice daily for 10 days or aciclovir 400 mg 5 times daily for 10 days, both treatments, or neither treatment, depending upon allocation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-16 07:43:04 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Primary outcome measure: recovery rated on House-Brackmann scale, where recovery was grade I</P>
<P>Secondary outcomes included health-related quality of life, Health Utilities Index Mark 3, facial appearance (Derriford Appearance Scale), pain, and adverse outcomes. Frequency of incomplete recovery at end of study was recorded</P>
<P>Follow-up at 3 and 9 months</P>
<P>Final outcomes reported at 9 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-21 08:33:21 +0100" MODIFIED_BY="[Empty name]">
<P>Multicentre: 17 hospitals</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-09 18:06:13 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-V_x00e1_zquez-2008">
<CHAR_METHODS MODIFIED="2015-04-09 17:50:28 +0100" MODIFIED_BY="Ruth Brassington">
<P>Double-blind, randomised trial. Simple randomisation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-04-09 17:50:32 +0100" MODIFIED_BY="Ruth Brassington">
<P>Included 42 participants assigned to 2 treatment groups. Participants with other causes of facial palsy were excluded</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-04-09 18:06:13 +0100" MODIFIED_BY="Ruth Brassington">
<P>Randomised to receive either valaciclovir plus prednisone or prednisone plus placebo. Both groups received 1 mg/kg weight prednisone for 7 days, then reduced doses for 14 days</P>
<P>Participants in the treatment group received 2 g valaciclovir for 7 days</P>
<P>All participants undertook eye protection and received rehabilitation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-09 17:50:38 +0100" MODIFIED_BY="Ruth Brassington">
<P>Primary outcome: recovery on facial grading system (Sunnybrook scale), where recovery was taken as &gt; 90</P>
<P>Follow-up at 1, 2, 4, 8, and 12 months</P>
<P>Final outcomes reported at 6 months</P>
<P>Adverse events were not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-21 08:33:21 +0100" MODIFIED_BY="[Empty name]">
<P>Single centre</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-16 07:43:05 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Yeo-2008">
<CHAR_METHODS MODIFIED="2014-08-17 18:30:50 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, 2-arm design</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-04-09 18:06:16 +0100" MODIFIED_BY="Ruth Brassington">
<P>91 participants; other causes of facial palsy were excluded. No maximum period after onset stated, but actual time to treatment recorded. All participants were admitted to hospital and received physical therapy and plasma volume expanders as adjuncts</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-04-16 07:43:04 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Randomised to receive either aciclovir and prednisolone or prednisolone alone. Aciclovir given at a dose of 2400 mg/day for 5 days. Prednisolone given as 1 mg/kg/day for 5 days, then tapered on days 6 to 10. All participants admitted to hospital and received physical therapy and plasma volume expanders as adjuncts</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-16 07:43:05 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Primary outcome: recovery on House-Brackmann scale, where recovery was grade &#8804; II</P>
<P>Subgroup analysis of early versus delayed treatment</P>
<P>Follow-up at 2 and 6 months</P>
<P>Final outcomes reported at 6 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-18 20:27:49 +0100" MODIFIED_BY="[Empty name]">
<P>Single centre. All participants admitted</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-04-16 07:43:07 +0100" MODIFIED_BY="Ruth  Brassington" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-12-19 21:09:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ahangar-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 21:09:23 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation was not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-04-09 18:06:36 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Antunes-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-04-09 18:06:36 +0100" MODIFIED_BY="Ruth Brassington">
<P>Small study numbers and insufficient information in original paper to assign a participant with incomplete recovery to the correct control group. Author contacted by Dr D Allen, but no response received</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-14 17:35:15 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Axelsson-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-14 17:35:15 +0100" MODIFIED_BY="Ruth Brassington">
<P>Use of a historical control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-08 14:47:16 +0000" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-Chen-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-08 14:47:16 +0000" MODIFIED_BY="Ruth  Brassington">
<P>Follow-up data for only 4 weeks from palsy onset</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-04-16 07:43:07 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-de-Aquino-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-04-16 07:43:07 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Methodology not clear from original paper. An author of a previous version of this review (D Allen) attempted to obtain further information but obtained no response</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-14 17:35:10 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Hato-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-14 17:35:10 +0100" MODIFIED_BY="Ruth Brassington">
<P>Retrospective analysis of treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 21:09:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hultcrantz-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 21:09:42 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation was not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-14 17:35:03 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Ibarrondo-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-14 17:35:03 +0100" MODIFIED_BY="Ruth Brassington">
<P>Retrospective study. 100 participants collected between 1983 and 1989 received corticotherapy. 100 participants treated after 1989 received aciclovir</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-04-09 18:06:53 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Inanli-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-04-09 18:06:53 +0100" MODIFIED_BY="Ruth Brassington">
<P>The paper was not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-19 21:10:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Minnerop-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-19 21:10:03 +0000" MODIFIED_BY="[Empty name]">
<P>Inadequate random allocation to treatment group, no blinding, 30% lost to follow-up, intervention group and control group of unequal size </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-04-09 18:07:00 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Ramos-Macias-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-04-09 18:07:00 +0100" MODIFIED_BY="Ruth Brassington">
<P>Inadequate allocation concealment. No information reported about methods of randomisation, diagnostic criteria used, length of follow-up, or number of participants lost to follow-up. Thirty-three percent had Ramsay Hunt syndrome, abstract only available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-04-09 18:07:02 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Roy-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-04-09 18:07:02 +0100" MODIFIED_BY="Ruth Brassington">
<P>Inadequate information on outcome data, 22% lost to follow-up, abstract only published in journal supplement and not traced as a full publication</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 15:22:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shahidullah-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 15:22:17 +0000" MODIFIED_BY="[Empty name]">
<P>Inadequate random allocation to treatment group, no blinding, 36% lost to follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-04-09 18:08:19 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Zhou-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-04-09 18:08:19 +0100" MODIFIED_BY="Ruth Brassington">
<P>Prospective study. 69 participants with Bell's palsy followed up for only 2 weeks. Not double blind, and allocation concealment not described. Used own scale for palsy grading, outcome measures not met. Did report adverse events. Four participants receiving aciclovir treatment had gastric malaise</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-10-12 20:58:40 +0100" MODIFIED_BY="Ildiko Gagyor" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2015-10-12 20:58:40 +0100" MODIFIED_BY="Ildiko Gagyor" STUDY_ID="STD-Abdelghany-2013">
<CHAR_METHODS MODIFIED="2015-09-14 14:54:41 +0100" MODIFIED_BY="Ruth  Brassington"/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2015-10-12 20:58:40 +0100" MODIFIED_BY="Ildiko Gagyor">
<P>To be assessed following completion of an investigation into the reliability of the trial data</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2015-10-08 14:44:04 +0100" MODIFIED_BY="Ruth  Brassington" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2015-04-16 07:43:12 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-IRCT201109187575N1">
<CHAR_STUDY_NAME MODIFIED="2015-04-09 18:08:26 +0100" MODIFIED_BY="Ruth Brassington">
<P>Comparison of therapeutic effects of prednisolone, aciclovir, and combination of these drugs in Bell's palsy</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-12-21 12:34:26 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel assignment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-04-09 18:08:30 +0100" MODIFIED_BY="Ruth Brassington">
<P>People with Bell's palsy over 10 years of age, less than 7 days from the onset of paralysis<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-04-16 07:43:12 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Group 1: prednisone 1 mg/kg body weight daily for 3 days. The treatment was tapered over the next 12 days </P>
<P>Group 2: aciclovir, 400 mg every 5 hours per day for 10 days</P>
<P>Group 3: combination of aciclovir and prednisone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-12-21 12:32:07 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: House-Brackmann score every 15 days</P>
<P>Treatment failure (no reduction of House-Brackmann score) at the end of month 3</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-12-21 12:32:07 +0000" MODIFIED_BY="[Empty name]">
<P>22 May 2010</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-12-21 12:32:07 +0000" MODIFIED_BY="[Empty name]">
<P>Dr Alireza Rezaei Ashtiani</P>
<P>Department of Internal Medicine,Valie-Asr Hospital, Arak</P>
<P>Islamic Republic of Iran</P>
<P>dr.ashtiani@arakmu.ac.ir</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-12-21 12:32:07 +0000" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2015-10-08 14:44:04 +0100" MODIFIED_BY="Ruth  Brassington" STUDY_ID="STD-IRCT2012062210087N1">
<CHAR_STUDY_NAME MODIFIED="2015-04-09 18:08:37 +0100" MODIFIED_BY="Ruth Brassington">
<P>Efficacy of corticosteroid and aciclovir in Bell's palsy</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-12-21 12:48:10 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-12-21 12:48:10 +0000" MODIFIED_BY="[Empty name]">
<P>Children 2 to 18 years old with Bell's palsy less than 3 days after the start of symptoms</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-04-16 07:43:13 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Combination therapy with prednisolone 2 mg/kg of body weight for 7 days and aciclovir or prednisolone alone 20 mg/kg of body weight for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-09 18:08:55 +0100" MODIFIED_BY="Ruth Brassington">
<P>Severity of Bell's palsy at House-Brackmann score 1 and 2 months after treatment</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-10-08 14:44:04 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Recruitment completed </P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-01-06 11:44:06 +0000" MODIFIED_BY="Ruth  Brassington">
<P>Ali Khwaja</P>
<P>Imam Ali Hospital in Zahedan</P>
<P>Zahedan</P>
<P>Sistan and Baluchestan</P>
<P>drkhajehneuro@gmail</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-10-08 14:44:03 +0100" MODIFIED_BY="Ruth  Brassington"/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-09-01 14:36:10 +0100" MODIFIED_BY="Ildiko Gagyor">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-09-01 14:36:10 +0100" MODIFIED_BY="Ildiko Gagyor" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-14 17:03:05 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Adour-1996">
<DESCRIPTION>
<P>Quote "the bottles [of aciclovir and placebo], provided by Burroughs Wellcome, were randomised in groups of 10"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-30 14:50:41 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-De-Diego-1998">
<DESCRIPTION>
<P>Quote "patients were randomly assigned". Randomisation method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-09 18:04:21 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Engstr_x00f6_m-2008">
<DESCRIPTION>
<P>Quote "...randomization code was developed by Glaxo Wellcome GmBH, with a computer number generator to select random permuted blocks of eight"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-09 18:05:06 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Hato-2007">
<DESCRIPTION>
<P>Quote "the patients were randomly divided into two groups using the envelope method". Randomisation was carried out without stratification. No central randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-30 14:52:29 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Kawaguchi-2007">
<DESCRIPTION>
<P>Sequence generation using envelope method</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-27 13:46:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lee-2013">
<DESCRIPTION>
<P>Random sequence generation using computer codes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-21 08:33:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li--1997">
<DESCRIPTION>
<P>Simple randomisation by coding of treatment drugs. </P>
<P>Little information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-09 17:50:23 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Sullivan-2007">
<DESCRIPTION>
<P>Quote "...patient was randomly assigned to a study group by an independent, secure, automated telephone randomisation service."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-14 10:51:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-V_x00e1_zquez-2008">
<DESCRIPTION>
<P>Simple randomisation, not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-09 21:14:17 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Yeo-2008">
<DESCRIPTION>
<P>States 'randomised' in study title, but no description of this in the article</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-09-01 14:36:10 +0100" MODIFIED_BY="Ildiko Gagyor" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-09 17:48:08 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Adour-1996">
<DESCRIPTION>
<P>Quote "Each bottle...had a sealed identification label which was removed intact and kept with the patient's record"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-30 14:50:51 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-De-Diego-1998">
<DESCRIPTION>
<P>No clear information on concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-09 18:04:25 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Engstr_x00f6_m-2008">
<DESCRIPTION>
<P>Randomisation code double blind and held by a third party. Medication dispensed in identical containers to conceal allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-09 18:05:09 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Hato-2007">
<DESCRIPTION>
<P>Participants were assigned to one of the groups by moderators, but the allocation concealment was not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-09 17:49:11 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Kawaguchi-2007">
<DESCRIPTION>
<P>Not used; when participants were entered into the trial, the allocation envelope contained the name of the treatment group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-21 08:33:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lee-2013">
<DESCRIPTION>
<P>No information on concealment. No placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-21 08:33:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li--1997">
<DESCRIPTION>
<P>Allocation concealment not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-14 17:14:42 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Sullivan-2007">
<DESCRIPTION>
<P>All parties blinded to allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-14 10:52:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-V_x00e1_zquez-2008">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-09 21:13:41 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Yeo-2008">
<DESCRIPTION>
<P>No clear statement of this in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-02-09 16:51:44 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="GROUP" NO="12">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-13" LEVEL="GROUP" NO="13">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-02-09 16:56:40 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-02-09 16:56:40 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2015-09-01 14:36:10 +0100" MODIFIED_BY="Ildiko Gagyor" NO="7">
<NAME>Blinding of participants?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated intervention adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-09 18:03:36 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Adour-1996">
<DESCRIPTION>
<P>Quote "eligible patients were given identical, unlabeled bottles of 100 capsules that contained either placebo or aciclovir (Zovirax), 200 mg"</P>
<P>Participants in each group received identical follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-30 14:50:57 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-De-Diego-1998">
<DESCRIPTION>
<P>Presence of blinding not clearly described, although groups received different treatment regimens</P>
<P>No placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-14 17:13:36 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Engstr_x00f6_m-2008">
<DESCRIPTION>
<P>Study drugs issued in identical containers. All participants blinded to treatment group until study completion</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-09 18:05:10 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Hato-2007">
<DESCRIPTION>
<P>Inadequate. Participants blinded to treatment, but different treatments with different frequencies meant that true blinding was not achieved</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-30 14:52:29 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Kawaguchi-2007">
<DESCRIPTION>
<P>Not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-21 08:33:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lee-2013">
<DESCRIPTION>
<P>No placebo. No information on concealment </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-21 08:33:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Li--1997">
<DESCRIPTION>
<P>Blinding procedure not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-21 08:33:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sullivan-2007">
<DESCRIPTION>
<P>Participants not receiving active drug received placebo. All administered medication identical and in identical containers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-28 17:54:35 +0000" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-V_x00e1_zquez-2008">
<DESCRIPTION>
<P>Different treatment regimens in both groups, blinding and usage of placebo not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-09 21:13:39 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Yeo-2008">
<DESCRIPTION>
<P>States 'double-blind' in study title, but no description of methods employed for this in text </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2015-09-01 14:36:10 +0100" MODIFIED_BY="Ildiko Gagyor" NO="8">
<NAME>Blinding of assessors?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated intervention adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-09 17:48:25 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Adour-1996">
<DESCRIPTION>
<P>The study was reported as double blind; the method reported was consistent with being able to achieve this</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-30 14:51:13 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-De-Diego-1998">
<DESCRIPTION>
<P>Not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-14 17:13:37 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Engstr_x00f6_m-2008">
<DESCRIPTION>
<P>All study personnel and data analysts blinded to treatment group until study completion</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-21 08:33:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hato-2007">
<DESCRIPTION>
<P>Not done. Assessors were not blinded to treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-30 14:52:29 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Kawaguchi-2007">
<DESCRIPTION>
<P>Not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-29 23:15:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lee-2013">
<DESCRIPTION>
<P>Different treatment regimens in both groups. No information on concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-21 08:33:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li--1997">
<DESCRIPTION>
<P>Blinding procedure not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-14 17:14:44 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Sullivan-2007">
<DESCRIPTION>
<P>Assessors blinded to treatment group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-28 17:54:42 +0000" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-V_x00e1_zquez-2008">
<DESCRIPTION>
<P>Blinding not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-09 21:13:37 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Yeo-2008">
<DESCRIPTION>
<P>States 'double-blind' in study title, but no description of methods employed for this in text </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2015-09-01 14:36:10 +0100" MODIFIED_BY="Ildiko Gagyor" NO="9">
<NAME>Incomplete outcome data?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-09 17:48:29 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Adour-1996">
<DESCRIPTION>
<P>The numbers of participants unable to complete the study was given. High dropout rate reported: 16.8%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-09 17:48:59 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-De-Diego-1998">
<DESCRIPTION>
<P>Number of dropouts was reported: 10% were lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-21 08:33:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Engstr_x00f6_m-2008">
<DESCRIPTION>
<P>Numbers lost to follow-up and reasons given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-09 18:05:13 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Hato-2007">
<DESCRIPTION>
<P>Frequency and reasons for dropouts documented. High dropout rate reported; 25.3%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-30 14:52:29 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Kawaguchi-2007">
<DESCRIPTION>
<P>Numbers of participants who did not complete clearly documented: 10% were lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-09 18:05:57 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Lee-2013">
<DESCRIPTION>
<P>Per protocol analysis only. High dropout rate reported: 13.1%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-21 08:33:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li--1997">
<DESCRIPTION>
<P>Per protocol analysis, 5 participants were lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-09 18:06:10 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Sullivan-2007">
<DESCRIPTION>
<P>All participants who were unable to complete were documented -- both frequency and reason</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-14 10:53:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-V_x00e1_zquez-2008">
<DESCRIPTION>
<P>All outcome data were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-09 21:13:34 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Yeo-2008">
<DESCRIPTION>
<P>Incomplete follow-up data not mentioned in the study </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2015-09-01 14:36:10 +0100" MODIFIED_BY="Ildiko Gagyor" NO="10">
<NAME>Selective outcome reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting? </P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-09 17:48:33 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Adour-1996">
<DESCRIPTION>
<P>Primary outcomes of facial paralysis recovery profile and bilateral facial nerve electrical testing reported, but no data given on audiometry with stapedial reflex testing, adverse events were not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-30 14:51:34 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-De-Diego-1998">
<DESCRIPTION>
<P>Adverse events were not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-21 08:33:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Engstr_x00f6_m-2008">
<DESCRIPTION>
<P>All primary outcomes reported. Other outcomes were reported in another paper due to space constrictions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-21 16:11:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hato-2007">
<DESCRIPTION>
<P>Main outcome measures, adverse events all reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-30 14:52:29 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="NO" STUDY_ID="STD-Kawaguchi-2007">
<DESCRIPTION>
<P>Frequency of incomplete recovery at end of the study and adverse events not reported in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-21 16:19:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lee-2013">
<DESCRIPTION>
<P>Adverse events were not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-03 21:55:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li--1997">
<DESCRIPTION>
<P>Primary outcomes were reported, adverse events were not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-14 17:14:46 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Sullivan-2007">
<DESCRIPTION>
<P>All planned outcome measures reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-09 18:06:14 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-V_x00e1_zquez-2008">
<DESCRIPTION>
<P>All planned outcome measures reported; authors reported synkinesis and adverse effects, but without assigning the cases to the groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-09 21:13:30 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Yeo-2008">
<DESCRIPTION>
<P>Stated primary outcome measure reported, no adverse events reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2015-09-01 14:36:10 +0100" MODIFIED_BY="Ildiko Gagyor" NO="11">
<NAME>Other sources of bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 21:43:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Adour-1996">
<DESCRIPTION>
<P>No other risks of bias reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-30 14:51:40 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-De-Diego-1998">
<DESCRIPTION>
<P>No other potential risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-14 17:13:39 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Engstr_x00f6_m-2008">
<DESCRIPTION>
<P>No other potential sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-21 08:33:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hato-2007">
<DESCRIPTION>
<P>Statistical tests employed not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-30 14:52:29 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Kawaguchi-2007">
<DESCRIPTION>
<P>No other potential sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-09 17:49:45 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Lee-2013">
<DESCRIPTION>
<P>Two participants with adverse events in the steroid group (not clearly specified) were excluded from the analysis</P>
<P>Diagnostic criteria not clearly defined in paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-17 21:44:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li--1997">
<DESCRIPTION>
<P>Not given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-06 11:43:00 +0000" MODIFIED_BY="Ruth  Brassington" RESULT="YES" STUDY_ID="STD-Sullivan-2007">
<DESCRIPTION>
<P>No other potential sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-21 09:07:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-V_x00e1_zquez-2008">
<DESCRIPTION>
<P>No other potential sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-09 21:13:58 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Yeo-2008">
<DESCRIPTION>
<P>No further potential risks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-10-15 14:17:42 +0100" MODIFIED_BY="Ruth  Brassington">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-10-15 14:17:42 +0100" MODIFIED_BY="Ruth  Brassington" NO="1" READONLY="YES">
<TITLE MODIFIED="2015-09-01 22:09:35 +0100" MODIFIED_BY="Grade Profiler">Antivirals plus corticosteroids compared to corticosteroids plus placebo or no treatment for Bell's palsy (idiopathic facial paralysis)</TITLE>
<TABLE COLS="7" ROWS="16">
<TR>
<TD COLSPAN="7">
<P>
<B>Antivirals plus corticosteroids compared to corticosteroids plus placebo or no treatment for Bell's palsy (idiopathic facial paralysis)</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> People with one-sided mild, moderate, or severe Bell&#8217;s palsy of unknown cause<BR/>
<B>Settings:</B> Primary and secondary care<BR/>
<B>Intervention:</B> Antivirals plus corticosteroids<BR/>
<B>Comparison: </B>Corticosteroids plus placebo or no treatment</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Corticosteroids plus placebo or no treatment</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Antivirals plus corticosteroids </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Incomplete recovery at end of study</B>
<BR/>House-Brackmann scale, Sunnybrook score, Yanagihara score<BR/>Follow-up: 3 to 12 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.61 </B>
<BR/>(0.39 to 0.97)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1315<BR/>(8 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>168 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>102 per 1000</B>
<BR/>(66 to 163)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>149 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>91 per 1000</B>
<BR/>(58 to 145)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Motor synkinesis or crocodile tears</B>
<BR/>Clinical assessment<BR/>Follow-up: 4 to 9 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.56 </B>
<BR/>(0.36 to 0.87)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>469<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>194 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>109 per 1000</B>
<BR/>(70 to 169)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>228 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>128 per 1000</B>
<BR/>(82 to 198)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events</B>
<BR/>Follow-up: 6 to 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>108 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>127 per 1000</B>
<BR/>(89 to 182)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.18 </B>
<BR/>(0.83 to 1.69)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>877<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> The benefit to people with Bell's palsy was greater from the combination of antivirals with corticosteroids than with corticosteroids alone or with placebo. We downgraded the quality of evidence for the outcome twice because the heterogeneity of the trials was high (inconsistency), the RR had wide CIs that included the possibility of very little effect (imprecision), and for risk of bias in the included studies. Heterogeneity may be due to clinical variation of participant characteristics, disease severity at baseline, delay in receiving treatment, different type of antiviral agent used, the choice of outcome assessment measures and recovery cut-off points, or the trial duration.<BR/>
<SUP>2</SUP> We assessed the quality of evidence for motor synkinesis or crocodile tears as moderate because only four of 10 trials provided data (selective reporting).<BR/>
<SUP>3</SUP> One of the trials did not report how adverse events were documented (<LINK REF="STD-Hato-2007" TYPE="STUDY">Hato 2007</LINK>). In this trial the numbers are very small.<BR/>
<SUP>4</SUP> We downgraded the quality of evidence for adverse events to low. We downgraded once for publication bias, as only three of the eight studies in this comparison reported adverse events, and a second time for imprecision as the CIs were wide and encompassed the possibility of an effect in either direction.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2015-10-14 21:59:28 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2015-04-16 07:43:14 +0100" MODIFIED_BY="Ruth  Brassington" NO="1">
<TITLE MODIFIED="2009-06-23 11:37:57 +0100" MODIFIED_BY="Kate Jewitt">House-Brackmann Scale</TITLE>
<TABLE COLS="2" ROWS="7">
<TR>
<TH>
<P>Grade</P>
</TH>
<TH>
<P>Description</P>
</TH>
</TR>
<TR>
<TD>
<P>I</P>
</TD>
<TD>
<P>Normal</P>
</TD>
</TR>
<TR>
<TD>
<P>II</P>
</TD>
<TD>
<P>Mild dysfunction; slight weakness noticeable only on close inspection; may have slight synkinesis</P>
</TD>
</TR>
<TR>
<TD>
<P>III</P>
</TD>
<TD>
<P>Moderate dysfunction; obvious but not disfiguring difference between the 2 sides; noticeable but not severe synkinesis</P>
</TD>
</TR>
<TR>
<TD>
<P>IV</P>
</TD>
<TD>
<P>Moderately severe dysfunction; obvious weakness or disfiguring asymmetry, or both</P>
</TD>
</TR>
<TR>
<TD>
<P>V</P>
</TD>
<TD>
<P>Only barely perceptible motion</P>
</TD>
</TR>
<TR>
<TD>
<P>VI</P>
</TD>
<TD>
<P>No movement</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>House JW. Facial nerve grading systems. Laryngoscope 1983; 93: 1056-69.</P>
<P>House JW, Brackmann DE. Facial nerve grading system. Otolaryngology, Head and Neck Surgery 1985; 93: 146-7.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2015-10-14 21:59:28 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-07-01 09:45:34 +0100" MODIFIED_BY="[Empty name]">Sunnybrook Scale</TITLE>
<TABLE COLS="4" ROWS="20">
<TR>
<TH COLSPAN="4" VALIGN="BOTTOM">
<P>Facial Grading System</P>
</TH>
</TR>
<TR>
<TH COLSPAN="2" VALIGN="BOTTOM">
<P>
<B>Resting symmetry</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Symmetry of voluntary movement</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Synkinesis</B>
</P>
</TH>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>Compared to normal side</P>
</TD>
<TD VALIGN="TOP">
<P>Degree of muscle EXCURSION compared to normal side</P>
</TD>
<TD VALIGN="TOP">
<P>Degree of INVOLUNTARY MUSCLE CONTRACTION associated with each expression</P>
</TD>
</TR>
<TR>
<TH COLSPAN="2">
<P>
<B>Eye</B>
</P>
</TH>
<TD ROWSPAN="14" VALIGN="TOP">
<P>
<B>STANDARD EXPRESSIONS</B>
</P>
<P>Forehead wrinkle</P>
<P>Gentle eye closure</P>
<P>Open mouth smile</P>
<P>Snarl</P>
<P>Lip pucker</P>
<P>Score each out of 5, where 5 is normal and 1 is gross asymmetry/no movement</P>
</TD>
<TD ROWSPAN="14" VALIGN="TOP">
<P>
<B>STANDARD EXPRESSIONS</B>
</P>
<P>Forehead wrinkle</P>
<P>Gentle eye closure</P>
<P>Open mouth smile</P>
<P>Snarl</P>
<P>Lip pucker</P>
<P>Score each facial movement listed under standard expressions on a scale 0 to 3, where 0 is no asymmetry and 3 is severe asymmetry</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Normal = 0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Narrow = 1</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Wide =1</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Eyelid surgery = 1</P>
</TD>
</TR>
<TR>
<TH COLSPAN="2">
<P>
<B>Cheek</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Normal = 0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Absent = 2</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Less pronounced = 1</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>More pronounced =1</P>
</TD>
</TR>
<TR>
<TH COLSPAN="2">
<P>
<B>Mouth</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Normal = 0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Corner drooped =1</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Corner pulled up/out = 1</P>
</TD>
</TR>
<TR>
<TD>
<P>TOTAL</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>TOTAL</P>
</TD>
<TD>
<P>TOTAL</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Resting symmetry score x 5</B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>Voluntary movement score</B>
</P>
<P>
<B>Total x 4</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Synkinesis score</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>Voluntary Movement Score - Resting Symmetry Score - Synkinesis Score = Composite Score</B>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Weighted regional evaluation using five separate expressions. Composite score from 0 (total paralysis) to 100 (normal function). </P>
<P>Ross BG, Fradet G, Nedzelski JM. Development of a sensitive clinical facial grading system. Otolaryngology, Head and Neck Surgery 1996; 114: 380-6.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2015-04-16 07:43:33 +0100" MODIFIED_BY="Ruth  Brassington" NO="3">
<TITLE MODIFIED="2014-01-21 22:26:50 +0000" MODIFIED_BY="Kate Jewitt">Yanagihara Scale</TITLE>
<TABLE COLS="6" ROWS="12">
<TR>
<TH>
<P>Mode</P>
</TH>
<TH COLSPAN="5">
<P>Degree of paralysis</P>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>
<B>4</B>
</P>
<P>normal</P>
</TD>
<TD>
<P>
<B>3</B>
</P>
<P>slight</P>
</TD>
<TD>
<P>
<B>2</B>
</P>
<P>moderate</P>
</TD>
<TD>
<P>
<B>1</B>
</P>
<P>severe</P>
</TD>
<TD>
<P>
<B>0</B>
</P>
<P>total</P>
</TD>
</TR>
<TR>
<TD>
<P>At rest</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Wrinkle forehead</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Blink</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Normal closure of eye</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Forced closure of eye</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Closure of eye on involved side</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Wrinkle nose</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Whistle</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Grin</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Depress lower lip/ blow out cheek</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Ten separate categories of function, each scored 0 (total paralysis) to 4 (normal), then summed, giving a total score from 0 (total paralysis) to 40 (normal function).</P>
<P>Yanighara N. Grading of facial palsy. Proceedings of the 3rd International Symposium on Facial Nerve Surgery, Zurich 1976. In Fish U ed. Facial Nerve Surgery. Amstelveen, The Netherlands: Kugler Medical Publications 1977: 533-5.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-10-15 10:20:17 +0100" MODIFIED_BY="Ruth  Brassington">
<COMPARISON ID="CMP-001" MODIFIED="2015-10-15 10:10:35 +0100" MODIFIED_BY="Ruth  Brassington" NO="1">
<NAME>Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment</NAME>
<DICH_OUTCOME CHI2="13.185441292519918" CI_END="0.9655599427355317" CI_START="0.3864391555000013" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6108438170722107" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="108" I2="46.91114355064408" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.015220759697961574" LOG_CI_START="-0.41291887564150603" LOG_EFFECT_SIZE="-0.21406981766973385" METHOD="MH" MODIFIED="2015-10-12 12:47:48 +0100" MODIFIED_BY="Ruth  Brassington" NO="1" P_CHI2="0.06771706867401239" P_Q="1.0" P_Z="0.03485938661451597" Q="0.0" RANDOM="YES" SCALE="14.052775232250953" SORT_BY="EFFECT_SIZE" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.18402899068895692" TOTALS="YES" TOTAL_1="672" TOTAL_2="643" WEIGHT="100.00000000000001" Z="2.1099880335832153">
<NAME>Incomplete recovery at end of study</NAME>
<GROUP_LABEL_1>AS</GROUP_LABEL_1>
<GROUP_LABEL_2>OS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OS</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6742062103727454" CI_START="0.09908298950104982" EFFECT_SIZE="0.25846153846153846" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.17120725134309242" LOG_CI_START="-1.004000898490893" LOG_EFFECT_SIZE="-0.5876040749169927" MODIFIED="2015-10-12 12:47:47 +0100" MODIFIED_BY="Ruth  Brassington" ORDER="36" O_E="0.0" SE="0.48918711072965665" STUDY_ID="STD-Li--1997" TOTAL_1="25" TOTAL_2="21" VAR="0.23930402930402933" WEIGHT="12.89140125506382"/>
<DICH_DATA CI_END="0.9238600521587879" CI_START="0.10781826723759226" EFFECT_SIZE="0.3156089193825043" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="-0.03439381144047726" LOG_CI_START="-0.9673076520584779" LOG_EFFECT_SIZE="-0.5008507317494776" MODIFIED="2015-10-12 12:47:47 +0100" MODIFIED_BY="Ruth  Brassington" ORDER="33" O_E="0.0" SE="0.5479982079770028" STUDY_ID="STD-Adour-1996" TOTAL_1="53" TOTAL_2="46" VAR="0.30030203594600646" WEIGHT="11.267822057909799"/>
<DICH_DATA CI_END="1.0393315242395738" CI_START="0.1120826433700847" EFFECT_SIZE="0.3413078149920255" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.016754100186924886" LOG_CI_START="-0.9504616351499763" LOG_EFFECT_SIZE="-0.46685376748152563" MODIFIED="2015-10-12 12:47:48 +0100" MODIFIED_BY="Ruth  Brassington" ORDER="35" O_E="0.0" SE="0.5681473107320021" STUDY_ID="STD-Hato-2007" TOTAL_1="114" TOTAL_2="107" VAR="0.32279136669200614" WEIGHT="10.767830742728815"/>
<DICH_DATA CI_END="1.6605653090881272" CI_START="0.12620624095197316" EFFECT_SIZE="0.4577922077922078" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.22025596082499527" LOG_CI_START="-0.898919168515124" LOG_EFFECT_SIZE="-0.33933160384506433" MODIFIED="2015-10-09 16:32:00 +0100" MODIFIED_BY="Ruth  Brassington" ORDER="39" O_E="0.0" SE="0.6574090109806243" STUDY_ID="STD-Yeo-2008" TOTAL_1="44" TOTAL_2="47" VAR="0.43218660771852263" WEIGHT="8.856244209577442"/>
<DICH_DATA CI_END="1.7112082951571" CI_START="0.2850502178399769" EFFECT_SIZE="0.6984126984126984" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.23330287683008172" LOG_CI_START="-0.5450786227648703" LOG_EFFECT_SIZE="-0.1558878729673943" MODIFIED="2015-10-12 12:47:48 +0100" MODIFIED_BY="Ruth  Brassington" ORDER="36" O_E="0.0" SE="0.457225145912639" STUDY_ID="STD-Kawaguchi-2007" TOTAL_1="84" TOTAL_2="66" VAR="0.20905483405483405" WEIGHT="13.883440329310424"/>
<DICH_DATA CI_END="1.2303554205163372" CI_START="0.5959806148610618" EFFECT_SIZE="0.8563106796116505" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="50" LOG_CI_END="0.090030586944918" LOG_CI_START="-0.22476786609162286" LOG_EFFECT_SIZE="-0.06736863957335246" MODIFIED="2015-09-14 13:25:52 +0100" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="0.1849141695911382" STUDY_ID="STD-Engstr_x00f6_m-2008" TOTAL_1="206" TOTAL_2="210" VAR="0.03419325011558022" WEIGHT="25.008247578832826"/>
<DICH_DATA CI_END="6.955017037422863" CI_START="0.2412937984636038" EFFECT_SIZE="1.2954545454545454" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8422981982029283" LOG_CI_START="-0.6174538398303203" LOG_EFFECT_SIZE="0.11242217918630396" MODIFIED="2015-10-09 16:32:01 +0100" MODIFIED_BY="Ruth  Brassington" ORDER="38" O_E="0.0" SE="0.8574655730298562" STUDY_ID="STD-V_x00e1_zquez-2008" TOTAL_1="22" TOTAL_2="19" VAR="0.7352472089314195" WEIGHT="5.936579047190827"/>
<DICH_DATA CI_END="5.347004248288406" CI_START="0.635621461616576" EFFECT_SIZE="1.8435483870967742" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.7281105291550403" LOG_CI_START="-0.1968014473609846" LOG_EFFECT_SIZE="0.26565454089702784" MODIFIED="2015-09-14 13:25:33 +0100" MODIFIED_BY="[Empty name]" ORDER="37" O_E="0.0" SE="0.543297873393636" STUDY_ID="STD-Sullivan-2007" TOTAL_1="124" TOTAL_2="127" VAR="0.2951725792340474" WEIGHT="11.388434779386053"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2483261847086718" CI_END="0.8743678563607706" CI_START="0.3583755391206642" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5597785740032131" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.05830581636226334" LOG_CI_START="-0.4456616407159762" LOG_EFFECT_SIZE="-0.25198372853911977" METHOD="MH" MODIFIED="2015-10-09 10:55:28 +0100" MODIFIED_BY="Ruth  Brassington" NO="2" P_CHI2="0.6182561684192387" P_Q="1.0" P_Z="0.01077223502098029" Q="0.0" RANDOM="NO" SCALE="27.28" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="237" TOTAL_2="232" WEIGHT="100.00000000000001" Z="2.550001841076273">
<NAME>Motor synkinesis or crocodile tears</NAME>
<GROUP_LABEL_1>
AS</GROUP_LABEL_1>
<GROUP_LABEL_2>OS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OS</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0713724757037237" CI_START="0.2038603731042814" EFFECT_SIZE="0.46734397677793904" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="0.02994048485601316" LOG_CI_START="-0.690667185279603" LOG_EFFECT_SIZE="-0.3303633502117949" MODIFIED="2009-05-28 16:48:49 +0100" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="0.423288512503157" STUDY_ID="STD-Adour-1996" TOTAL_1="53" TOTAL_2="46" VAR="0.1791731648171353" WEIGHT="30.426977878884085"/>
<DICH_DATA CI_END="1.0195104634149432" CI_START="0.35335057332019076" EFFECT_SIZE="0.600203804347826" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="32" LOG_CI_END="0.008391687377574841" LOG_CI_START="-0.4517941996949691" LOG_EFFECT_SIZE="-0.22170125615869718" MODIFIED="2014-08-17 13:22:25 +0100" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.27031546802329176" STUDY_ID="STD-Engstr_x00f6_m-2008" TOTAL_1="184" TOTAL_2="186" VAR="0.07307045225265127" WEIGHT="69.57302212111593"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3035834794129616" CI_END="1.694048737851143" CI_START="0.8259772391081576" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1828971634951815" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="47" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.22892590084434966" LOG_CI_START="-0.0830319200717791" LOG_EFFECT_SIZE="0.07294699038628527" METHOD="MH" MODIFIED="2015-10-15 10:10:35 +0100" MODIFIED_BY="Ruth  Brassington" NO="3" P_CHI2="0.8591672074406849" P_Q="1.0" P_Z="0.3593415251194527" Q="0.0" RANDOM="NO" SCALE="28.9177285766589" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="440" TOTAL_2="437" WEIGHT="99.99999999999999" Z="0.9166205451611215">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>AS</GROUP_LABEL_1>
<GROUP_LABEL_2>OS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OS</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2082962052973314" CI_START="0.7559985275238198" EFFECT_SIZE="1.2920792079207921" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="21" LOG_CI_END="0.3440573261668996" LOG_CI_START="-0.12147905038358522" LOG_EFFECT_SIZE="0.1112891378916572" MODIFIED="2015-10-15 10:10:30 +0100" MODIFIED_BY="Ruth  Brassington" ORDER="15" O_E="0.0" SE="0.2734583720279843" STUDY_ID="STD-Engstr_x00f6_m-2008" TOTAL_1="202" TOTAL_2="203" VAR="0.07477948123219547" WEIGHT="44.833189439491"/>
<DICH_DATA CI_END="8.26254855777383" CI_START="0.2398978446139086" EFFECT_SIZE="1.4078947368421053" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9171140247855285" LOG_CI_START="-0.619973653976692" LOG_EFFECT_SIZE="0.1485701854044183" MODIFIED="2015-10-15 10:10:32 +0100" MODIFIED_BY="Ruth  Brassington" ORDER="30" O_E="0.0" SE="0.9028929112116499" STUDY_ID="STD-Hato-2007" TOTAL_1="114" TOTAL_2="107" VAR="0.8152156091162485" WEIGHT="4.41597461374469"/>
<DICH_DATA CI_END="1.7633462099503059" CI_START="0.6454818228715841" EFFECT_SIZE="1.0668682795698925" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="24" LOG_CI_END="0.24633758870868686" LOG_CI_START="-0.19011598320038003" LOG_EFFECT_SIZE="0.02811080275415339" MODIFIED="2015-10-15 10:10:35 +0100" MODIFIED_BY="Ruth  Brassington" ORDER="11" O_E="0.0" SE="0.2563749886194106" STUDY_ID="STD-Sullivan-2007" TOTAL_1="124" TOTAL_2="127" VAR="0.06572813478960292" WEIGHT="50.7508359467643"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2015-09-15 17:08:34 +0100" MODIFIED_BY="Ruth  Brassington" NO="2">
<NAME>Antivirals versus corticosteroids</NAME>
<DICH_OUTCOME CHI2="8.782059032401145" CI_END="7.3230909321539475" CI_START="1.0876958740486622" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.822285561772058" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="58" I2="77.22629747054694" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.8646944268840175" LOG_CI_START="0.03650748112876086" LOG_EFFECT_SIZE="0.4506009540063893" METHOD="MH" MODIFIED="2015-09-15 14:41:08 +0100" MODIFIED_BY="Ruth  Brassington" NO="1" P_CHI2="0.012388014617622178" P_Q="1.0" P_Z="0.03294448927462282" Q="0.0" RANDOM="YES" SCALE="24.69" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.5322649090680579" TOTALS="YES" TOTAL_1="384" TOTAL_2="384" WEIGHT="99.99999999999999" Z="2.132759145210921">
<NAME>Incomplete recovery at end of study</NAME>
<GROUP_LABEL_1>A</GROUP_LABEL_1>
<GROUP_LABEL_2>S</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours S</GRAPH_LABEL_2>
<DICH_DATA CI_END="11.596196545225567" CI_START="1.0452317929096226" EFFECT_SIZE="3.4814814814814814" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="1.0643155676508391" LOG_CI_START="0.01921261123058355" LOG_EFFECT_SIZE="0.5417640894407113" MODIFIED="2015-09-15 14:41:08 +0100" MODIFIED_BY="Ruth  Brassington" ORDER="57" O_E="0.0" SE="0.613898649944327" STUDY_ID="STD-De-Diego-1998" TOTAL_1="54" TOTAL_2="47" VAR="0.3768715524034673" WEIGHT="26.031721518526272"/>
<DICH_DATA CI_END="2.0331067354621997" CI_START="1.1088202538336167" EFFECT_SIZE="1.5014492753623188" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="50" LOG_CI_END="0.30816017913260657" LOG_CI_START="0.04486115021131117" LOG_EFFECT_SIZE="0.1765106646719589" MODIFIED="2009-07-24 10:42:53 +0100" MODIFIED_BY="Pauline Lockhart" ORDER="16" O_E="0.0" SE="0.15466315293958227" STUDY_ID="STD-Engstr_x00f6_m-2008" TOTAL_1="207" TOTAL_2="210" VAR="0.02392069087721262" WEIGHT="42.55124043070144"/>
<DICH_DATA CI_END="14.01126858271588" CI_START="2.218744431938114" EFFECT_SIZE="5.575609756097561" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="5" LOG_CI_END="1.146477458164544" LOG_CI_START="0.34610728051451073" LOG_EFFECT_SIZE="0.7462923693395274" MODIFIED="2009-07-24 10:44:11 +0100" MODIFIED_BY="Pauline Lockhart" ORDER="9" O_E="0.0" SE="0.47014140424790557" STUDY_ID="STD-Sullivan-2007" TOTAL_1="123" TOTAL_2="127" VAR="0.22103293998819257" WEIGHT="31.417038050772277"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5000621145947934" CI_END="2.1247511383418" CI_START="1.0826902933766491" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5167225960351658" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="43" I2="33.33609386767784" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.32730807058677186" LOG_CI_START="0.03450424322430136" LOG_EFFECT_SIZE="0.1809061569055366" METHOD="MH" MODIFIED="2015-09-15 17:08:34 +0100" MODIFIED_BY="Ruth  Brassington" NO="2" P_CHI2="0.22066217742777716" P_Q="1.0" P_Z="0.015439959195985991" Q="0.0" RANDOM="NO" SCALE="5.78" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="239" TOTAL_2="233" WEIGHT="100.0" Z="2.421891512213546">
<NAME>Motor synkinesis and crocodile tears</NAME>
<GROUP_LABEL_1>A</GROUP_LABEL_1>
<GROUP_LABEL_2>S</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours S</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0741203987175667" CI_START="0.5101237784034431" EFFECT_SIZE="1.0286195286195285" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.31683396274782183" LOG_CI_START="-0.29232443222510046" LOG_EFFECT_SIZE="0.012254765261360654" MODIFIED="2015-09-15 17:08:34 +0100" MODIFIED_BY="Ruth  Brassington" ORDER="34" O_E="0.0" SE="0.3578226565897812" STUDY_ID="STD-De-Diego-1998" TOTAL_1="54" TOTAL_2="47" VAR="0.12803705356896847" WEIGHT="26.930907473353095"/>
<DICH_DATA CI_END="2.4983617172667127" CI_START="1.1521649995914838" EFFECT_SIZE="1.6966216216216217" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="32" LOG_CI_END="0.39765531652025327" LOG_CI_START="0.06151467811567678" LOG_EFFECT_SIZE="0.22958499731796506" MODIFIED="2014-08-17 13:06:22 +0100" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="0.19745067492184373" STUDY_ID="STD-Engstr_x00f6_m-2008" TOTAL_1="185" TOTAL_2="186" VAR="0.038986769027091604" WEIGHT="73.0690925266469"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.049935144522062214" CI_END="1.276895294764981" CI_START="0.5717884471049303" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8544670723376417" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.10615528663684509" LOG_CI_START="-0.2427646237406496" LOG_EFFECT_SIZE="-0.06830466855190226" METHOD="MH" MODIFIED="2015-04-16 07:43:33 +0100" MODIFIED_BY="Ruth  Brassington" NO="3" P_CHI2="0.8231761666843362" P_Q="1.0" P_Z="0.44286376559754403" Q="0.0" RANDOM="NO" SCALE="7.24" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="328" TOTAL_2="330" WEIGHT="100.0" Z="0.7673663001508612">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>A</GROUP_LABEL_1>
<GROUP_LABEL_2>S</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours S</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6153608566714606" CI_START="0.49691649272643873" EFFECT_SIZE="0.8959349593495934" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" LOG_CI_END="0.20826955487466792" LOG_CI_START="-0.30371658872193136" LOG_EFFECT_SIZE="-0.04772351692363171" MODIFIED="2013-11-21 15:56:54 +0000" MODIFIED_BY="[Empty name]" ORDER="17" O_E="0.0" SE="0.30074319512092706" STUDY_ID="STD-Engstr_x00f6_m-2008" TOTAL_1="205" TOTAL_2="203" VAR="0.090446469411544" WEIGHT="47.19016287347643"/>
<DICH_DATA CI_END="1.4145439710800591" CI_START="0.47235170298888085" EFFECT_SIZE="0.8174119241192412" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="24" LOG_CI_END="0.15061645204088822" LOG_CI_START="-0.3257345145253245" LOG_EFFECT_SIZE="-0.0875590312422181" MODIFIED="2009-02-05 16:06:24 +0000" MODIFIED_BY="Pauline Lockhart" ORDER="12" O_E="0.0" SE="0.2798109157363068" STUDY_ID="STD-Sullivan-2007" TOTAL_1="123" TOTAL_2="127" VAR="0.07829414856519057" WEIGHT="52.809837126523576"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2015-09-01 14:34:41 +0100" MODIFIED_BY="Ildiko Gagyor" NO="3">
<NAME>Antivirals plus corticosteroids versus placebo</NAME>
<DICH_OUTCOME CHI2="0.1386503705348055" CI_END="0.7550952475484504" CI_START="0.4134405370005336" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5587369547765587" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="91" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-0.12199826310500973" LOG_CI_START="-0.38358694393381637" LOG_EFFECT_SIZE="-0.252792603519413" METHOD="MH" MODIFIED="2015-09-01 14:34:41 +0100" MODIFIED_BY="Ildiko Gagyor" NO="1" P_CHI2="0.7096265397325071" P_Q="1.0" P_Z="1.5179274178009087E-4" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="330" TOTAL_2="328" WEIGHT="100.0" Z="3.7881180247276314">
<NAME>Incomplete recovery at end of study</NAME>
<GROUP_LABEL_1>AS</GROUP_LABEL_1>
<GROUP_LABEL_2>OO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OO</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7977165440033535" CI_START="0.4149581143672997" EFFECT_SIZE="0.5753424657534246" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="73" LOG_CI_END="-0.098151400935032" LOG_CI_START="-0.3819957385100789" LOG_EFFECT_SIZE="-0.24007356972255547" MODIFIED="2009-07-24 10:54:07 +0100" MODIFIED_BY="Pauline Lockhart" ORDER="23" O_E="0.0" SE="0.16673156894371396" STUDY_ID="STD-Engstr_x00f6_m-2008" TOTAL_1="206" TOTAL_2="206" VAR="0.027799416082432443" WEIGHT="80.0909820711801"/>
<DICH_DATA CI_END="1.0520159250474372" CI_START="0.23003503514497745" EFFECT_SIZE="0.49193548387096775" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="18" LOG_CI_END="0.022022314064753124" LOG_CI_START="-0.6382060143676892" LOG_EFFECT_SIZE="-0.308091850151468" MODIFIED="2009-07-24 10:56:18 +0100" MODIFIED_BY="Pauline Lockhart" ORDER="24" O_E="0.0" SE="0.3878213883041509" STUDY_ID="STD-Sullivan-2007" TOTAL_1="124" TOTAL_2="122" VAR="0.150405429226159" WEIGHT="19.90901792881991"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.1292722230178717" CI_END="1.651536603800145" CI_START="0.7922137864918328" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.143840052816116" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.21788820361160127" LOG_CI_START="-0.10115760406094872" LOG_EFFECT_SIZE="0.05836529977532627" METHOD="MH" MODIFIED="2014-07-21 17:17:37 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7191878999023729" P_Q="1.0" P_Z="0.47331235786222636" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="326" TOTAL_2="323" WEIGHT="100.0" Z="0.7171000699932746">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>AS</GROUP_LABEL_1>
<GROUP_LABEL_2>OO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OO</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7855812675176308" CI_START="0.6467810183665653" EFFECT_SIZE="1.0746534653465347" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="25" LOG_CI_END="0.25177962111030766" LOG_CI_START="-0.18924273418867799" LOG_EFFECT_SIZE="0.03126844346081483" MODIFIED="2013-11-21 15:57:23 +0000" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.2590587145984914" STUDY_ID="STD-Engstr_x00f6_m-2008" TOTAL_1="202" TOTAL_2="201" VAR="0.06711141760942263" WEIGHT="55.416774469831466"/>
<DICH_DATA CI_END="2.0940687441005856" CI_START="0.722279655852773" EFFECT_SIZE="1.2298387096774193" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="20" LOG_CI_END="0.3209909345985539" LOG_CI_START="-0.1412946175574148" LOG_EFFECT_SIZE="0.08984815852056954" MODIFIED="2009-04-01 11:17:22 +0100" MODIFIED_BY="[Empty name]" ORDER="27" O_E="0.0" SE="0.2715488216868052" STUDY_ID="STD-Sullivan-2007" TOTAL_1="124" TOTAL_2="122" VAR="0.07373876255949234" WEIGHT="44.58322553016853"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2015-10-15 10:20:17 +0100" MODIFIED_BY="Ruth  Brassington" NO="4">
<NAME>Antivirals versus placebo</NAME>
<DICH_OUTCOME CHI2="1.6304783481458307" CI_END="1.3955890525323404" CI_START="0.8728208085430873" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1036752988198832" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="91" I2="38.66830546157246" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.14475755403815194" LOG_CI_START="-0.05907490846953766" LOG_EFFECT_SIZE="0.04284132278430715" METHOD="MH" MODIFIED="2015-04-16 07:43:33 +0100" MODIFIED_BY="Ruth  Brassington" NO="1" NOTES="&lt;p&gt;Is there a reason why 1.1 forest plot is ordered by effect size under the tab but the other analyses are ordered by study id? &lt;/p&gt;" NOTES_MODIFIED="2015-04-16 07:43:33 +0100" NOTES_MODIFIED_BY="Ruth  Brassington" P_CHI2="0.20163695981828866" P_Q="1.0" P_Z="0.41000382188984386" Q="0.0" RANDOM="NO" SCALE="5.399008461478719" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="330" TOTAL_2="328" WEIGHT="100.0" Z="0.8238869184453832">
<NAME>Incomplete recovery at end of study</NAME>
<GROUP_LABEL_1>AO</GROUP_LABEL_1>
<GROUP_LABEL_2>OO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OO</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3076619479109137" CI_START="0.7782443614424701" EFFECT_SIZE="1.0088015353054067" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="73" LOG_CI_END="0.11649548624192867" LOG_CI_START="-0.10888401719641677" LOG_EFFECT_SIZE="0.0038057345227559677" MODIFIED="2014-01-21 23:01:19 +0000" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="0.13238903596621907" STUDY_ID="STD-Engstr_x00f6_m-2008" TOTAL_1="207" TOTAL_2="206" VAR="0.017526856844064846" WEIGHT="80.19350700746462"/>
<DICH_DATA CI_END="2.5563247359690067" CI_START="0.8659163384055226" EFFECT_SIZE="1.4878048780487805" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="18" LOG_CI_END="0.40761602244461087" LOG_CI_START="-0.0625240658625478" LOG_EFFECT_SIZE="0.17254597829103155" MODIFIED="2014-01-21 23:02:18 +0000" MODIFIED_BY="[Empty name]" ORDER="56" O_E="0.0" SE="0.27616261510259527" STUDY_ID="STD-Sullivan-2007" TOTAL_1="123" TOTAL_2="122" VAR="0.07626578998030417" WEIGHT="19.80649299253538"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3261346325934746" CI_END="1.2449601816484557" CI_START="0.5566820682355395" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8324944497057954" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.09515546133786279" LOG_CI_START="-0.2543927679005023" LOG_EFFECT_SIZE="-0.07961865328131977" METHOD="MH" MODIFIED="2015-04-16 07:43:33 +0100" MODIFIED_BY="Ruth  Brassington" NO="2" P_CHI2="0.5679442111582207" P_Q="1.0" P_Z="0.3719294726851956" Q="0.0" RANDOM="NO" SCALE="6.2427376983737135" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="328" TOTAL_2="323" WEIGHT="100.0" Z="0.8928650176199554">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>AO</GROUP_LABEL_1>
<GROUP_LABEL_2>OO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OO</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3096552822986516" CI_START="0.4239889892389204" EFFECT_SIZE="0.7451707317073171" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="25" LOG_CI_END="0.1171569989409364" LOG_CI_START="-0.37264542164988457" LOG_EFFECT_SIZE="-0.12774421135447409" MODIFIED="2014-01-21 23:05:43 +0000" MODIFIED_BY="[Empty name]" ORDER="57" O_E="0.0" SE="0.28771236641613296" STUDY_ID="STD-Engstr_x00f6_m-2008" TOTAL_1="205" TOTAL_2="201" VAR="0.08277840578877116" WEIGHT="55.697008274984086"/>
<DICH_DATA CI_END="1.6758746969534388" CI_START="0.5298038442321669" EFFECT_SIZE="0.9422764227642276" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="0.224241543855096" LOG_CI_START="-0.2758848948066998" LOG_EFFECT_SIZE="-0.025821675475801942" MODIFIED="2014-01-21 23:06:10 +0000" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.29377674573573725" STUDY_ID="STD-Sullivan-2007" TOTAL_1="123" TOTAL_2="122" VAR="0.08630477633508" WEIGHT="44.30299172501591"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2015-10-15 10:20:17 +0100" MODIFIED_BY="Ruth  Brassington" NO="5">
<NAME>Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment in severe cases</NAME>
<DICH_OUTCOME CHI2="5.198103797143224" CI_END="0.9936528053400348" CI_START="0.4122490978023876" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6400253686614623" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="69" I2="42.28664687979603" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-0.0027653369959779574" LOG_CI_START="-0.38484028612582905" LOG_EFFECT_SIZE="-0.19380281156090354" METHOD="MH" MODIFIED="2015-10-09 16:29:47 +0100" MODIFIED_BY="Ruth  Brassington" NO="1" P_CHI2="0.15785289895294452" P_Q="1.0" P_Z="0.04677463281425524" Q="0.0" RANDOM="YES" SCALE="11.447477383558256" SORT_BY="USER" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.08062695042093336" TOTALS="YES" TOTAL_1="238" TOTAL_2="240" WEIGHT="100.0" Z="1.9883351767868975">
<NAME>Incomplete recovery at end of study</NAME>
<GROUP_LABEL_1>AS</GROUP_LABEL_1>
<GROUP_LABEL_2>OS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OS</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1412099485056595" CI_START="0.541799228440265" EFFECT_SIZE="0.7863247863247863" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="18" LOG_CI_END="0.05736554896670604" LOG_CI_START="-0.2661616177679188" LOG_EFFECT_SIZE="-0.10439803440060638" MODIFIED="2015-09-14 13:27:56 +0100" MODIFIED_BY="[Empty name]" ORDER="40" O_E="0.0" SE="0.19004145922522242" STUDY_ID="STD-Engstr_x00f6_m-2008" TOTAL_1="26" TOTAL_2="23" VAR="0.03611575622445187" WEIGHT="43.146202145913385"/>
<DICH_DATA CI_END="0.9785456859729833" CI_START="0.10735086687224701" EFFECT_SIZE="0.3241106719367589" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="-0.009418893355196816" LOG_CI_START="-0.9691944442290056" LOG_EFFECT_SIZE="-0.4893066687921012" MODIFIED="2015-10-09 16:29:47 +0100" MODIFIED_BY="Ruth  Brassington" ORDER="41" O_E="0.0" SE="0.5637769095488747" STUDY_ID="STD-Hato-2007" TOTAL_1="92" TOTAL_2="82" VAR="0.3178444037404801" WEIGHT="12.640819389848684"/>
<DICH_DATA CI_END="0.8481583721468227" CI_START="0.3071235040027361" EFFECT_SIZE="0.5103815937149271" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="36" LOG_CI_END="-0.07152304664944778" LOG_CI_START="-0.5126869459532596" LOG_EFFECT_SIZE="-0.29210499630135356" MODIFIED="2015-10-09 16:29:47 +0100" MODIFIED_BY="Ruth  Brassington" ORDER="42" O_E="0.0" SE="0.25914185824758035" STUDY_ID="STD-Lee-2013" TOTAL_1="99" TOTAL_2="107" VAR="0.06715450269600902" WEIGHT="34.0841446185874"/>
<DICH_DATA CI_END="4.7248385182665125" CI_START="0.3762621242831433" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6743869701311649" LOG_CI_START="-0.4245094969145651" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2013-11-21 16:02:27 +0000" MODIFIED_BY="[Empty name]" ORDER="43" O_E="0.0" SE="0.6454972243679028" STUDY_ID="STD-Sullivan-2007" TOTAL_1="21" TOTAL_2="28" VAR="0.4166666666666667" WEIGHT="10.12883384565053"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-10-12 12:47:49 +0100" MODIFIED_BY="Ruth  Brassington">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-10-12 12:46:48 +0100" MODIFIED_BY="Ruth  Brassington" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study selection flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAaYAAAWwCAYAAAAWseWWAABCqElEQVR42u3djZKjPJJG4br0ufPe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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-09-01 14:36:12 +0100" MODIFIED_BY="Ildiko Gagyor" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>A summary of review authors' 'Risk of bias' assessments for included studies. Red = high risk of bias; yellow = unclear risk of bias; green = low risk of bias.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUcAAAJFCAIAAADBC6KqAAAdjElEQVR42u3dsW4cydWG4QEECAoY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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-10-12 12:47:49 +0100" MODIFIED_BY="Ruth  Brassington" NO="3" REF_ID="CMP-001.01" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment, outcome: 1.1 Incomplete recovery at end of study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvoAAAEACAMAAAD1ICIFAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2015-09-15 14:41:09 +0100" MODIFIED_BY="Ruth  Brassington" NO="4" REF_ID="CMP-002.01" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Antivirals versus corticosteroids, outcome: 2.1 Incomplete recovery at end of study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvoAAACwCAMAAABJnTrEAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2015-09-01 14:36:12 +0100" MODIFIED_BY="Ildiko Gagyor" NO="5" REF_ID="CMP-003.01" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Antivirals plus corticosteroids versus placebo, outcome: 3.1 Incomplete recovery at end of study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAukAAACgCAMAAACG0gK0AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2015-10-09 16:29:48 +0100" MODIFIED_BY="Ruth  Brassington" NO="6" REF_ID="CMP-005.01" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 5 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment in severe cases, outcome: 5.1 Incomplete recovery at the end of the study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvoAAADACAMAAABCvzcFAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2014-11-26 07:56:49 +0000" MODIFIED_BY="Ruth Brassington"/>
<APPENDICES MODIFIED="2015-10-15 10:25:40 +0100" MODIFIED_BY="Ruth  Brassington">
<APPENDIX ID="APP-01" MODIFIED="2015-10-15 10:25:40 +0100" MODIFIED_BY="Ruth  Brassington" NO="1">
<TITLE MODIFIED="2015-10-15 10:25:40 +0100" MODIFIED_BY="Ruth  Brassington">Cochrane Neuromuscular Disease Group Specialized Register (CRS) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-09-03 13:47:26 +0100" MODIFIED_BY="Angela A Gunn">
<P>#1 MeSH DESCRIPTOR Facial Nerve Diseases [REFERENCE] [STANDARD]<BR/>#2 MeSH DESCRIPTOR Bell Palsy [REFERENCE] [STANDARD]<BR/>#3 MeSH DESCRIPTOR Facial Paralysis [REFERENCE] [STANDARD]<BR/>#4 MeSH DESCRIPTOR Hemifacial Spasm [REFERENCE] [STANDARD]<BR/>#5 (((bell* or facial* or hemifacial* or cranial*) NEAR3 (pals* or paralys* or paresi* or spasm*))) [REFERENCE] [STANDARD]<BR/>#6 #1 or #2 or #3 or #4 or #5 [REFERENCE] [STANDARD]<BR/>#7 MeSH DESCRIPTOR Acyclovir Explode 1 [REFERENCE] [STANDARD]<BR/>#8 MeSH DESCRIPTOR 2-Aminopurine [REFERENCE] [STANDARD]<BR/>#9 MeSH DESCRIPTOR Antiviral Agents Explode 1 [REFERENCE] [STANDARD]<BR/>#10 (aciclovir or valaciclovir or famciclovir or antiviral*) [REFERENCE] [STANDARD]<BR/>#11 (acyclovir or valacyclovir or famcyclovir) [REFERENCE] [STANDARD]<BR/>#12 #7 or #8 or #9 or #10 or #11 [REFERENCE] [STANDARD]<BR/>#13 #6 and #12 [REFERENCE] [STANDARD]<BR/>#14 (#13) AND (INREGISTER) [REFERENCE] [STANDARD]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-01-27 13:46:40 +0000" MODIFIED_BY="Angela A Gunn" NO="2">
<TITLE MODIFIED="2014-01-27 13:46:40 +0000" MODIFIED_BY="Angela A Gunn">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-11-06 09:14:41 +0000" MODIFIED_BY="Angela A Gunn">
<P>#1 (Bell or "Bell's" or Bells or facial or hemifacial or cranial) NEAR (palsy or palsies or paralysis or paresis or spasm or spasms)<BR/>#2 aciclovir or acyclovir or valaciclovir or valacyclovir or famciclovir or famcyclovir or antiviral*<BR/>#3 (#1 AND #2)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-10-07 13:14:07 +0100" MODIFIED_BY="Angela A Gunn" NO="3">
<TITLE MODIFIED="2014-01-27 13:46:33 +0000" MODIFIED_BY="[Empty name]">MEDLINE (OvidSP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-10-07 13:14:07 +0100" MODIFIED_BY="Angela A Gunn">
<P>Database: Ovid MEDLINE(R) &lt;1946 to September Week 4 2014&gt;<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 randomized controlled trial.pt. (389226)<BR/>2 controlled clinical trial.pt. (89867)<BR/>3 randomized.ab. (285185)<BR/>4 placebo.ab. (151031)<BR/>5 drug therapy.fs. (1748071)<BR/>6 randomly.ab. (201598)<BR/>7 trial.ab. (296312)<BR/>8 groups.ab. (1285103)<BR/>9 or/1-8 (3290339)<BR/>10 exp animals/ not humans.sh. (4016034)<BR/>11 9 not 10 (2802960)<BR/>12 exp Facial Nerve Diseases/ (6620)<BR/>13 bell palsy/ (743)<BR/>14 facial paralysis/ or hemifacial spasm/ (11010)<BR/>15 ((Bell$ or facial$ or hemifacial$ or cranial$) adj3 (pals$ or paralys$ or paresi$ or spasm$)).mp. (18408)<BR/>16 12 or 13 or 14 or 15 (22556)<BR/>17 Acyclovir/ (7824)<BR/>18 exp Acyclovir/ (12494)<BR/>19 2-Aminopurine/ (1203)<BR/>20 exp Antiviral Agents/ (293597)<BR/>21 (aciclovir or valaciclovir or famciclovir or antiviral$).tw. (54604)<BR/>22 (acyclovir or valacyclovir or famcyclovir).tw. (6662)<BR/>23 or/17-22 (315614)<BR/>24 11 and 16 and 23 (375)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2014-10-07 13:27:08 +0100" MODIFIED_BY="Angela A Gunn" NO="4">
<TITLE MODIFIED="2014-01-27 13:46:24 +0000" MODIFIED_BY="[Empty name]">EMBASE (OvidSP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-10-07 13:27:08 +0100" MODIFIED_BY="Angela A Gunn">
<P>Database: Embase &lt;1980 to 2014 Week 40&gt;<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 crossover-procedure.sh. (40306)<BR/>2 double-blind procedure.sh. (115609)<BR/>3 single-blind procedure.sh. (18869)<BR/>4 randomized controlled trial.sh. (350916)<BR/>5 (random$ or crossover$ or cross over$ or placebo$ or (doubl$ adj blind$) or allocat$).tw,ot. (1065137)<BR/>6 trial.ti. (163276)<BR/>7 or/1-6 (1198699)<BR/>8 (animal/ or nonhuman/ or animal experiment/) and human/ (1290984)<BR/>9 animal/ or nonanimal/ or animal experiment/ (3256545)<BR/>10 9 not 8 (2727334)<BR/>11 7 not 10 (1100982)<BR/>12 limit 11 to embase (913119)<BR/>13 bell palsy/ (2339)<BR/>14 facial nerve paralysis/ or hemifacial spasm/ (17444)<BR/>15 ((Bell$ or facial$ or hemifacial$ or cranial$) adj3 (pals$ or paralys$ or paresi$ or spasm$)).mp. (27210)<BR/>16 or/13-15 (27210)<BR/>17 exp antivirus agent/ (651212)<BR/>18 aciclovir/ (30615)<BR/>19 famciclovir/ (3428)<BR/>20 (aciclovir or valaciclovir or famciclovir or antiviral$).tw. (70997)<BR/>21 (acyclovir or valacyclovir or famcyclovir).tw. (9086)<BR/>22 or/17-21 (672393)<BR/>23 12 and 16 and 22 (103)<BR/>24 remove duplicates from 23 (102)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2013-09-03 13:45:48 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2013-09-03 13:45:48 +0100" MODIFIED_BY="[Empty name]">LILACS (IAHx) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-11-06 09:15:16 +0000" MODIFIED_BY="[Empty name]">
<P>("Bell palsy" or "paralisis de Bell" or "paralisia de Bell" or "facial or paralysis" or "paralisis facial" or "paralisia facial" or "hemifacial spasm" or "espasmo hemifacial") and (MH:D03.438.759.758.399.454.250$ or acyclovir or 2-Aminopurine or 2-Aminopurina or MH:D27.505.954.122.388$ or aciclovir or acyclovir or valaciclovir or valacyclovir or famciclovir or famcyclovir or antivira$) and ((PT:"Randomized Controlled Trial" or "Randomized Controlled trial" or "Ensayo Clínico Controlado Aleatorio" or "Ensaio Clínico Controlado Aleatório" or PT:"Controlled Clinical Trial" or "Ensayo Clínico Controlado" or "Ensaio Clínico Controlado" or "Random allocation" or "Distribución Aleatoria" or "Distribuição Aleatória" or randon$ or Randomized or randomly or "double blind" or "duplo-cego" or "duplo-cego" or "single blind" or "simples-cego" or "simples cego" or placebo$ or trial or groups) AND NOT (B01.050$ AND NOT (humans or humanos or humanos)))</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2014-11-26 07:56:49 +0000" MODIFIED_BY="Ruth Brassington">
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;1&lt;span class=&quot;inserted&quot; modified=&quot;2015-09-01 19:41:00 +0200&quot; modified_by=&quot;Ildiko Gagyor&quot;&gt;0&lt;/span&gt;&lt;span class=&quot;deleted&quot; modified=&quot;2015-09-01 19:41:00 +0200&quot; modified_by=&quot;Ildiko Gagyor&quot;&gt;1&lt;/span&gt; studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1&lt;span class=&quot;inserted&quot; modified=&quot;2015-09-01 19:40:00 +0200&quot; modified_by=&quot;Ildiko Gagyor&quot;&gt;0&lt;/span&gt;&lt;span class=&quot;deleted&quot; modified=&quot;2015-09-01 19:40:00 +0200&quot; modified_by=&quot;Ildiko Gagyor&quot;&gt;1&lt;/span&gt; studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;30 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;121 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Numbers of references retrieved by October 2014 search (for this update)&lt;/p&gt;&lt;p&gt;MEDLINE: 375&lt;/p&gt;&lt;p&gt;EMBASE: 102&lt;/p&gt;&lt;p&gt;LILACS: 4&lt;/p&gt;&lt;p&gt;Neuromuscular Disease Group Specialized Register: 28&lt;/p&gt;&lt;p&gt;CENTRAL: 39&lt;/p&gt;&lt;p&gt;DARE: 8&lt;/p&gt;&lt;p&gt;HTA: 1&lt;/p&gt;&lt;p&gt;EED: 1&lt;/p&gt;&lt;p&gt;Papers identified through handsearching of records in database searches: 2&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;7 trials in previous version of the review&lt;/p&gt;"/>
<OUT TEXT="&lt;p&gt;91 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;19 full-text articles excluded, with reasons&lt;/p&gt;&lt;p&gt;- no randomised trial&lt;/p&gt;&lt;p&gt;- using historical cohort groups&lt;/p&gt;&lt;p&gt;- no random allocation of treatment group&lt;/p&gt;&lt;p&gt;- retrospective analysis&lt;/p&gt;&lt;p&gt;- unclear trial design&lt;/p&gt;&lt;p&gt;- unpublished data not available&lt;/p&gt;&lt;p&gt;- original paper not available&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2015-09-14 16:39:00 +0100&quot; modified_by=&quot;Ruth  Brassington&quot;  class=&quot;inserted&quot;&gt;1 paper 'Awaiting classification'&lt;/span&gt;&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>